bismuth has been researched along with Helicobacter Infections in 919 studies
*Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.11) | 18.7374 |
| 1990's | 391 (42.55) | 18.2507 |
| 2000's | 174 (18.93) | 29.6817 |
| 2010's | 195 (21.22) | 24.3611 |
| 2020's | 158 (17.19) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, JM; Jeon, JW; Kwak, MS; Yoon, JY | 1 |
| Ang, D; Ang, TL; Lim, KW; Tan, M; Wong, YJ; Yih Wong, AS | 1 |
| Alcedo, J; Amador, J; Bujanda, L; Calvet, X; Castro-Fernández, M; Fernández-Salazar, L; Gené, E; Gisbert, JP; Lanas, Á; Lucendo, AJ; Molina-Infante, J; Nyssen, OP; Pérez-Aisa, A; Puig, I | 1 |
| Arcidiacono, PG; Armuzzi, A; Bazzoli, F; Biagi, F; Cannizzaro, R; Cavestro, GM; Ciacci, C; Dajti, E; Frazzoni, L; Marasco, G; Monica, F; Peralta, S; Radaelli, F; Romano, M; Zagari, RM | 1 |
| Dao, HV; Dao, LV; Dat, VQ; Hoang, LB; Nguyen, HT; Nguyen, HTV; Nguyen, TD; Tran, ATN; Vu, VT | 1 |
| Cho, JH; Jin, SY; Park, S | 1 |
| Dutta, AK; Phull, PS | 1 |
| Cao, Y; Huo, L; Liu, J; Liu, Y; Lv, H; Qi, Y; Shi, Y; Wang, J; Wang, L; Wei, X; Zhang, J; Zhang, L | 1 |
| Cao, Y; He, W; Li, X; Wang, J | 1 |
| Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I | 1 |
| An, P; Chen, ZF; Ding, XW; Guan, JL; He, Q; Hu, YL; Li, PY; Long, H; Luo, HS; Wu, SS; Xiong, JG; Zhou, L | 1 |
| Fan, J; Guan, J; Han, B; Jia, X; Li, M; Qi, R; Wang, H; Wang, Q; Xie, Z; Xu, Y; Xue, R; Yu, H; Yu, W | 1 |
| Baik, GH; Bang, CS; Jang, HJ; Kae, SH; Kim, HY; Kim, J; Lee, SP; Lim, H; Seo, SI; Shin, WG; Yang, YJ | 1 |
| Ding, SZ; Hu, RB; Jia, BL; Lan, L; Ma, J; Qi, YB; Shao, QQ; Wei, PR; Xiao, W; Yu, M; Yu, XC; Yuan, L; Zhang, LZ; Zhao, JB | 1 |
| Apostolopoulos, P; Argyriou, K; Christodoulou, DK; Georgopoulos, SD; Giouleme, O; Kotzampassi, K; Koustenis, K; Liatsos, C; Mantzaris, GJ; Moutzoukis, M; Mylonas, II; Poutakidis, C; Stogiannou, D; Tseti, I; Veretanos, C; Viazis, N | 1 |
| Hubscher, E; Jacob, R; Pelletier, C; Shah, S; Vinals, L; Yadlapati, R | 1 |
| Continisio, A; D'Abramo, FS; Di Leo, A; Ierardi, E; Losurdo, G; Piazzolla, M; Pricci, M; Rima, R | 1 |
| Inge, AK; Nero, M; Rooth, V; Svensson Grape, E; Willhammar, T | 1 |
| Daugule, I; Leja, M; Lielause, A; Park, JY; Paršutins, S; Poļaka, I; Rūdule, A; Sjomina, O; Stonāns, I; Vangravs, R | 1 |
| De Reuse, H; Kumar, S; Vinella, D | 1 |
| Antonowicz, S; Dabrowski, A; Daniluk, J; Gugnacki, P; Krzyzak, M; Maslach, D; Mlynarczyk, M; Rogalski, P; Swidnicka-Siergiejko, A; Wasielica-Berger, J | 1 |
| Huang, W; Lei, X; Li, H; Li, J; Xu, D; Xu, G; Yin, Z; Zhang, J | 1 |
| Mladenova, I | 1 |
| Hsu, PI; Kao, J; Lin, MH; Shie, CB; Tsay, FW; Wang, JW; Wu, DC; Wu, IT | 1 |
| Cheng, S; Chi, J; Li, H; Liu, P; Liu, X; Luo, J; Qu, P; Xia, X; Xie, X; Xu, C; Yang, H; Zhao, W | 1 |
| Ding, YM; Duan, M; Han, ZX; Ji, R; Kong, QZ; Li, YQ; Li, YY; Lin, BS; Lin, MJ; Liu, J; Wan, M; Wang, J; Wang, ST; Zhang, WL; Zuo, XL | 1 |
| Abbondio, M; Bibbò, S; Dore, MP; Loria, M; Niolu, C; Pes, GM; Sau, R; Tanca, A; Uzzau, S | 1 |
| Gou, LZ; Han, TY; Li, XL; Lin, YM; Wang, C; Xu, HM; Yi, GR; Yu, Y; Yun, JW; Zhang, DK | 1 |
| Ayvaz, MA; Koroglu, M; Ozturk, MA | 1 |
| De Reuse, H; Duchateau, M; Giai Gianetto, Q; Gorgette, O; Guigner, JM; Kumar, S; Marbouty, M; Matondo, M; Schmitt, C | 1 |
| Choe, Y; Kim, BW; Kim, JS; Kim, MJ; Na, SY | 1 |
| Almeida, N; Bastos, I; Branquinho, D; Calhau, C; Correia, C; Fernandes, A; Figueiredo, P; Gravito-Soares, E; Leal, C; Vasconcelos, H | 1 |
| Bi, H; Chen, X; Chen, Y; Han, S; Li, M; Lin, T; Liu, J; Lyu, T; Shi, Y; Wang, J; Wang, S; Yuan, D; Zhao, X | 1 |
| Dong, XY; Du, YQ; Li, ZS; Wu, Y; Zhou, XZ | 1 |
| Li, T; Zhou, Y | 1 |
| Andreev, DN; Bektemirova, LG; Dicheva, DT; Maev, IV; Mkrtumyan, AM | 1 |
| Iakovenko, AV; Ivanov, AN; Soluyanova, IP; Strokova, TV; Vasilyev, NN; Yakovenko, EP | 1 |
| Li, CL; Lu, HP; Ren, XL; Song, ZQ; Suo, BJ; Tian, XL; Yao, XY; Zhang, H; Zhang, YX; Zhou, LY | 1 |
| Kim, GH; Lee, MW | 1 |
| He, XJ; Huang, XY; Li, DL; Li, DZ; Liu, G; Wang, W; Wang, XL | 1 |
| Hei, QW; Ji, YH; Qi, YX; Shi, YM; Sun, DL; Sun, JM; Wu, T; Yang, XF | 1 |
| Guo, Q; He, C; Huo, L; Lu, N; Lyu, B; Shu, X; Xie, Y; Xiong, Z; Yu, Y; Zhang, Z; Zhu, Y; Zhuang, K | 1 |
| Du, Q; Han, Y; Li, Y; Lou, G; Lu, L; Wang, Y; Yan, H; Ye, J | 1 |
| Huang, J; Lin, Y | 1 |
| Chen, J; Ding, S; Li, T; Liu, Y; Shao, F; Wang, L; Xie, L; Zhang, Z; Zhou, C; Zhou, S; Zhu, B; Zhu, J | 1 |
| Hu, Y; Lu, NH; Zhu, Y | 3 |
| Ding, YM; Duan, M; Han, ZX; Kong, QZ; Li, YQ; Li, YY; Lin, BS; Lin, MJ; Liu, J; Mu, YJ; Wan, M; Wang, J; Wang, ST; Zhang, WL; Zuo, XL | 2 |
| Bair, MJ; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; El-Omar, EM; Fang, YJ; Hsu, YC; Hu, WH; Jiang, XT; Kuo, CC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Wu, MS; Yang, TH; Yu, CC | 1 |
| Bellini, M; Borghi, C; Di Leo, A; Dore, MP; Farinati, F; Fiorini, G; Franceschi, F; Gasbarrini, A; Gatta, L; Ghisa, M; Gisbert, JP; Granata, L; Gravina, AG; Holton, J; Losurdo, G; Mégraud, F; Nardone, G; Nyssen, OP; O'Morain, C; Pavoni, M; Pellicano, R; Puig, I; Rocco, A; Romano, M; Saracino, IM; Vaira, D | 1 |
| Chen, Y; Lu, H; Lyu, B; Song, Z; Wang, J; Xia, J; Zhao, Z; Zhou, L | 1 |
| Niu, Z; Ren, X; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
| Chehter, EZ; de Moraes Andrade, PV; Monteiro, YM | 1 |
| Love, BL; Yunusa, I | 1 |
| Dang, YN; Gao, X; Li, LR; Li, WJ; Li, X; Qian, HS; Xu, XB; Yang, Z; Yuan, L; Zhang, GX; Zhang, M; Zhang, WF | 1 |
| Li, C; Lu, H; Ren, X; Song, Z; Suo, B; Tian, X; Yao, X; Zhang, H; Zhang, Y; Zhou, L | 2 |
| Abavisani, M; Azadbakht, MK; Barani, M; Fathizadeh, H; Feizabadi, MM; Khaledi, M; Kodori, M; Moghadaszadeh, M; Neamati, F; Zeinali, M | 1 |
| Boal Carvalho, P; Cotter, J; Freitas, M; Lima Capela, T; Macedo Silva, V; Magalhães, J | 1 |
| Liang, M; Shi, J; Yuan, B; Zhao, P; Zhu, C; Zhu, X | 1 |
| Chen, CL; Chen, KY; Chuah, SK; Graham, DY; Hsu, PI; Kao, JY; Kuo, CH; Lee, CL; Lee, HC; Liu, YH; Shie, CB; Shiu, SI; Tai, WC; Tsay, FW; Wu, DC; Yamaoka, Y; Yang, JC; Yeh, HZ | 1 |
| Hu, Y; Li, YQ; Liu, XW; Lu, NH; Wang, H; Wang, JB; Wang, QZ; Xie, Y; Zhang, DK; Zhang, ZY; Zhu, Y | 1 |
| Chen, J; Chen, X; Ding, Z; Han, Y; Huang, Y; Liang, X; Lu, H; Xu, F; Zeng, X | 1 |
| Chen, ZY; Han, JL; Han, XY; Huang, XX; Lan, C; Li, PY; Li, YQ; Liu, DN; Mo, CY; Pan, J; Tan, Y; Tang, J; Wang, QY; Wu, DH; Yang, WZ | 1 |
| Chua, EG; Gao, X; Han, X; Lai, B; Marshall, BJ; Tay, CY; Wang, X; Wei, X; Yu, X; Zhang, X | 1 |
| Chen, J; Ding, Z; Guo, Y; Han, Y; Huang, Y; Liang, X; Lu, H; Wang, J; Xu, P | 1 |
| Chung, JW; Kim, JS; Kim, TH; Ko, W | 1 |
| Chen, DL; Chen, YL; Li, ZS; Zhang, HQ | 1 |
| Chen, HW; Liu, JJ; Lu, Y; Peng, X; Su, PZ; Wan, Y; Yao, JY; Yu, J; Zhang, M; Zhi, M | 1 |
| Fan, LL; Guo, Y; He, P; Hu, J; Lan, CH; Liu, YX; Mei, H; Pan, J; Su, NY; Sun, WJ; Wang, XW; Zhang, DK; Zou, PY | 1 |
| Chouhan, MI; Hallur, VK; Kumar, C; Makashir, MS; Nayak, HK; Padhy, BM; Panigrahi, MK; Samal, SC; Sethi, S | 1 |
| Kim, JH; Lee, SY; Park, HS; Sung, IK | 1 |
| Ding, YM; Li, YY | 1 |
| Hu, B; Huanfei, D | 1 |
| Chan, P; Cheung, K; Deng, Z; Han, S; Li, K; Li, Y; Luo, X; Lyu, T; Ni, L | 1 |
| Czerniak, R; Gu, L; Hu, C; Men, R; Miao, J; Tang, J; Wang, W; Wang, Y; Yang, L; Yoshida, N | 1 |
| Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y | 1 |
| Du, Q; Li, Y; Liao, O; Liu, X; Lou, G; Wang, Y; Wu, H; Wu, Y; Ye, J | 1 |
| Bai, FH; Chen, C; Chen, RX; Chen, SJ; Huang, SM; Li, D; Zeng, F; Zhang, DY; Zhang, XD | 1 |
| Guerra, W; Moreira, FH; Rosa, LHF; Rosário, JDS; Silva-Caldeira, PP | 1 |
| Ang, TL; Aye, TT; Basir, DN; Lee, YY; Luu, MN; Mahachai, V; Miftahussurur, M; Quach, DT; Sollano, JD; Vannarath, S; Vilaichone, RK; Vutha, K | 1 |
| Huang, L; Li, A; Li, K; Lin, K; Wang, Y; Yang, S; Ye, Y | 1 |
| Eiamsitrakoon, T; Graham, DY; Mahachai, V; Ratana-Amornpin, S; Sanglutong, L; Siramolpiwat, S | 1 |
| Almajano, EA; Babayeva, G; Boltin, D; Bordin, DS; Boyanova, L; Brglez Jurecic, N; Bujanda, L; Buzás, GM; Cano-Català, A; Capelle, LG; Castro-Fernandez, M; Denkovski, M; Doulberis, M; Fiorini, G; Gasbarrini, A; Gisbert, JP; Gridnyev, O; Jonaitis, L; Jonaitis, P; Keco-Huerga, A; Kupcinskas, J; Lanas, Á; Leja, M; Lerang, F; Lucendo, AJ; Mahmudov, U; Marcos-Pinto, R; Marlicz, W; Martínez-Domínguez, SJ; Matysiak-Budnik, T; Mégraud, F; Milivojevic, V; Moreira, L; Nyssen, OP; O'Morain, C; Pabón-Carrasco, M; Pérez-Aísa, Á; Phull, PS; Rodrigo, L; Rokkas, T; Saracino, IM; Šembera, Š; Şimşek, H; Smith, SM; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzanina, L; Voynovan, I | 1 |
| Gao, W; Wang, L; Yin, Y; Zhang, X; Zhu, M | 1 |
| Cho, KB; Jung, HR; Kim, SW; Lee, JW; Lee, JY; Lee, YJ; Park, M | 1 |
| Fan, X; Lu, D; Yao, G | 1 |
| Ou, S; Xu, Y; Yang, T; Yao, J; Yuan, X; Zuo, X | 1 |
| Dong, RN; Feng, LN; Guan, JL; Han, YY; Huang, YJ; Li, JY; Li, PY; Liao, JZ; Xia, SH; Zhang, MY; Zhang, Y; Zhao, K | 1 |
| Jiang, Y; Lv, Y; Qin, X; Wang, X; Yang, P; Yu, J | 1 |
| Cai, X; Lu, J; Song, H; Sun, Q; Yuan, C; Zeng, M; Zhou, S | 1 |
| Cho, SJ; Kim, JY; Kim, SG | 1 |
| Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z | 1 |
| Liu, W; Liu, Y; Wang, X; Wang, Y; Zhu, J | 1 |
| Chotivitayatarakorn, P; Poonyam, P; Vilaichone, RK | 1 |
| Gisbert, JP; Mcnicholl, AG | 1 |
| Ciancio, A; Ponzetto, A; Riva, P | 1 |
| Arenas, A; Camargo, MC; Echeverría, A; Fuentes-López, E; Harris, P; Jorquera, A; Lavanderos, M; Maquilón, S; Pizarro, M; Quiñones, L; Ríos, C; Riquelme, A; Rojas, L; Sandoval, M; Sepúlveda, R; Serrano, C | 1 |
| Jin, Z; Li, Y; Lin, D; Lin, L; Meng, F; Pan, J; Shi, Z; Wu, J; Yang, N; Zhang, J; Zhou, Q | 1 |
| Huang, Y; Jiang, Y; Tang, Z; Wang, Y; Yan, W; Ye, Z; Zhang, Y; Zhou, Y | 1 |
| Avramenko, AA | 1 |
| Lee, YC; Liou, JM; Wu, MS | 2 |
| Graham, DY; Huang, Y; Ji, Y; Liang, X; Lu, H; Luo, L; Yu, L | 1 |
| Kim, N; Lee, DH; Lee, JW; Park, YS; Shin, CM; Yoon, H; Yoon, K | 1 |
| Cogdill, AG; Guevara, B | 1 |
| Alcaide, N; Areia, M; Ariño, I; Axon, T; Barrio, J; Bordin, D; Boyanova, L; Brglez Jurecic, N; Bujanda, L; Buzas, G; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernández, M; Dominguez-Cajal, M; Garre, A; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Kunovský, L; Kupcinskas, L; Lamy, V; Leja, M; Lerang, F; Lucendo, A; Marcos Pinto, R; María Botargues Bote, J; Mégraud, F; Milosavljevic, T; Modolell, I; Niv, Y; Nyssen, OP; O'Morain, C; Ortuño, J; Pérez Lasala, J; Pérez-Aisa, Á; Perona, M; Phull, P; Przytulski, K; Rodrigo-Sáez, L; Rokkas, T; Romero, PM; Shvets, O; Simsek, I; Tepes, B; Tonkic, A; Venerito, M; Voynovan, I | 1 |
| Avallone, L; Bazzoli, F; Compare, D; Dallio, M; Federico, A; Granata, L; Gravina, AG; Loguercio, C; Martorano, M; Miranda, A; Mucherino, C; Nardone, G; Priadko, K; Romano, L; Romano, M; Romiti, A; Romito, MR; Sgambato, D; Tuccillo, C; Zagari, RM | 1 |
| Chang, WL; Cheng, HC; Hsieh, MT; Kuo, HY; Lin, MY; Sheu, BS; Tsai, YC; Wu, CT; Yang, HB | 1 |
| Bordin, DS; Embutnieks, YV; Megraud, F; Nyssen, OP; O Morain, C; Perez-Gisbert, J; Voynovan, IN | 1 |
| Andreev, DN; Bektemirova, LG; Dicheva, DT; Lobanova, EG; Maev, IV; Veliev, AM; Zaborovskii, AV | 1 |
| Cheng, L; Feng, R; Ma, X; Su, Y; Wang, W; Xu, H; Yang, Y; Zhang, D | 1 |
| Antonelli, G; Borghi, C; Cavallo, R; Fiorini, G; Lazzarotto, T; Pavoni, M; Saccomanno, L; Saracino, IM; Vaira, D; Zullo, A | 1 |
| Chen, J; Chen, Q; Fang, HM; Huang, YT; Kan, LD; Li, LC; Qiu, Y; Yu, XL | 1 |
| Huang, Y; Lu, J; Lu, X; Miao, S; Sun, H; Wang, Y; Wu, J; Ye, Z; Zhou, Y | 1 |
| Alcaide, N; Barrio, J; Bujanda, L; Burgos, D; Caldas, M; Calvet, X; Castro, M; de la Coba, C; Di Maira, T; Dominguez-Cajal, M; Fernandez, N; Fernández-Salazar, L; Ferrer, L; Figuerola, A; Garre, A; Gisbert, JP; Gomez Rodriguez, BJ; Gomez, B; Gomez-Camarero, J; Hinojosa, J; Huguet, JM; Jimenez-Moreno, M; Lucendo, A; Mata Romero, P; Megraud, F; Modollel, I; Molina-Infante, J; Nyssen, OP; O'Morain, C; Ortuño, J; Perez-Aisa, A; Perona, M; Pozzati, L; Puig, I; Resina, E; Rodrigo, L; Tito, L; Varela, P | 1 |
| Calvo, PL; Cisarò, F; Pizzol, A | 1 |
| Bazzoli, F; Frazzoni, L; Fuccio, L; Marasco, G; Zagari, RM | 1 |
| Abbas, Z; Asim, M; Baqai, K; Laique, N; Samejo, SA | 1 |
| Chi, JS; Gong, RJ; Kun, KX; Li, H; Liu, P; Liu, XM; Tian, DL; Wu, H; Xia, XJ; Xie, XR; Xu, CX; Zhang, LF | 1 |
| Hu, JN; Ji, CR; Ji, R; Li, LX; Li, YQ; Li, YY; Lin, MJ; Liu, J; Qiao, C; Qu, JY; Zuo, XL | 1 |
| Chang, YL; Hsu, PI; Kim, SE; Liou, WS; Shiu, SI; Tu, YK; Tung, YC; Wu, MF; Yang, JC; Yeh, HZ | 1 |
| Furuta, T; Gisbert, JP; O'Connor, A; O'Morain, C | 1 |
| Hu, F; Liu, Y; Teng, G; Wang, H; Wang, W; Wu, T | 1 |
| Arslan, M; Balamtekin, N; Günal, A | 1 |
| Mukhopadhyay, AK; Nandi, SP; Saxena, A | 1 |
| Niu, Z; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
| Chen, Y; Ke, H; Li, J; Liu, L; Lu, B; Wang, J; Wang, Z; Yang, C | 1 |
| Cho, SJ; Choi, J; Chung, H; Chung, SJ; Kim, JL; Kim, SG; Lee, A | 1 |
| Brglez Jurecic, N; Espada Sanchez, M; Gisbert, J; Mégraud, F; O'Morain, C; Perez Nyssen, O; Tepes, B; Tepes, K | 1 |
| Ahn, JY; Choi, KD; Gong, EJ; Jung, HY; Jung, KW; Kim, DH; Lee, GH; Lee, JH; Na, HK; Pih, GY; Song, HJ | 1 |
| Areia, M; Castro-Fernandez, M; Fernanadez-Salazar, L; Fernandez-Bermejo, M; Gasbarrini, A; Gisbert, JP; Gomez-Rodriguez, BJ; Gravina, AG; Huguet, JM; Malfertheiner, P; Megraud, F; Nuñez, O; Nyssen, OP; O'Morain, C; Ortuñ, J; Pellicano, R; Perez-Aisa, A; Perona, M; Pinto, RM; Pozzati, L; Puig, I; Rodrigo, L; Romano, M; Vaira, D; Venerito, M | 1 |
| Mori, H; Suzuki, H | 1 |
| Coşkun Sökmen, F; Demirci, S; Kasapoğlu, B; Yozgat, A | 1 |
| Cao, NW; Chu, XJ; Guo, B; Li, BZ; Zhou, HY | 1 |
| Barcenilla Laguna, J; Bonoso Criado, R; Cabezudo Molleda, L; García Castro, MA; González de Castro, E; Maestro Antolín, S; Montero Moretón, Á; Moreira Da Silva, BA; Pérez Citores, L; Pérez Millán, AG; Santos Santamarta, F | 1 |
| Bozic, J; Bukic, J; Jukic, I; Leskur, D; Modun, D; Rusic, D; Seselja Perisin, A; Vukovic, J | 1 |
| Graham, DY; Howden, CW | 1 |
| Han, MH; Hwang, JY; Jeon, SW; Kim, C; Kwon, YH; Lee, JE; Nam, SY; Park, JH; Seo, AN | 1 |
| Barranco, R; Bautista-Villanueva, S; Galleani, C; García-Moguel, I; Herráez, L; Mielgo, R; Sotomayor-Contreras, JA | 1 |
| He, XJ; Jiang, CS; Li, DZ; Liu, G; Wang, W; Zeng, XP | 1 |
| Alsamman, MA; Argueta, EA; D'Agata, EMC; Moss, SF | 1 |
| Li, Q; Liu, H; Rao, W; Tian, QJ; Xie, M; Zang, YJ; Zhang, B; Zhang, Q | 1 |
| Jeon, JY; Kim, B; Kim, MG; Kim, SY; Lee, J; Moon, SJ; Oh, K; Song, GS | 1 |
| Chung, WC; Kim, DB; Kim, YJ | 1 |
| Chen, Y; Deng, X; Hou, X; Shi, Z; Ye, H; Yuan, H; Zhang, X | 1 |
| Choi, IJ; Kim, CG; Kim, YI; Lee, JY; Park, B; Park, JY | 1 |
| Hu, J; Ji, C; Ji, R; Li, Y; Lin, B; Lin, M; Liu, J; Qi, Q; Qiao, C; Qu, J; Wan, M; Zuo, X | 1 |
| Chen, H; Huang, K; Jin, D; Kong, S; Ye, F; Zhang, G | 1 |
| Chen, CC; Chiang, TH; Graham, DY; Lee, YC; Liou, JM; Shun, CT; Tseng, PH; Wu, MS | 1 |
| De Francesco, V; Fiorini, G; Gatta, L; Manta, R; Saracino, IM; Vaira, D; Zullo, A | 1 |
| Chang, EJ; Chang, YW; Jang, JY; Kim, JW; Moon, JC; Oh, CH; Shin, GY | 1 |
| Alekseenko, S; Areia, M; Barrio, J; Bordin, D; Bujanda, L; Buzas, GM; Caldas, M; Camarero, JG; Castro-Fernandez, M; Dekhnich, NN; Dominguez-Cajal, M; Fadeenko, G; Fernandez-Salazar, L; Georgopoulos, S; Gisbert, JP; Gomez Rodriguez, BJ; Heluwaert, F; Huguet, JM; Ilchishina, T; Jonaitis, L; Jurecic, NB; Kikec, Z; Kupcinskas, J; Lafuente, MR; Leja, M; Lerang, F; Lucendo, A; Machado, JC; Megraud, F; Modolell, I; Ntouli, V; Nuñez, O; Nyssen, OP; O'Morain, C; Ortuño, J; Pellicano, R; Perez-Aisa, A; Perez-Lasala, J; Perona, M; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Romero, PM; Shvets, O; Simsek, C; Simsek, I; Tepes, B; Tonkic, A; Venerito, M; Vologzhanina, L; Voynovan, I; Zaytsev, O | 1 |
| Huang, Y; Huang, Z; Shi, J; Tang, W; Wang, S; Wang, Y; Ye, Z; Zhang, P; Zheng, C; Zhou, Y | 1 |
| Argüelles Arias, F; Castro Laria, L; Caunedo Álvarez, Á; Fernández Álvarez, P; Gómez Rodríguez, BJ; Moreno Márquez, C; Valdés Delgado, T | 1 |
| Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS | 1 |
| Bontems, P; Cadranel, S; Kotilea, K; Mahler, T; Miendje Deyi, VY; Nguyen, J; Salame, A; Verset, L | 1 |
| Alaa Eddin, K; Alassi, MW; Alhalabi, M; Cheha, K | 1 |
| Huang, L; Lu, N; Ouyang, Y; Wu, WK; Xie, C; Zeng, C; Zhang, L; Zhu, Z | 1 |
| Cao, ZQ; Chen, DF; Chen, GX; Du, Q; Fan, YH; Gan, C; Huo, XH; Jin, HF; Li, TW; Li, Y; Lyu, B; Ma, PP; Meng, J; Meng, LN; Sha, WH; Shi, ZH; Tang, XF; Wang, MT; Yang, P; Zha, AS | 1 |
| Li, SZ; Niu, ZY; Shi, YY; Xue, Y | 1 |
| Hu, JN; Ji, CR; Li, LX; Li, YY; Lin, BS; Lin, MJ; Liu, J; Qiao, C; Wan, M; Wang, J; Zha, J; Zuo, XL | 1 |
| Xiao, S; Yao, X; Zhou, L | 1 |
| Boyle, B; Brennan, D; Buckley, M; Crotty, P; Doyle, M; Farrell, R; Hussey, M; Kevans, D; Malfertheiner, P; McNamara, D; Megraud, F; Nugent, S; O'Connor, A; O'Morain, C; Smith, S; Weston, S | 1 |
| Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP | 1 |
| Ding, Y; Fu, W; Song, Z; Suo, B; Tian, X; Wang, L; Xue, Y; Zhou, L | 1 |
| Abbasi, J | 1 |
| Chen, CY; Lyu, B; Wang, XT; Zhang, M | 1 |
| Akay, S; Akpinar, Z; Unsal, B | 1 |
| Ang, D; Ang, TL; Chew, CA; Lye, TF | 1 |
| Attaran, B; Graham, DY; Malekzadeh, R; Mohammadi, M | 1 |
| Davydkin, IL; Gricenko, TA; Osadchuk, AM | 1 |
| Gou, QY; Shi, RH; Yu, RB | 1 |
| Chen, A; Cheng, JS; Chuah, SK; Hsu, PI; Hsu, WH; Hu, HM; Kao, SS; Peng, NJ; Tsai, FW; Tsai, KW; Wang, YK; Wu, DC | 1 |
| Ang, TL; Aung, MM; Chakravuth, O; Chotivitayatarakorn, P; Fock, KM; Goh, KL; Graham, D; Harnsomburana, P; Kositchaiwat, C; Lee, YC; Leelakusolvong, S; Leow, A; Mahachai, V; Mairiang, P; Maneerattanaporn, M; Mya, SM; Pisespongsa, P; Pittayanon, R; Rani, A; Rasachak, B; Rojborwonwitaya, J; Sansak, I; Sollano, JD; Sugano, K; Syam, AF; Treeprasertsuk, S; Trong Quach, D; Vannarath, S; Vilaichone, RK; Wiwattanachang, O; Yamaoka, Y | 1 |
| Aguilera Castro, L; Albillos Martínez, A; Barreiro Alonso, E; de la Coba Ortiz, C; Ferre Aracil, C; Flores de Miguel, A; García García de Paredes, A; Jorge Turrión, MÃ; Marcos Prieto, HM; Martín de Argila de Prados, C; Pérez Álvarez, G; Rodríguez de Santiago, E; Rodríguez Escaja, C; Rodríguez Pérez, A | 1 |
| Chen, Y; Ke, L; Li, CJ; Liang, J; Ni, Z; Shang, L; Shi, YQ; Zhang, D; Zhang, LH; Zhu, SH | 1 |
| Andresen, V; Eisele, B; Frederking, D; Glocker, E; Günther, T; Miehlke, S; Morgner, A; Schröder, S | 1 |
| Gisbert, JP; Lamarque, D; O'Connor, A; O'Morain, C | 1 |
| Alvaro, D; Bellesia, A; Brambilla, G; Bresci, G; D'Angelo, A; De Francesco, V; Di Ciaula, A; Eramo, A; Londoni, C; Manta, R; Portincasa, P; Ridola, L; Sacco, R; Scaccianoce, G; Tanzilli, A; Vassallo, R; Zullo, A | 1 |
| Bellesia, A; De Francesco, V; Palma, R; Panetta, C; Pontone, S; Serviddio, G; Zullo, A | 1 |
| Fiorini, G; Gatta, L; Pavoni, M; Saracino, IM; Vaira, D; Zullo, A | 1 |
| Hong, JB; Lu, NH; Luo, LY; Shu, X; Xie, C; Xie, Y; Ye, JF; Zhu, Y; Zhu, ZH | 1 |
| Göktaş, Z; Kahramanoğlu Aksoy, E; Nazlıgül, Y; Pirinçci Sapmaz, F; Uzman, M | 1 |
| Bazzoli, F; Eusebi, LH; Rabitti, S; Zagari, RM | 1 |
| Abanades-Tercero, M; Andrés Esteban, EM; Blanco-González, JJ; Jordán-Castro, JA; Muñoz-Gómez, P; Valle-Muñoz, J | 1 |
| He, X; Li, H; Liao, X; Sun, H; Xia, W | 1 |
| De Francesco, V; Vaira, D; Zullo, A | 1 |
| Bishu, S; El-Zaatari, M; Grasberger, H; Kao, JY; Owyang, SY; Qian, JM; Tan, B; Yang, JC; Young, CL; Zhang, M | 1 |
| Morgando, A; Younes, R | 1 |
| Randel, A | 1 |
| Choe, JW; Hyun, JJ; Jung, SW; Jung, YK; Kim, SY; Koo, JS; Lee, SW; Yim, HJ | 1 |
| Coşkun, DÖ; Deniz, K; Gürsoy, Ş; Özbakir, Ö; Yagbasan, A; Yücesoy, M | 1 |
| Chan, EW; Chen, L; Cheung, KS; Graham, DY; Leung, WK; Wong, AYS; Wong, ICK; Wong, IOL; Yeung, KF | 1 |
| Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G | 1 |
| Graham, DY; Hsu, PI; Kao, JY; Kao, SS; Kuo, CH; Lin, TF; Peng, NJ; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC | 1 |
| Allegretta, L; Baldassarre, G; Brandimarte, G; Cassieri, C; De Bastiani, R; Di Mario, F; Elisei, W; Ferronato, A; Franceschi, M; Licci, C; Miraglia, C; Penna, A; Picchio, M; Pranzo, G; Rizzo, GL; Savarino, E; Scida, S; Tursi, A | 1 |
| Choi, YJ; Kang, JB; Kim, N; Kwon, S; Lee, DH; Park, YS; Shin, CM; Yoon, H | 1 |
| Chen, Q; Liang, X; Liu, W; Long, X; Lu, H; Yu, L | 1 |
| Bair, MJ; Chang, CY; Chen, CC; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; Fang, YJ; Hsu, WF; Hu, WH; Kuo, CC; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Twu, G; Wu, MS; Yang, TH; Yu, JJ | 1 |
| Chen, L; Chen, S; Chen, X; Chen, Y; Chu, H; Deng, Y; Ge, Q; He, H; He, J; Li, A; Long, Y; Wang, L | 1 |
| Baghbanian, M; Mirvakili, M; Salmanroghani, H; Salmanroghani, R; Sanati, G; Yazdian, P | 1 |
| Robotis, J; Rokkas, T; Tsiodras, S | 1 |
| Chen, CL; Hsu, PI; Kao, JY; Kao, SS; Pan, CY; Peng, NJ; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC | 1 |
| Gan, HY; Huang, YM; Peng, TL; Su, KH; Yang, RJ; Yao, LY; Zhao, LL | 1 |
| Chen, S; Liu, D; Lu, H; Lv, N; Wang, J; Xie, Y; Zeng, Z; Zhang, L; Zhang, Z; Zhu, Z | 1 |
| Bazzoli, F; Conigliaro, R; Eusebi, LH; Farinati, F; Grande, G; Gravina, AG; Ierardi, E; Maconi, G; Panarese, A; Romano, M; Romiti, A; Savarino, E; Stasi, E; Zagari, RM | 1 |
| Karakan, T; Yalinay, M; Yildiz, SS | 1 |
| Fischbach, W; Malfertheiner, P | 1 |
| Dore, MP; Graham, DY; Lu, H | 2 |
| Cai, T; Tang, D; Wang, F; Yao, Y; Yuan, L; Yue, C | 1 |
| Chen, PY; Kuo, YT; Liou, JM; Wu, MS | 1 |
| Azmi, AN; Goh, KL; Graham, DY; Leow, AH; Loke, MF; Vadivelu, J | 1 |
| Bastón-Rey, I; Calviño-Suárez, C; de la Iglesia-García, D; Domínguez-Muñoz, JE; Macías-García, F; Nieto-García, L | 1 |
| Cai, Y; Dai, N; Du, Q; Hu, WL; Kao, JY; Kim, JJ; Si, JM; Zhang, YW; Zheng, WF | 1 |
| Heo, JJ; Jung, K; Kim, JH; Kim, SE; Moon, W; Park, MI; Park, SJ; Roh, JH | 1 |
| Chung, WC; Kim, YJ; Ko, SW; Lee, SJ | 1 |
| Andreev, DN; Dicheva, DT; Maiev, IV; Partzvania-Vinogradova, EV; Yurenev, GL | 1 |
| Kim, JM; Kim, N; Lee, DH; Lee, JW; Lee, SM; Nam, RH; Soo In, C | 1 |
| Gao, CP; Han, SX; Wang, JX; Yang, X | 1 |
| Gisbert, JP; McNicholl, AG; Nyssen, OP | 1 |
| Chen, Y; Li, J; Liu, L; Lu, B; Wang, J | 1 |
| Fei, GJ; Guo, T; Li, JN; Li, XQ; Li, Y; Qian, JM; Shu, HJ; Wang, Q; Wu, X | 1 |
| Ji, C; Li, L; Li, Y; Liu, J; Sun, Y; Wang, T; Yang, X; Zuo, X | 1 |
| Alcedo, J; Alekseenko, S; Alonso-Galan, H; Barrio, J; Bordin, DS; Bujanda, L; Caldas, M; Coba, C; Dominguez-Jimenez, JL; Donday, MG; Fadeenko, G; Fernandez, MC; Gisbert, JP; Gonzalez-Cordero, PL; Hinojosa, J; Ilchishina, T; Lasala, JP; Lucendo, A; McNicholl, AG; Megraud, F; Modolell, I; Molina-Infante, J; Moreno, NF; Nuñez, O; Nyssen, OP; O'Morain, C; Perez-Aisa, Á; Ruiz-Zorrilla Lopez, R; Santaella, I; Sarsenbaeva, AS; Shvetz, O; Varela, P; Vologzhanina, L; Voynovan, I; Zakharova, NV; Zaytsev, O | 1 |
| Fallone, CA; Malfertheiner, P; Moss, SF | 1 |
| Chen, Q; Chen, Y; Gao, H; Graham, DY; Ji, Y; Li, D; Liang, X; Liu, M; Liu, W; Long, X; Lu, H; Song, Y; Sun, Y; Xu, B; Xu, G; Yu, L; Zhang, W; Zhao, Y | 1 |
| Bignon, E; Blin, P; Diquet, B; Droz-Perroteau, C; Guiard, E; Lassalle, R; Lelievre, B; Mégraud, F; Moore, N; Rouyer, M; Tison, F; Zerbib, F | 1 |
| Birkenfeld, S; Boltin, D; Dickman, R; Dotan, I; Gabay, H; Gingold-Belfer, R; Levi, Z; Niv, Y; Shochat, T | 1 |
| Graham, DY; Ji, Y; Liang, X; Long, X; Lu, H; Luo, L; Yu, L | 1 |
| Chen, Y; Gu, L; He, Y; Jiang, Y; Li, S; Liu, X; Peng, Y; Yang, H | 1 |
| He, C; Lu, N; Ouyang, Y; Peng, C; Shu, X; Wang, H; Zhu, Y; Zhu, Z | 1 |
| Acosta-Gonzales, G; Alsamman, MA; Moss, SF; Resnick, MB; Shawwa, K; Vecchio, EC | 1 |
| He, CX; Kong, FL; Kong, FT; Li, H; Liang, F; Liu, YL; Wang, KX; Zhao, W; Zhou, PP | 1 |
| Kılıç, ZMY; Özer Etik, D; Öztaş, E; Sezer, S; Suna, N | 1 |
| Graham, DY; Lu, H | 1 |
| Argueta, EA; Moss, SF | 1 |
| de Andrés, E; Gómez Hernando, C; Gómez Rodríguez, R; Muñoz Gómez, P; Sierra Bernal, C; Valle Muñoz, J | 1 |
| Fu, W; Song, Z; Zhou, L | 1 |
| Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M | 1 |
| Gholamrezaei, A; Hashemi, H; Khodadoostan, M; Minakari, M; Shavakhi, A; Shavakhi, S; Tabesh, E; Tabesh, F; Yaghoutkar, A | 1 |
| Andrews, PC; Busse, M; Ferrero, RL; Junk, PC; Trinh, I | 1 |
| Gisbert, JP; Marin, AC; McNicholl, AG | 1 |
| Graham, DY; Liang, X; Liao, J; Liu, W; Lu, H; Sun, Q; Xiao, S; Zhang, W; Zheng, Q | 1 |
| Graham, DY; Lee, YC; Wu, MS | 1 |
| Graham, DY; Lu, H; Zhang, W | 1 |
| Abbas, Z; Awan, S; Hamid, S; Jafri, F; Jafri, W; Naz, S; Usman, MW; Yakoob, J | 1 |
| Ecker, T; Krieger, T; Leandro, G; Malfertheiner, P; Venerito, M | 1 |
| Jang, JY; Jung, HK; Kim, CG; Kim, SG; Lee, H; Lee, HL; Lee, YC; Shin, ES; Shin, WG | 1 |
| Doğan, Z; Ergül, B; Filik, L; Sarikaya, M | 1 |
| Chen, A; Chen, WC; Hsu, PI; Kao, SS; Kuo, CH; Lai, KH; Peng, NJ; Shih, CA; Tsay, FW; Tseng, HH; Wang, HM; Wu, DC; Yu, HC | 1 |
| Ateş, Y; Avşar, E; Aytuğ, N; Bektaş, A; Bölükbaş, C; Dinçer, D; Ellidokuz, E; Erzin, Y; Güliter, S; Kaymakoğlu, S; Kocakaya, O; Onuk, MD; Poturoğlu, S; Taşan, G; Tiftikçi, A; Türkay, C; Yıldırım, B; Yılmaz, U | 1 |
| Bazzoli, F; Calvet, X; Fallone, C; Fischbach, L; Ford, AC; Forman, D; Gisbert, JP; Khan, KJ; Leontiadis, GI; Moayyedi, P; Oderda, G; Tse, F; Yuan, Y | 1 |
| Li, H; Sun, H; Xia, W | 1 |
| Graham, DY; Liou, JM; Wu, JY | 1 |
| Ang, TL; Song, M | 1 |
| Lee, SY | 1 |
| Chu, Y; Hu, F; Teng, G; Wang, S; Wang, W | 1 |
| Cheng, H; Gao, W; Hu, F; Zhang, X; Zhang, Y | 1 |
| Haider, RB; McNamara, D; O'Connor, H; O'Morain, C; Smith, SM | 1 |
| Chen, Y; Feng, W; Li, Q; Takase, M; Wu, X; Yang, L; Zhang, M; Zhao, T; Zhou, Z; Zhu, Y | 1 |
| Heo, J; Jeon, SW | 1 |
| Jo, HJ; Kim, N; Lee, DH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, IS | 1 |
| Aisa, AP; Barrio, J; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Gisbert, JL; Gisbert, JP; Marcos, S; Marín, AC; McNicholl, AG; Modolell, I; Molina-Infante, J; Rodrigo, L | 1 |
| Malfertheiner, P; Selgrad, M | 1 |
| Lv, ZF; Wang, B; Wang, H; Wang, YH; Xie, Y; Xiong, HF; Yang, Y | 1 |
| Mahachai, V; Siramolpiwat, S; Srinarong, C; Vilaichone, RK; Wongcha-um, A | 1 |
| Algaba, A; Angueira, T; Barrio, J; Bermejo, F; Castro-Fernández, M; Del Castillo, F; Domínguez, JL; Federico, A; Fernández-Salazar, L; Gisbert, JP; Gómez, B; Gómez, J; Gravina, AG; Herranz, M; Lucendo, AJ; Marín, AC; Martorano, M; McNicholl, AG; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Pabón, M; Romano, M; Solís-Muñoz, P; Velayos, B | 1 |
| Cellini, L; Ciccaglione, AF; Grossi, L; Manzoli, L; Marzio, L | 1 |
| Cao, Z; Chen, Q; Liang, X; Liao, J; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Aktaş, B; Başyiğit, S; Kefeli, A; Nazlıgül, Y; Uzman, M; Yeniova, AÖ | 1 |
| Mahachai, V; Prapitpaiboon, H; Vilaichone, RK | 1 |
| Bair, MJ; Hsu, PI; Hsu, WH; Hu, CT; Hu, HM; Jheng, GH; Kuo, CH; Kuo, FC; Liu, CJ; Shih, HY; Wu, DC; Wu, IC; Wu, MC | 1 |
| Ahishali, E; Akkus, EE; Dabak, R; Dolapcioglu, C; Dolapcioglu, H; Kural, A; Sayiner, M | 1 |
| Bai, P; He, L; Li, Y; Lin, S; Qian, J; Song, Z; Wang, Y; Xue, Y; Zhang, J; Zhou, L | 1 |
| Ataseven, H; Baglıcakoglu, M; Biyik, M; Demir, A; Goktepe, H; Gungor, G; Kayacetin, E; Ucar, R | 1 |
| Gokcan, H; Onal, IK; Oztas, E | 1 |
| Annibale, B; Calabrese, C; Caselli, M; Di Mario, F; Farinati, F; Gasbarrini, G; Gullini, S; Ierardi, E; Luzza, F; Maconi, G; Ojetti, V; Pretolani, S; Romano, M; Rugge, M; Savio, A; Stockbrugger, R; Zagari, RM | 1 |
| Akhtar, N; Asif, HM; Sugiyama, T; Usmanghani, K; Zaidi, SF | 1 |
| Molina-Infante, J; Shiotani, A | 1 |
| Graham, DY; Lee, SY | 1 |
| Chaithongrat, S; Gamnarai, P; Mahachai, V; Namtanee, J; Prapitpaiboon, H; Vilaichone, RK; Wongcha-um, A | 1 |
| Chen, Q; Graham, DY; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Andrews, PC; Blair, VL; Ferrero, RL; Junk, PC; Pathak, A; Tabor, RF | 1 |
| Birk, JW; Senatore, FJ; Wilmot, J | 1 |
| Jang, BI; Kim, KO; Kim, SB; Kim, TN; Lee, SH | 1 |
| Asilturk, Z; Basyigit, S; Hokkaomeroglu, M; Kefeli, A; Nazligul, Y; Sapmaz, F; Uzman, M; Yeniova, AO | 1 |
| Cellini, L; Ciccaglione, AF; Grossi, L; Manzoli, L; Marzio, L; Tavani, R | 1 |
| Bai, P; He, L; Song, Z; Xue, Y; Zhang, J; Zhou, L | 1 |
| Hwang, JC; Kang, JK; Kim, JH; Kim, SS; Lee, KM; Lim, SG; Park, RW; Shin, SJ; Yoon, D | 1 |
| An, HJ; Chen, Y; Cheng, H; Cui, M; Dong, L; Gao, H; Gao, W; Gong, J; Hu, F; Jiang, B; Jiang, K; Li, J; Li, Y; Liang, H; Meng, F; Sheng, J; Wang, B; Wang, H; Wei, H; Yang, L; Yang, Y; Zhang, G; Zhang, S; Zhao, P; Zhao, Y; Zuo, X | 1 |
| Arnold, CA; Coss, E; Cryer, B; Doern, CD; Dunbar, KB; Lam-Himlin, DM; Mitui, M; Okwara, C; Park, JY; Thung, I; Valasek, MA | 1 |
| Song, Z; Suo, B; Zhang, L; Zhou, L | 1 |
| Dore, MP; Graham, DY | 1 |
| Chiba, N; Fallone, CA; Fischbach, L; Gisbert, JP; Hunt, RH; Jones, NL; Leontiadis, GI; Marshall, JK; Moayyedi, P; Render, C; van Zanten, SV | 1 |
| Oberhofer, E | 1 |
| Marcus, EA; Sachs, G; Scott, DR | 1 |
| Amador, J; Bermejo, F; Bujanda, L; Calvet, X; Castro-Fernández, M; Cuadrado-Lavín, A; Elizalde, JI; Gene, E; Gisbert, JP; Gomollón, F; Lanas, Á; Martín de Argila, C; McNicholl, AG; Mearin, F; Molina-Infante, J; Montoro, M; Pérez-Aisa, Á; Pérez-Trallero, E | 1 |
| Amorena, E; Campillo, A; Kutz, M; La Iglesia, M; Ostiz, M | 1 |
| Fallone, CA; Shaikh, T | 1 |
| Baik, GH; Choi, SC; Hong, SJ; Jo, Y; Kim, GH; Kim, HJ; Kim, N; Kim, SE; Kim, WH; Lee, BE; Lee, JY; Oh, JH; Park, KS; Park, SM; Park, SY; Shim, KN | 1 |
| Bennison, J; Govan, L; Harbour, R; Manson, J; Watson, E; Wu, O; Xin, Y | 1 |
| Chen, Q; Fu, Q; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Atherton, J; Axon, AT; Bazzoli, F; El-Omar, EM; Gasbarrini, A; Gisbert, JP; Graham, DY; Hunt, R; Kuipers, EJ; Malfertheiner, P; Megraud, F; Moayyedi, P; O'Morain, CA; Rokkas, T; Rugge, M; Selgrad, M; Suerbaum, S; Sugano, K | 1 |
| Lin, JT; Liou, JM; Wu, MS | 1 |
| Chey, WD; Howden, CW; Leontiadis, GI; Moss, SF | 1 |
| Baldassarre, G; Boscariolo, L; De Bastiani, R; De Polo, M; Di Mario, F; Elisei, W; Ferronato, A; Franceschi, M; Grillo, S; Landi, S; Picchio, M; Tursi, A; Zamparella, M | 1 |
| Chen, H; Hao, B; Su, J; Zhang, G; Zhang, W; Zhou, X | 1 |
| Jung, K; Kim, HK; Kim, JH; Kim, SE; Lee, YD; Moon, W; Park, MI; Park, SJ | 1 |
| Ford, AC; Giguere, M; Khan, M; Malfertheiner, P; Moayyedi, P; Santana, J | 1 |
| Ran, ZH; Shen, J; Tong, JL; Xiao, SD | 1 |
| Cheng, H; Hu, FL | 1 |
| Akay, S; Akyildiz, M; Aydin, A; Musoglu, A; Tuncyurek, M | 1 |
| Balkarli, A; Baştürk, A; Cerçi, S; Senol, A; Songür, Y | 1 |
| Derakhshan, F; Haghazali, M; Mirsattari, D; Mohsenian, N; Molaei, M; Talaie, R; Zali, MR; Zojaji, H | 1 |
| Kandulski, A; Malfertheiner, P; Selgrad, M | 1 |
| O'Connor, HJ; O'Morain, CA; Qasim, A; Saleem, A | 1 |
| Chey, WD; Higgins, PD; Luther, J; Moayyedi, P; Schoenfeld, PS; Vakil, N | 1 |
| Amini, M; Tajik, A | 1 |
| Demir, M; Gokturk, HS; Ozturk, NA; Serin, E; Yilmaz, U | 1 |
| Vakil, N | 2 |
| Choe, YH; Chung, IS; Kim, HS; Kim, JI; Kim, JJ; Kim, N | 1 |
| Cheung, DY; Jung, HC; Jung, HY; Jung, SW; Song, HJ | 1 |
| Gökçe, S | 1 |
| Classen, M; Liu, W; Ma, J; Pan, K; Winawer, S; You, W; Zauber, A; Zhang, L; Zhao, H; Zhou, T | 1 |
| Andrews, PC; Ferrero, RL; Junk, PC; Kumar, I; Luu, Q; Nguyen, K; Taylor, JW | 1 |
| Baryshnikova, NV; Tkachenko, EI; Uspenskiĭ, IuP | 1 |
| BOBRANSKI, B; JANKOWSKI, J; WIERZCHOWSKI, J | 1 |
| Hwang, JH; Hwang, TJ; Jeong, SH; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Park, YS; Song, IS | 1 |
| Hibi, T; Nishizawa, T; Suzuki, H | 1 |
| Demir, M; Göktürk, S; Oztürk, NA; Serin, E; Yilmaz, U | 1 |
| Ceroni, L; Eusebi, LH; Fuccio, L; Kurelac, I; Laterza, L | 1 |
| Cai, M; Chen, Z; Hu, B; Huang, X; Huang, Y; Jiang, Y; Lin, H; Lu, L; Qu, X; Rong, L; Sun, D; Sun, X; Wu, L; Xiong, P; Yan, W; Zhong, L; Zhu, C | 1 |
| Kamysz, W; Kozlowski, H; Rowinska-Zyrek, M; Valensin, D; Witkowska, D | 1 |
| Huang, X; Li, Y; Shi, R; Yao, L; Zhang, G | 1 |
| Gao, XZ; Liu, F; Qiao, XL; Song, WC; Wang, XF | 1 |
| Chey, WD; Malfertheiner, P; Vakil, N | 1 |
| Malfertheiner, P | 4 |
| Gisbert, JP; McNamara, D; O'Connor, A; O'Morain, C | 1 |
| Fischbach, LA; Graham, DY | 1 |
| Chen, X; Li, MY; Liu, J; Wang, ZQ; Wu, C; Zhang, ZQ | 1 |
| Bytzer, P; Dahlerup, JF; Eriksen, JR; Jarbøl, DE; Rosenstock, S; Wildt, S | 1 |
| Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A | 1 |
| Gao, W; Hu, FL; Wang, XM | 1 |
| Gisbert, JP | 1 |
| Astegiano, M; Cisarò, F; De Angelis, C; Pellicano, R; Rizzetto, M; Saracco, G | 1 |
| Li, CJ; Xu, MH; Zhang, GY | 1 |
| Choi, KD; Chung, JW; Jung, HY; Kim, JH; Lee, GH; Lee, JH; Oh, TH; Song, HJ; Yun, SC | 1 |
| Cuccu, M; Dore, MP; Farina, V; Graham, DY; Mameli, L; Massarelli, G | 1 |
| Chen, Z; Ge, R; Zhou, Q | 2 |
| Choi, JH; Hyun, JJ; Jung, SW; Kim, JH; Kim, SY; Koo, JS; Kwon, BS; Lee, SK; Lee, SW; Park, JY; Yim, HJ | 1 |
| Chuah, SK; Hsu, PI; Tsay, FW; Wu, DC | 1 |
| Bari, Z; Fakheri, H; Hosseini, V; Taghvaei, T | 1 |
| Anania, C; Chiesa, C; Olivero, E; Osborn, JF; Pacifico, L; Vaira, D | 1 |
| Inoue, H; Inoue, T; Maruoka, Y; Nakajima, S | 1 |
| Başer, O; Emer, O; Kadayifci, A; Kantarcioğlu, M; Kılcıler, G; Ozcan, A; Polat, Z; Uygun, A | 1 |
| Bari, Z; Fakheri, H; Sardarian, H | 1 |
| Agah, S; Ekhlasi, G; Ghourchian, S; Salehpour, A; Shidfar, F | 1 |
| Agarwal, A; Agrawal, GP; Agrawal, H; Jain, AK | 1 |
| Andrews, PC; Busse, M; Deacon, GB; Ferrero, RL; Junk, PC; MacLellan, JG; Vom, A | 1 |
| Buzás, GM | 1 |
| Cardenas, VM; Dominguez, DC; Graham, DY; Reddy, RK; Salazar, CO; Snyder, LK | 1 |
| Liang, X; Liu, W; Lu, H; Sun, Q; Xiao, S; Xu, X; Zhang, W; Zheng, Q | 1 |
| Wang, Y; Yu, Z; Zhang, S | 1 |
| Ammon, S; Klotz, U; Malfertheiner, P; Treiber, G | 1 |
| Bermejo, F; Boixeda, D; Defarges, V; García-Plaza, A; Hernández-Ranz, F; López-Sanromán, A; Martín-De-Argila, C; Milicua, JM | 1 |
| Cuena Boy, R | 1 |
| Michetti, P; Suerbaum, S | 1 |
| Coyle, W; Dunteman, T; Nemec, R; Sullivan, B | 1 |
| Bago, J; Bevanda, M; Bilić, A; Halle, ZB; Jandrić, D; Kućisec, N; Strinić, D; Tomić, M | 1 |
| Chan, CK; Fung, FM; Ho, VY; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, GS; Wong, WM; Xia, HH; Yip, AW; Yuen, MF | 1 |
| Kullavanijaya, P; Tangkijvanich, P; Thong-Ngam, D; Treeprasertsuk, S; Wisedopas, N | 1 |
| Farup, PG; Høie, O; Lange, OJ; Tholfsen, J; Torp, R; Wetternus, S | 1 |
| Berstad, A; Hatlebakk, JG; Olafsson, S | 1 |
| Hopkins, RJ; Meyer, JM | 1 |
| Borody, T; Dallaire, C; De Boer, WA; Fallone, CA; Farley, A; Mégraud, F; O'Morain, C; Piotrowski, J; Schuman, R; Spénard, J; Tytgat, G | 1 |
| Chehter, EZ; Eisig, JN; Hashimoto, C; Laudanna, AA; Silva, FM | 1 |
| Azagra, R; Calvet, X; Gené, E; Gisbert, JP | 1 |
| Nurbaev, FE; Orziev, ZM; Rakhimova, GSh | 1 |
| Laine, L | 2 |
| Correa, P; Feldman, M; Fischbach, LA; Fontham, E; Goodman, KJ; Jain, R; Priest, E | 1 |
| Dore, MP; Graham, DY; Manca, A; Maragkoudakis, E; Marras, L; Nieddu, S; Realdi, G | 1 |
| Bästlein, E; Bayerdörffer, E; Haferland, C; Jacobs, E; Kirsch, C; Lehn, N; Miehlke, S; Neumeyer, M; Papke, J; Schneider-Brachert, W; Stolte, M; Vieth, M | 1 |
| de Boer, SY; de Boer, WA; Siem, H; v d Meeberg, PC | 1 |
| Cammarota, G; Candelli, M; Carloni, E; Cazzato, IA; Cremonini, F; Di Caro, S; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Santarelli, L; Zocco, MA | 1 |
| Cisneros, G; Gurney, M; Jarjoura, D; Lara, LF; Moauro, B; Polen, A; Rutecki, G; Van Ness, M; Whittier, F | 1 |
| Barkun, A; Chiba, N; Cockeram, A; Dallaire, C; Fallone, C; Farley, A; Nicholls, B; Simms, L; Veldhuyzen van Zanten, S | 1 |
| Andriulli, A; Barberani, F; Festa, V; Merla, A; Perri, F; Pilotto, A | 1 |
| Balatsinou, C; Caldarella, MP; Cuccurullo, F; Di Bonaventura, G; Lapenna, D; Laterza, F; Milano, A; Neri, M; Piccolomini, R | 1 |
| Bianchi Porro, G; Cucino, C; Parente, F | 1 |
| Candelli, M; Franceschi, F; Gasbarrini, G; Mettimano, M; Migneco, A; Montebelli, R; Ojetti, V; Savi, L; Specchia, L | 1 |
| Berge, T; Berstad, A; Henriksen, TH; Lerang, F; Lia, A; Ragnhildstveit, E; Schøyen, R; Thoresen, T; Tveten, Y | 1 |
| de Boer, WA; Kuipers, EJ; Kusters, JG | 1 |
| Abudayyeh, S; Belson, G; Dore, MP; El-Zimaity, HM; Graham, DY; Osato, MS | 1 |
| Altintaş, E; Aydin, O; Camdeviren, H; Sezgin, O; Ulu, O | 1 |
| Calvet, X; Gené, E; Güell, M; Montserrat, A; Vergara, M | 1 |
| Choi, JH; Choung, RS; Chun, HJ; Han, WS; Hyun, JH; Jeen, YT; Jung, SW; Keum, B; Kim, CD; Kim, YS; Lee, HS; Lee, SW; Park, SC; Ryu, HS; Um, SH | 1 |
| de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ | 1 |
| Dickason, J; Fischbach, LA; van Zanten, S | 1 |
| De Francesco, V; Gatta, L; Hassan, C; Ierardi, E; Morini, S; Panella, C; Vaira, D; Zullo, A | 1 |
| Candelli, M; Carloni, E; Cazzato, A; Di Campli, C; Fini, L; Gasbarrini, A; Gasbarrini, G; Nista, EC; Pignataro, G; Zocco, MA | 1 |
| Cheon, JH; Hwang, JH; Jung, HC; Kim, JM; Kim, JW; Kim, N; Lee, DH; Park, YS; Song, IS; Suh, SO | 1 |
| Filik, L; Köksal, AS; Odemiş, B; Ozden, A; Parlak, E; Sahin, B; Saşmaz, N; Ulker, A; Yolcu, OF | 1 |
| Shao, Y; Wang, YS; Yang, H; Yu, ZL; Zhang, L; Zhang, ST | 1 |
| Calvet, X; Carpio, D; Fuentes, J; Gisbert, JP; Guardiola, J; Olivares, D; Tito, L; Tomas, A | 1 |
| Huang, JQ; Hunt, RH; Karlberg, J; Lam, SK; Wong, BC; Wong, WM; Zheng, GF | 1 |
| Calvet, X; Gisbert, JP; Gonzalez, L | 1 |
| Shao, Y; Yu, ZL; Zhang, L; Zhang, ST | 1 |
| Almeida, JR; Campos, LT; Guerrazzi, F; Lorena, SL; Mesquita, MA; Montes, CG; Zeitune, JM | 1 |
| Aeed, H; Avni, Y; Birkenfeld, S; Eliakim, R; Levine, A; Shabat-Sehayek, V; Shevah, O; Shirin, H; Wardi, J | 1 |
| Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Lee, JH; Park, MJ; Song, IS | 1 |
| Gisbert, JP; Pajares, JM | 2 |
| Aumais, C; Brunet, JS; Grace, M; Lefebvre, M; Massicotte, J; Spénard, J; Tremblay, C | 1 |
| Pan, Y; Xiao, SD; Zhang, L; Zheng, Q | 1 |
| Borody, TJ | 2 |
| Fukuda, Y; Sakagami, T | 1 |
| Bray, R; Hiratsuka, H; Hiratsuka, T; Kimura, K; Suzuki, T; Tamura, K | 1 |
| Gisbert, JP; Morena, F | 1 |
| Azuma, T; Ishibashi, M; Migita, K; Mikata, Y; Miyoshi, Y; Murafuji, T; Rahman, AF; Sugihara, Y | 1 |
| Donovan, JL; Egger, M; Harvey, IM; Harvey, RF; Lane, JA; Murray, LJ; Nair, P; Noble, S | 1 |
| Benito, LM; Bermejo, F; Bory, F; Castro-Fernández, M; Cosme, A; Ducons, J; Fernández-Bermejo, M; Gisbert, JP; Lamas, E; López-Rivas, L; Olivares, D; Pabón, M; Pérez-Aisa, A | 1 |
| Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P | 1 |
| Akarca, US; Aydin, A; Musoğlu, A; Onder, GF; Tekin, F; Tunçyürek, M | 1 |
| Kerton, A; Warden, P | 1 |
| Lule, GN | 1 |
| Lee, KH; Tam, YH; Yeung, CK | 1 |
| Altintaş, E; Sezgin, O; Tataroğlu, C; Uçbilek, E | 1 |
| Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Kim, SG; Lee, DH; Song, IS | 1 |
| Pistiolas, D; Robotis, J; Rokkas, T; Sechopoulos, P | 1 |
| Hausinger, RP; Ko, BB; Leung, AF; Mulrooney, SB; Sun, H; Zeng, Y; Zhang, L | 1 |
| Buzás, GM; Józan, J | 2 |
| Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR | 1 |
| Bair, MJ; Chang, WH; Ke, HL; Kuo, FC; Lu, CY; Wang, SW; Wang, TE; Wang, YY; Wu, DC; Wu, IC; Yuan, SS | 1 |
| Choe, YH; Choi, J; Jang, JY; Kim, JS; Kim, KM; Park, HY | 1 |
| Gisbert, JL; Gisbert, JP; Marcos, S; Moreno-Otero, R; Pajares, JM | 1 |
| Arvanitakis, SN; Ashorn, M; Bontems, P; Cadranel, S; Canani, RB; Casswall, T; Celinska-Cedro, D; De Giacomo, C; Drumm, B; Gandullia, P; Gómez, MJ; Gottrand, F; Kalach, N; Oderda, G; Pehlivanoglu, E; Ravelli, A; Roggero, P; Roma, E; Romano, C; Rutigliano, V; Shcherbakov, P; Urruzuno, P | 1 |
| Aiello, F; Brandimarte, G; Elisei, W; Giorgetti, GM; Modeo, ME; Tursi, A | 1 |
| Kadayifçi, A | 1 |
| Fernández-Bermejo, M; Gisbert, JP; González-García, G; Mateos-Rodríguez, JM; Molina-Infante, J; Pérez-Gallardo, B; Prieto-Bermejo, AB; Robledo-Andrés, P | 1 |
| Mahachai, V; Thong-Ngam, D | 1 |
| Bagci, S; Ilgan, S; Kadayifci, A; Safali, M; Uygun, A | 1 |
| Bravo, JC; Bravo, LE; Camargo, MC; Ceron, C; Correa, P; Delgado, AG; Fontham, ET; Mera, RM; Piazuelo, MB; Yepez, MC | 1 |
| Buzás, GM; Széles, I | 1 |
| Cun, S; Ge, R; Li, H; Lin, MC; Sun, H | 1 |
| Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B | 1 |
| Baker, DE | 1 |
| Anver, MR; Battles, JK; Blumenauer, LL; Gonda, MA; Gorelick, PL; Haines, DC; Russell, RJ; Ward, JM | 1 |
| Alvarez Baleriola, I; Boixeda, D; de Rafael, L; Gisbert, JP; Martín de Argila, C; Vila, T | 1 |
| Alvarez Baleriola, I; Bermejo, F; Boixeda, D; de Rafael, L; García Plaza, A; Gisbert, JP; Martín de Argila, C | 1 |
| Becker, T; Börsch, G; Köhl, H; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B | 1 |
| Dettmer, A; Domschke, W; Fenner, T; Gregor, M; Hesse, P; Holtmann, G; Miederer, SE; Schentke, KU; Schütz, E; van Husen, N | 1 |
| Wilson, WH | 1 |
| Jablonská, M | 1 |
| Contreras, L; Giglio, M; Hoffenberg, P; Ossa, P; Reyes, V; Weitz, JC | 1 |
| Folwaczny, C | 1 |
| Foltz, CJ; Fox, JG; Shames, B; Yan, L | 2 |
| Kim, EC; Seo, JK; Sim, JG | 1 |
| Forman, D; Harwood, D; Logan, RP; Milne, R; Misiewicz, JJ | 1 |
| Bour, LJ; Eekhof, JL; Noach, LA; Ongerboer de Visser, BW; Posthumus Meyjes, FE; Tytgat, GN | 1 |
| Talley, NJ | 3 |
| Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Nesje, LB; Wilhelmsen, I | 1 |
| Golochevskaia, VS; Grebenev, AL; Lapina, TL; Miagkova, LP; Sklianskaia, OA | 1 |
| Appelman, HD; Barnett, JL; Behler, EM; Crause, I; Elta, GH; Nostrant, TT; Scheiman, JM | 1 |
| Asnicar, MA; Chong, SK; Croffie, JM; Fitzgerald, JF; Lee, CH; Lou, Q; Zimmerman, SE | 1 |
| de Boer, WA; Tytgat, GN | 2 |
| Fennerty, MB | 2 |
| Beattie, S; Gilvarry, J; Hamilton, H; Keane, CT; O'Morain, CA; Sweeney, EC; Xia, HX | 1 |
| Ciociola, AA; Goodwin, BB; Perschy, TB; Webb, DD | 1 |
| Blecker, U; Hart, J; Kirschner, BS; McKeithan, TW | 1 |
| Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S | 1 |
| Cheng, AF; Chung, SC; Leung, VK; Li, AK; Ling, TK; Suen, R; Sung, JJ | 1 |
| Peterson, WL; Walsh, JH | 1 |
| de Graaf, B; Thijs, JC; van Zwet, AA | 1 |
| Barnes, J | 1 |
| Börsch, G; Labenz, J | 3 |
| Coll, I; Espinós, JC; Forné, M; Garau, J; Tresserra, F; Viver, JM | 1 |
| O'Connor, HJ | 2 |
| Cohen, MH | 1 |
| Clyne, M; Daly, LE; Drumm, B; Durnin, MT; Gormally, SM; Kierce, BM; Prakash, N | 1 |
| Müller, P; Simon, B | 2 |
| Burette, A; Glupczynski, Y | 2 |
| Bajador, E; Gomollón, F | 1 |
| Klotz, O; Treiber, G | 1 |
| Coudron, PE; Stratton, CW | 2 |
| Harvey, I; Murray, L | 1 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
| de Boer, WA; Driessen, WM | 1 |
| Berstad, A; Wilhelmsen, I | 1 |
| Rune, SJ | 1 |
| Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K | 1 |
| al-Assi, MT; Cole, RA; Genta, RM; Graham, DY; Karttunen, TJ | 1 |
| Giannikos, N; Kalogeropoulos, N; Karameris, A; Mavrogeorgis, A; Papatheodorou, G; Rokkas, T | 1 |
| Berndt, H | 1 |
| Banerjee, S; el-Omar, E; McColl, KE | 1 |
| Dhillon, AP; Fraser, AG; Pounder, RE; Sankey, EA; Sim, R | 1 |
| Marshall, BJ | 3 |
| Bertrams, J; Börsch, G; Labenz, J; Rühl, GH | 1 |
| Noach, LA; Reijers, MH; Tytgat, GN | 1 |
| Lee, WY; Lin, JT; Wang, JT; Wang, TH; Wu, MS; Yang, JC | 1 |
| Asaka, M; Horita, S; Inoue, K; Kato, M; Kimura, T; Kudo, M; Meguro, T; Ohtaki, T | 1 |
| Lamouliatte, H | 1 |
| Gad, A; Unge, P | 1 |
| Schütz, E; Stolte, M | 1 |
| Andersen, L; Krasilnikoff, PA; Wewer, V | 1 |
| Bang, CJ; Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Hjartholm, AS; Hundal, O; Nesje, LB; Nysaeter, G; Wilhelmsen, I | 1 |
| de Boer, WA; Driessen, WM; Potters, VP; Tytgat, GN | 1 |
| Azian, M; Chuah, SY; Goh, KL; Lo, YL; Ong, KK; Parasakthi, N; Peh, SC; Wong, NW | 1 |
| Hentschel, E | 1 |
| Cuccurullo, F; Di Iorio, P; Laterza, F; Mezzetti, A; Neri, M; Seccia, G; Susi, D | 1 |
| Campbell, DR; Cherian, R; McGregor, DH; Weston, AP | 1 |
| Berstad, A; Berstad, K; Sjödahl, R | 1 |
| Dent, J; Eyre-Brook, IA; Lobo, AJ; McNulty, CA; Uff, JS; Wilkinson, SP | 1 |
| al-Assi, MT; Genta, RM; Graham, DY | 1 |
| Graham, DY; Peura, DA | 1 |
| al-Assi, MT; Genta, RM; Graham, DY; Lew, GM; Ramirez, FC | 1 |
| Bleck, J; Gebel, M; Gladziwa, U; Haruma, K; Manns, M; Schmidt, H; Soudah, B; Wagner, S | 1 |
| Boixeda, D | 1 |
| Martínez, MJ | 1 |
| Corinaldesi, R; De Giorgio, R; Gasperoni, S; Paparo, GF; Poli, L; Stanghellini, V; Tucci, A; Varoli, O | 1 |
| Reilly, TG; Walt, RP | 1 |
| Chang, FY; Chen, TS; Lee, SD; Tsay, SH | 1 |
| Berman, D; George, J; Groisman, GM; Harpaz, N | 1 |
| McGuffey, EC | 1 |
| Correa, P; Fontham, ET; Hunter, FM; Johnson, WD; Malcom, GT; Rood, JC; Ruiz, B; Sobhan, M | 1 |
| Beglinger, C | 1 |
| Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I | 1 |
| Berstad, A; Berstad, K | 1 |
| Brazer, SR; Maniatis, AG | 1 |
| Genta, RM; Go, MF; Graham, DY; Lew, GM; Rehfeld, JF | 1 |
| Graham, DY; Hazell, SL; Lichtenberger, LM; Ottlecz, A; Romero, JJ | 1 |
| Correa, P; Fontham, E; Hunter, FM; Ruiz, B; Samloff, IM; Sobhan, M | 1 |
| Hammar, CH; Jaspersen, D | 1 |
| Aoyama, N; Morimoto, S; Nakashima, T; Ohmoto, A | 1 |
| Kihira, K; Kimura, K; Sato, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
| Graham, DY; Hepps, KS; Lew, GM; Ramirez, FC; Saeed, ZA | 1 |
| Gottrand, F; Husson, MO; Leclerc, H; Turck, D | 1 |
| Nasu, M | 1 |
| Hassall, E; Israel, DM | 1 |
| Börsch, G; Gyenes, E; Labenz, J; Rühl, GH | 2 |
| Andrews, P; Borody, TJ; Carroll, M; Ferch, N; Jankiewicz, E | 1 |
| Calam, J; Moss, SF | 1 |
| Cohen, H; Dooley, CP; Field, LG; Frierson, HF; Guerrant, RL; Jerdack, GR; Marshall, BJ; McCallum, RW; Mitra, S; Valenzuela, JE | 1 |
| Asaka, M; Inoue, K; Kato, M; Kimura, T; Kudo, M; Meguro, T; Miyazaki, T | 1 |
| Fedotin, MS | 1 |
| Cutler, AF; Schubert, TT | 2 |
| Campbell, CJ; Clayton, NM; Clitherow, JW; Grinham, CJ; McColm, AA; McLaren, A; Stables, R; Trevethick, MA | 1 |
| Axon, AT | 2 |
| Della Casa, G; Di Gregorio, C; Ferrari, AM; Frazzoni, M; Grisendi, A; Lonardo, A; Melini, L; Pulvirenti, M | 1 |
| Aimo, G; Bonesi, R; Pistoso, S; Piubello, W; Raggi, G; Soldinger, E; Superti, G; Vitali, E | 1 |
| Bagshaw, JA; McColm, AA; O'Malley, CF | 1 |
| Kanayama, S; Matsuzawa, Y; Nakanishi, T; Shinomura, Y | 1 |
| Genta, RM; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Ramirez, FC | 1 |
| Glassman, MS; Halata, MS; Rosioru, C; Schwarz, SM | 1 |
| Jaskiewicz, K; Louw, JA; Marks, IN | 1 |
| Ramírez Ramos, A | 1 |
| Boixeda, D; Gisbert, JP; Martín de Argila, C; Monés, J; Mur Villacampa, M; Sáinz Samitier, R | 1 |
| Boixeda, D; Gisbert, JP; Hernández Ranz, F; Martín de Argila, C | 1 |
| Harris, AW; Misiewicz, JJ | 1 |
| Karita, M; Nakazawa, T; Okita, K; Sugiyama, T; Tsuda, M | 1 |
| Bardhan, KD; Dekkers, CP; Forster, JK; Kler, L; Lacey, LF; Lam, SK; Nowak, A; Schaffalitzky de Muckadell, OB; Schutze, K; Tildesley, G | 1 |
| Bästlein, E; Bayerdörffer, E; Heldwein, W; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Müller-Lissner, S; Sommer, A; Weingart, J | 1 |
| Soll, AH | 1 |
| Fennerty, MB; Vakil, N | 1 |
| Treiber, G | 1 |
| Davis, S | 1 |
| Bang, CJ; Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Hundal, O; Nesje, LB; Nysaeter, G; Olafsson, S; Tefera, S | 1 |
| Laine, LA | 1 |
| Alvarez Baleriola, I; Boixeda, D; de Rafael, L; García Plaza, A; García, M; Gisbert, JP; Martín de Argila, C | 1 |
| Acuña, R; Albornoz, V; Figueroa, G; Portell, DP; Toledo, MS; Troncoso, M; Vigneaux, J | 1 |
| Alkan, S; Cohen, P; Karcher, DS; Newman, MA | 1 |
| Keller, JJ; Rauws, EA; Tytgat, GN; van der Hulst, RW | 2 |
| Coyle, W; Dresner, D; Duntemann, T; Lawson, JM; Nemec, R; Peterson, R | 1 |
| Tytgat, GN | 2 |
| Unge, P | 2 |
| Axon, AT; Moayyedi, P | 1 |
| Jönsson, B | 1 |
| Bell, GD; Powell, KU | 1 |
| Satoh, K | 1 |
| Caucheteur, B; De Koster, E; Deltenre, M; Jonas, C; Otero, J | 1 |
| Bermejo, F; Boixeda, D; de Rafael, L; Gisbert, JP; Martín de Argila, C; Redondo, C | 1 |
| Arnold, R; Bayerdörffer, E; Behrens, R; Birkner, B; Braden, B; Caspary, WF; Domschke, W; Koletzko, S; Labenz, J; Malfertheiner, P; Menge, H; Rösch, W; Schepp, W; Stolte, M; Strauch, M | 1 |
| de Boer, WA | 3 |
| Bergseth, M; Berstad, A; Berstad, K; Hundal, O; Olafsson, S; Tefera, S; Wilhelmsen, I | 1 |
| Gabryelewicz, A | 1 |
| Bästlein, E; Bayerdörffer, E; Bolle, KH; Hatz, R; Heldwein, W; Höchter, W; Klann, H; Lehn, N; Mannes, GA; Meining, A; Miehlke, S; Ruckdeschel, G; Simon, T; Sommer, A; Stolte, M; Weingart, J | 1 |
| de Boer, WA; Driessen, WM; Jansz, AR; Tytgat, GN | 1 |
| Ciociola, AA; McSorley, DJ; Peterson, WL; Sykes, DL; Webb, DD | 1 |
| de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ | 1 |
| Cilleruelo Pascual, ML; Echávarri Olavarría, F; Manzanares López-Manzanares, J; Medina Benítez, E; Molina Arias, M; Román Riechman, E; Urruzuno Tellería, P | 1 |
| De Boer, WA; Driessen, WM; Tytgat, GN | 1 |
| Geypens, B; Ghoos, Y; Hiele, M; Maes, B; Perri, F; Rutgeerts, P | 1 |
| Webb, DD | 1 |
| Dammann, HG | 1 |
| Bardhan, KD; Buckley, MJ; De Koster, EH; Duggan, AE; Gilvarry, J; Gummett, PA; Logan, RP; O'Morain, CA; Pounder, RE; Rauws, EA; Schaufelberger, HD; Wyeth, JW | 1 |
| De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY | 1 |
| Hackelsberger, A; Malfertheiner, P | 1 |
| Beastall, G; Beattie, AD; Morton, R; Park, RH; Taha, AS | 1 |
| Behler, EM; Chey, WD; Crause, I; Elta, GH; Scheiman, JM | 1 |
| Bonagura, AF; Dabezies, MA | 1 |
| Daróczy, J; Ferenczi, K; Kalas, D; Pálos, G; Prónai, L | 1 |
| Bardhan, KD | 1 |
| Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y | 1 |
| Ciociola, AA; Heath, A; Walsh, JH; Webb, DD | 1 |
| Goddard, AF; Spiller, RC | 1 |
| Harris, A; Misiewicz, JJ | 2 |
| Lux, G | 1 |
| Bästlein, E; Bayerdörffer, E; Lehn, N; Mannes, GA; Meining, A; Miehlke, S; Stolte, M | 1 |
| Goh, KL; Navaratnam, P; Peh, SC | 1 |
| Carmichael, JM; Patchin, GM; Wieland, KA | 1 |
| Freston, JW; Murphy, K; Taylor, JL; Zagari, M | 1 |
| Goodwin, CS; Mendall, MM; Northfield, TC | 1 |
| Axon, AT; Ireland, A; Rooprams, PD; Smith, MJ | 1 |
| Scott, BB; Vautier, G | 1 |
| de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ | 1 |
| Seifrit, B | 1 |
| Choi, CH; Chung, EC; Kung, NN; Kwok, SP; Li, TH; Lim, BH; Ma, HC; Ng, PW; Sung, JJ; Wong, KC; Yuen, NW | 1 |
| Chan, FK; Chan, LY; Chung, SC; Lee, YT; Leung, WK; Sung, JJ; Yung, MY | 1 |
| Biasco, G; Paparo, GF; Tucci, A | 1 |
| Blecker, U; Gold, BD | 1 |
| Agrawal, BK; Dayal, VM; Kamal, J; Kumar, P; Shahi, SK | 1 |
| Hunt, RH | 1 |
| Aubert, E; Berge, T; Efskind, PS; Haug, JB; Hauge, T; Henriksen, M; Lerang, F; Moum, B; Nicolaysen, K; Odegaard, A; Ragnhildstveit, E; Søberg, T; Tolås, P | 1 |
| Peterson, WL | 1 |
| Lambert, JR; Midolo, P | 1 |
| Pounder, RE; Williams, MP | 1 |
| Drumm, B; Durnin, M; Goggin, N; Moriarty, S; Rowland, M; Walsh, D | 1 |
| Damianos, AJ; McGarrity, TJ | 1 |
| Forbes, GM | 1 |
| Fock, KM | 1 |
| Lee, SD; Lin, HJ; Lo, WC; Perng, CL; Wang, K | 1 |
| Beattie, S; Buckley, MJ; Gilvarry, J; Hamilton, H; O'Morain, CA | 1 |
| Angeletti, S; Annibale, B; Bordi, C; Delle Fave, G; Malagnino, F; Mancino, C; Marignani, M | 1 |
| Pounder, RE | 1 |
| Kim, MJ; Michener, R; Triadafilopoulos, G | 1 |
| Angel, A; Genta, RM; Graham, DY; Gutiérrez, O; Otero, W; Segura, AM | 1 |
| Hoffman, JS | 1 |
| Myers, D | 1 |
| Hogan, J; Krasner, N; Lombard, M; Purkayastha, SK; Tan, WC | 1 |
| Bardhan, KD; Dallaire, C; Duggan, AE; Eisold, H | 1 |
| Bisso, G; Caroli, M; Celle, G; Mansi, C; Mela, GS; Mele, MR; Olivieri, A; Saggioro, A; Savarino, V; Termini, R; Tosatto, R; Vigneri, S | 1 |
| Hamilton, MR; Pounder, RE; Sercombe, JC; Williams, MP | 1 |
| Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM | 1 |
| Chan, CS; Chan, FK; Chung, SC; Lee, YT; Leung, VK; Li, EK; Sung, JJ; To, KF; Woo, J; Yung, MY | 1 |
| Abdel-Rahman, SM; Nahata, MC; Robinson, DM | 1 |
| El-Zaatari, F; Engstrand, L; Genta, RM; Graham, D; Scheynius, A | 1 |
| el-Zimaity, HM; Graham, DP; Graham, DY; Hoffman, J; Osato, M | 1 |
| Cervantes Bustamante, R; Cuevas, S; Mata Rivera, N; Oyervides Garcia, I; Ramirez Mayans, JA; Zamora Davila, E; Zarate Mondragón, FE | 1 |
| Eaton, KA; Kramer, LW; Wack, RF | 1 |
| Malfertheiner, P; Mégraud, F | 1 |
| Batchelder, M; Fox, JG; Hayward, A; Murphy, JC; Palley, L; Shames, B; Yan, L | 1 |
| Bierman, JC; Blanchard, TG; Czinn, SJ; Diters, RW; Leunk, RD | 1 |
| Cheng, AF; Chung, SS; Ling, TK; Sung, JJ; Yiu, PY | 1 |
| Emami, S; Estrada, R; Laine, L; Trujillo, M | 1 |
| Minocha, A; Srinivasan, R | 1 |
| Carrazco, J; Checkley, W; Cordero, L; Gilman, RH; Leon-Barua, R; McDonald, J; Ramirez-Ramos, A; Recavarren-Arce, S; Salazar, G; Valdez, Y; Watanabe, J | 1 |
| Bielański, W; Bobrzyński, A; Budzyński, A; Gedliczka, O; Konturek, S; Stachura, J | 2 |
| Bolin, TD; Engelman, JL; Korman, MG; Pianko, S | 1 |
| Bazzoli, F; Pozzato, P | 1 |
| Dixon, JS; Mills, JG; Pipkin, GA; Wood, JR | 1 |
| Chan, FK; Cheng, AF; Chung, SC; Lau, JY; Lee, YT; Leung, VK; Leung, WK; Ling, TK; Ng, EK; Suen, R; Sung, JJ | 1 |
| Berge, T; Haug, JB; Henriksen, M; Lerang, F; Moum, B; Ragnhildstveit, E; Sandvei, PK; Tolås, P; Whist, JE | 1 |
| Drumm, B; Walsh, D | 1 |
| Parsonnet, J | 1 |
| Berg, DE; Blaser, MJ; Dubois, A; Fiala, N; Heman-Ackah, LM; Perez-Perez, GI | 1 |
| Dibrova, IuA; Gomoliako, IV; Grigorova, IV; Saenko, VF; Shmatko, VI | 1 |
| Pipkin, GA; Williamson, R; Wood, JR | 2 |
| Bardhan, KD; Jahnsen, J; Lotay, N; Marcelino, M; Roberts, PM; Wurzer, H | 1 |
| Ariano, RE; Tkach, CL | 1 |
| Scott, BB | 1 |
| De Wolff, FA; Noach, LA; Slikkerveer, A; Tytgat, GN; Van der Voet, GB | 1 |
| Ducóns, JA; Fuentes, J; García, S; Gimeno, L; Gomollón, F; Montoro, M; Vera, J | 1 |
| Battaglia, G; Benvenuti, ME; Del Bò, N; Di Mario, F; Donisi, PM; Leandro, G; Pasini, M; Pasquino, M; Vianello, F; Vigneri, S | 1 |
| Calvet Calvo, X | 1 |
| Vondracek, TG | 1 |
| Breslin, NP; O'Morain, C | 1 |
| Bardhan, KD; Blakemore, CB; Cary, BA; Hinchliffe, RF; Morris, P; Singh, S; Thompson, M; Wall, RM | 1 |
| Macri, G; Milani, S; Passaleva, MT; Salvadori, G; Surrenti, C; Surrenti, E | 1 |
| Brullet, E; Calvet, X; Campo, R; Comet, R; García, N; Navarro, M | 1 |
| Ara, JR; Bertol, V; Brieva, L; Canellas, A; del Agua, C | 1 |
| Bazzoli, F; Cardelli, A; Catalano, FA; Giglio, A; Lami, F; Olivieri, A; Pilotto, A; Pozzato, P; Roda, E; Scarpulla, G; Spadaccini, A; Susi, D; Tosatto, R; Zagari, M | 1 |
| Crobach, LF; Geraedts, AA; Kolkman, JJ; Nicolai, JJ; Oudkerk Pool, M; Tan, TG; Timmerman, RJ; Van Der Laan, J; Van Kleef, WA; Wolff, AA | 1 |
| de Boer, WA; Haeck, PW; Mulder, CJ; Otten, MH | 1 |
| Ahsan, K; Hadjiyane, C; Karakurum, A; Mohammed, I; Nawaz, A; Pellecchia, C | 1 |
| Fendrick, AM; Jeffries, MA; Scheiman, JM | 1 |
| Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M | 1 |
| Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianei, R; Cuoco, L; Fedeli, G; Fedeli, P; Gasbarrini, A; Gasbarrini, G; Papa, A; Tursi, A | 1 |
| Carvalho, AF; Da Silva, CM; De Nucci, G; Ferraz, JG; Fiorelli, LA; Jorge, VN; Pedrazzoli, J | 1 |
| Bashirova, ES; Butorov, IL; Darvin, VV; Lokhvitskiĭ, SV; Proshin, AV | 1 |
| Kleibeuker, JH; Kooy, A; Thijs, JC; van der Wouden, EJ; van Zwet, AA | 1 |
| Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Sung, JJ; Yung, MY | 1 |
| Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB | 1 |
| Ciociola, AA; Heath, A; Lanza, FL; McSorley, DJ; Sontag, SJ; Sykes, DL | 1 |
| Funch-Jensen, P; Hallas, J; Juul, KV; Kolmos, HJ; Lauritsen, K; Nissen, A; Thomsen, OO | 1 |
| Oderda, G | 1 |
| Malfertheiner, P; Menegatti, M; Peitz, U; Vaira, D | 1 |
| Howden, CW; Hunt, RH | 1 |
| Bardhan, KD; Duggan, AE; Gudjonsson, H; Hoie, O; Kliebe-Frisch, C; Kristensen, ES; Pipkin, GA; Schuetz, E | 1 |
| Bellin, EY; Fletcher, DD; Shuter, J; Simone, VJ | 1 |
| Barnett, J; Chey, WD; Delvalle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Palaniappan, J; Scheiman, J | 1 |
| Chang, MH; Hsu, HY; Huang, FC; Lee, PI; Shun, CT | 1 |
| Biagini, R; Bilardi, C; Bisso, G; Celle, G; Mansi, C; Mele, MR; Pivari, M; Savarino, V; Termini, R; Vigneri, S; Zentilin, P | 1 |
| Eshraghi, J; Fassihi, R; Yang, L | 1 |
| Dial, EJ; Fox, JG; Lechago, J; Lichtenberger, LM; Ottlecz, A; Romero, JJ | 1 |
| Fukuda, Y; Shimoyama, T; Yamamoto, I | 1 |
| Aoyama, N; Sakai, T; Shirakawa, K; Shirasaka, D | 1 |
| DiBaise, JK; Dy, RM; Lof, J; Quigley, EM | 1 |
| Ozbakir, O; Turasan, A; Utaş, C; Utaş, S | 1 |
| Anti, M; Armuzzi, A; Bianchi Porro, G; Cammarota, G; Deltenre, M; Franceschi, F; Gasbarrini, A; Gasbarrini, G; Malfertheiner, P; Mégraud, F; O'Morain, C; Pajares-García, J; Pretolani, S; Quina, M | 1 |
| Choi, CH; Kung, NN; Lai, WM; Lam, KN; Leung, EM; Li, TH; Lui, YH; Ng, PW; Sung, JJ; Yuen, NW | 1 |
| Kabala, A; Pawłowski, W; Petsch, B | 1 |
| Attili, AF; De Francesco, V; Faleo, D; Hassan, C; Rinaldi, V; Stoppino, V; Winn, S; Zullo, A | 1 |
| Anderson, SY; El-Zimaity, HM; Graham, DY; Hoffman, J; Osato, MS; Qureshi, W | 1 |
| Kleibeuker, JH; Kooy, A; Thijs, JC; Van der Wouden, EJ; Zwet, AA | 1 |
| Fennerty, MB; Kelly, C; Knigge, K; Peterson, WL | 1 |
| Marshall, JB | 1 |
| Aasen, AJ; Berdal, BP; Bergan, T; Dahlgren, A; Gammelsaether, M; Gløgård, C; Klaveness, J | 1 |
| Blanchard, J; Boden, J; Ermak, T; Georgakopoulos, K; Giannasca, P; Gray, H; Hill, J; Ingrassia, J; Kleanthous, H; Lee, CK; Monath, TP; Soike, K; Tibbitts, T; Weltzin, R | 1 |
| Ashktorab, H; Hinds, T; Jagtap, J; Kim, KS; Scott, VF; Smoot, DT | 1 |
| Cave, DR; Hoffman, JS; Katz, LM | 1 |
| Buring, SM; Doering, PL; Hatton, RC; Winner, LH | 1 |
| Hirschowitz, BI; Mönkemüller, KE | 1 |
| Cutler, A; Vakil, N | 1 |
| Anderson, SY; Graham, DY; Lang, T | 1 |
| Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Chodash, HB; Dawson, BK; Luca, S; Michalos, A; Terranova, R | 1 |
| Gisbert, JP; Pajares, JM; Valle, J | 1 |
| Yao, X | 1 |
| McSorley, DJ; Perschy, TB; Schwartz, HI; Sorrells, SC | 1 |
| Choe, YH; Hong, YC; Kim, SK; Lee, DH; Pai, SH; Son, BK | 1 |
| Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H | 1 |
| Jansen, JB; Laheij, RJ; Rossum, LG; Straatman, H; Verbeek, AL | 1 |
| Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M | 1 |
| Lichtenberger, LM; Ottlecz, A; Romero, JJ | 1 |
| Berstad, A; Hatlebakk, JG; Tefera, S | 1 |
| Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL | 1 |
| Neiger, R; Schmassmann, A; Seiler, G | 1 |
| Cabanillas, FF; Ford, R; Genta, RM; Glober, G; Graham, DY; Hagemeister, FB; Johnson, CM; Lahoti, S; Lee, JE; Luthra, R; Lynch, PM; Manning, JT; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sample, D; Sarris, AH; Shen, Y; Steinbach, G; Winn, RJ; Younes, A | 1 |
| Dashti, M; Massarrat, S; Pahlewanzadeh, MR; Roghani, HS | 1 |
| Bardhan, KD; Farley, A; French, PC; Paré, P; Roberts, PM; Romãozinho, JM | 1 |
| Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Suen, R; Sung, JJ; Wu, JC | 1 |
| Chippendale, GR; Garner, RM; Gilbert, JV; Kane, AV; Mobley, HL; Plaut, AG | 1 |
| Bravo, LE; Campo, C; Correa, P; Mera, R; Realpe, JL | 1 |
| Axon, A | 1 |
| Angeles Arpa, M; Bermejo, F; Boixeda, D; García Arata, I; García Plaza, A; Gisbert, JP; Jesús Higes, M; Martín de Argila, C; Nieves Rincón, M | 1 |
| Coyle, WJ; Duntemann, T; Lawson, JM; Murphy, M; Nemec, R; Peterson, R; Sedlack, RE | 1 |
| Dagalp, K; Kadayifci, A; Kilinc, R; Uygun, A | 1 |
| Berstad, A; Olafsson, S | 1 |
| Carpio, D; Gisbert, JL; Gisbert, JP; Grávalos, RG; Marcos, S; Pajares, JM | 1 |
| Canning, A; Egan, C; Farraye, FA; Kemp, JA; Lee, M; Tataronis, G | 1 |
| Mach, T; Zahradnik-Bilska, J | 1 |
| Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y | 1 |
| Dubois, A; Heman-Ackah, LM; Mysore, JV; Simon, PM; Wigginton, T; Zopf, D | 1 |
| Borda, F; Domínguez, E; Gisbert, JP; Sainz, R | 1 |
| Alonso García, I; García Pérez, A; Giménez Samper, M; Valverde de La Osa, J | 1 |
| Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, G; Papa, A; Pastorelli, A | 1 |
| Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, G; Gentiloni, N; Ojetti, V; Pastorelli, A; Pirozzi, G | 1 |
| Anti, M; Armuzzi, A; Branca, G; Candelli, M; Canducci, F; Fadda, G; Fedeli, G; Gasbarrini, A; Gasbarrini, G; Ojetti, V; Pastorelli, A; Pola, P; Torre, ES | 1 |
| De Boer, WA; Jansen, JB; Schneeberger, PM; Van De Wouw, BA; Van Etten, RJ; Van Oijen, AH | 1 |
| Chan, FK; Chung, SC; Ling, TK; Suen, R; Sung, JJ; Wu, JC | 1 |
| Chey, WD; Chien, NN; Chung, NQ; Connor, BA; Henley, KS; Hoan, PQ; Hop, TV; Lak, BV; Long, T; Mao, HV; Perez-Perez, GI; Stone, CD; Thang, DM | 1 |
| Gurer, I; Hilmioglu, F; Ozyilkan, E; Sare, M; Taskin, V | 1 |
| Bravo, JC; Bravo, LE; Correa, P; Realpe, JL; Ruiz, B; van Doorn, LJ | 1 |
| Brousal, A; Kearney, DJ | 1 |
| Ballardini, G; Boni, F; Bortoli, A; Colombo, E; Minoli, G; Spinzi, GC; Venturelli, R | 1 |
| Barkun, AN; Beech, R; Best, L; Fallone, CA; Friedman, G; Joseph, L; Loo, V; Mayrand, S | 1 |
| Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG | 1 |
| Bisson, S; Bojarski, C; Epple, HJ; Fromm, M; Kirstein, FW; Riecken, EO; Schulzke, JD | 1 |
| Fox, JG; Marini, RP; McColm, AA; Taylor, NS; Williamson, R; Yan, L | 1 |
| Sung, JJ | 1 |
| Anderson, SY; El-Zimaity, HM; Graham, DY; Hoffman, J; Kwon, DH; Opekun, AR; Osato, MS | 1 |
| Fairman, KA; Motheral, BR | 1 |
| Chmiela, M; Czkwianianc, E; Lawnik, M; Płaneta-Małecka, I; Rudnicka, W | 1 |
| Bilardi, C; Bisso, G; Borgonovo, G; Borro, P; De Salvo, L; Dulbecco, P; Mansi, C; Pivari, M; Raffaella Mele, M; Savarino, V; Tessieri, L; Vigneri, S; Zentilin, P | 1 |
| De Boer, WA; Jansen, JB; Van Oijen, AH; Verbeek, AL | 1 |
| Castellote, J; Porta, F | 1 |
| Calvet, X; Gabriel, R; Gisbert, JP; González, L; Pajares, JM; Roqué, M | 1 |
| Delves, HT; Phillips, RH; Powell, JJ; Seed, PT; Sieniawska, CE; Thompson, RP; Whitehead, MW | 1 |
| Champion, M; Lacey, S; Phillips, RH; Powell, JJ; Thompson, RP; Whitehead, MW | 1 |
| Asaka, M; Hokari, K; Kagaya, H; Kato, M; Sugiyama, T; Takeda, H | 1 |
| Buzás György, M; Illyés, G; Székely, E; Széles, I | 1 |
| Thomson, AB | 1 |
| Ching, CK; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, WM | 1 |
| Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R | 1 |
| Cooper, R; Miskovitz, P; Nagler, J | 1 |
| Lam, SK; Wang, WH; Wong, BC | 1 |
| Chiba, N | 1 |
| Blanco, M; Gisbert, JP; Pajares, JM | 1 |
| Mégraud, F | 1 |
| Akhunov, ED; Farztdinov, KM; Katayev, VA; Kazykhanov, NS; Khusnutdinov, SM; Nijevitch, AA; Sataev, VU | 1 |
| Baena Díez, JM; García Lareo, M; López Mompó, C; Rams Rams, F; Rosario Hernández Ibáñez, M; Teruel Gila, J | 1 |
| Cabezudo, JG; Ducóns, J; Gomollon, F; Guirao, R; Montoro, M; Santolaria, S | 1 |
| Mégraud, F; Roberts, P; Williamson, R | 1 |
| Marshall, BJ; Mégraud, F | 1 |
| Chan, CK; Chu, KM; Fung, FM; Hu, WH; Lai, KC; Lam, SK; Lau, GK; Leung, SY; Wang, WH; Wong, BC; Wong, WM; Yuen, MF; Yuen, ST | 1 |
| Dashkova, S; Farztdinov, KM; Kazykhanov, NS; Nijevitch, AA; Sataev, VU | 1 |
| El-Zimaity, HM; Graham, DY; Hoffman, J; Kwon, DH; Osato, MS; Saeed, MA | 1 |
| De Boer, WA; Jansen, JB; Janssen, MJ; Van Oijen, AH; Verbeek, AL | 1 |
| Eshraghian, MR; Fazel, A; Malekzadeh, R; Massarrat, S; Sotudehmanesh, R; Ziad-Alizadeh, B | 1 |
| Kearney, DJ | 1 |
| Chejfec, G; O'Connell, S; Schnell, T; Seidel, J; Sonnenberg, A; Sontag, SJ | 1 |
| Bravo, JC; Bravo, LE; Casabon, AL; Collazos, T; Correa, P; Fischbach, LA; Ramirez, H; Realpe, JL; Ruiz, B; Schmidt, BA | 1 |
| Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V | 1 |
| Andriulli, A; Annese, V; Niro, GA; Perri, F; Quitadamo, M; Villani, MR | 1 |
| Hopkins, RJ | 1 |
| Dixon, CA; Hopkins, RJ; Meyer, JM; Siepman, NY; Silliman, NP; Sugg, JE | 1 |
| Delves, HT; Doig, LA; Phillips, RH; Powell, JJ; Sieniawska, CE; Thompson, RP; Whitehead, MW | 1 |
| Gisbert, JL; Gisbert, JP; Marcos, S; Pajares, JM | 2 |
| Campo, SM; De Matthaeis, M; Febbraro, I; Hassan, C; Lorenzetti, R; Morini, S; Porto, D; Zullo, A | 1 |
| Bardhan, KD; Mitchell, TR; Morris, P; Morton, D; Perry, MJ; Roberts, PM; Rowland, A; Sanders, DS; Thompson, M | 1 |
| Bayerdörffer, E; Graham, DY; Miehlke, S | 1 |
| Ananthakrishnan, N; Badrinath, S; Kate, V | 1 |
| Amini, M; Kamalian, N; Kaviani, MJ; Malekzadeh, R; Massarrat, S; Sotoudeh, M; Vahedi, H | 1 |
| Bujanda, L; Cosme, A; Iriondo, C; Muñoz, C; Sánchez, A; Santos, A | 1 |
| Beales, IL | 1 |
| Burm, M; Faigel, D; Fennerty, MB; Kelly, C; Magaret, N; Peterson, W | 1 |
| Doulgeroglou, V; Kamberoglou, D; Patra, E; Polymeros, D; Sanidas, I; Savva, S; Tzias, V | 1 |
| Dudik, TV; Il'chenko, AA; Kaprel'yants, AS; Loginov, AS; Reshetnyak, VI; Vostroknutova, GN | 1 |
| Corder, FA; Howden, CW; Sahai, AV; Sharma, VK | 1 |
| Fang, XC; Hu, PJ; Li, ZS; Lu, H; Lu, XH; Xiao, SD; Zhang, DZ | 1 |
| De Francesco, V; Faleo, D; Hassan, C; Ierardi, E; Morini, S; Panella, C; Zullo, A | 1 |
| Annibale, B; Bordi, C; Caruana, P; D'Ambra, G; Delle Fave, G; Di Giulio, E; Grossi, C; Lahner, E; Milione, M | 1 |
| Artikis, V; Georgopoulos, SD; Karatapanis, S; Ladas, SD; Mentis, A; Raptis, SA; Spiliadi, C; Triantafyllou, K | 1 |
| Markova, T; Schwartz, K | 1 |
| Amsler, KM; Foster, LA; Merrill, JJ; Modzelewski, TC; Quispe, JD; Sizemore, CF; Slee, AM; Stevenson, DA | 1 |
| Andriulli, A; Clemente, R; Festa, V; Merla, A; Perri, F; Quitadamo, M | 1 |
| Takahashi, S; Tanaka, A | 1 |
| Ohkusa, T; Sato, N | 1 |
| Gómez Rodríguez, B; Hergueta Delgado, P; Herrerías Gutiérrez, JM; Mendoza Olivares, FJ; Pellicer Bautista, FJ; Rojas Feria, M; Romero Castro, R | 1 |
| Bird, N; Butcher, GP; Haqqani, MT; Hughes, SJ; Rhodes, JM; Ryder, SD; Stewart, M | 1 |
| Katelaris, P | 1 |
| Bell, GD; Powell, K | 1 |
| Bär, W; Freise, J; Gebel, M; Gladziwa, U; Haruma, K; Lange, P; Schmidt, FW; Wagner, S | 1 |
| Seppälä, K | 1 |
| Muñoz, DJ; Pybus, J; Tasman-Jones, C | 1 |
| Ainley, C; Chandrakumaran, K; D'Anna, L; Falzon, M; Holton, J; McNeil, I; Osborn, J; Romanos, A; Vaira, D | 1 |
| Cheng, A; Chung, SC; Hosking, SW; Leung, JW; Li, AK; Ling, TK; Yung, MY | 1 |
| Bellis, D; Boero, M; Chiandussi, L; Di Napoli, A; Petrino, R | 1 |
| Adeyemi, EO; al-Homsi, M; Boehme, D; Fadlalla, H; Goodwin, S; Nnalue, NA; Sim, AJ | 1 |
| Corbishley, CM; Goggin, PM; Jackson, PA; Marrero, JM; Northfield, TC; Spychal, RT | 1 |
| Chiba, N; Hunt, RH; Rademaker, JW; Rao, BV | 1 |
| Garner, A | 1 |
| Demling, L | 1 |
| Bell, GD; Bolton, G; Brooks, S; Burridge, SM; Gant, PW; Harrison, G; Powell, KU; Prosser, S; Purser, K; Spencer, G | 1 |
| Duriex, DE; Madan, E; Midkiff, BR; Subik, MA; Westblom, TU | 1 |
| Littlewood, JM; Mahony, MJ; Wyatt, JI | 1 |
| Cave, DR | 1 |
| Beattie, S; Keane, C; O'Morain, C; Patchett, S | 1 |
| Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Saeed, ZA | 1 |
| Andrews, P; Borody, TJ; Brandl, S; Devine, M; George, LL; Lenne, J; Moore-Jones, D; Walton, M | 1 |
| Blecker, U; Lanciers, S; Peeters, S; Vandenplas, Y | 1 |
| Glassman, MS | 1 |
| Alpert, LC; Evans, DG; Evans, DJ; Genta, RM; Graham, DY; Klein, PD; Lew, GM; Malaty, HM | 1 |
| Beattie, S; Keane, C; Leen, E; O'Morain, C; Patchett, S | 1 |
| Goh, KL; Lo, YL; Parasakthi, N; Peh, SC; Puthucheary, SD; Wong, NW | 1 |
| Casaubón-Garcín, P; Cervantes, R; Ramírez-Mayans, J; Tovar-Calderón, S | 1 |
| Bär, W; Gebel, M; Haruma, K; Lange, P; Müller, MJ; Schorn, T; Soudah, B; Varrentrapp, M; Wagner, S | 1 |
| Balzano, A; Di Blasi, A; Gigliotti, T; Mosca, S; Piccirillo, MM; Rocco, VP | 1 |
| Chittajalu, R; Dahill, SW; el Nujumi, AM; Fullarton, GM; Hilditch, TE; MacDonald, AM; McColl, KE | 1 |
| Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM | 1 |
| Ali, MR; Brown, P; Hamilton, I; Lane, M; Morris, A; Nicholson, G; Samarasinghe, D | 1 |
| Alpert, LC; Evans, DG; Evans, DJ; Graham, DY; Jerdack, GR; Klein, PD; Morgan, DR; Opekun, A | 1 |
| Bell, GD; Jobson, RC; Weil, J; Williams, PF | 1 |
| Bokemeyer, B; Freise, J; Fritsch, RS; Iserhard, R; Schmidt, FW; Soudah, B; Wagner, S; Weissbrodt, H | 1 |
| Ali, MR; Blaser, MJ; Morris, AJ; Nicholson, GI; Perez-Perez, GI | 1 |
| Avunduk, C; Eastwood, GL; Gang, D; Polakowski, N; Suliman, M | 1 |
| Korsten, MA; Lateef, SK; Lieber, CS; Paronetto, F; Uppal, R | 1 |
| Campbell, AN | 1 |
| Raedsch, R | 1 |
| Gorodinskaia, VS; Il'chenko, AA; Zhukhovitskiĭ, BG; Zurabishvili, NG | 1 |
| Colimon, R; Flourié, B; Lavergne, A; Mignon, M; Modigliani, R; Rambaud, JC; Sobhani, I | 1 |
| Ahmed, W; Alam, SM; Jafarey, NA; Kazi, AM; Kazi, JI; Qureshi, H; Zuberi, SJ | 1 |
| Korman, MG | 1 |
| Loizeau, E | 1 |
| Börsch, GM; Graham, DY | 1 |
| Annibale, B; Corleto, V; de Magistris, L; Delle Fave, G; Giordano, E; Puoti, M; Torsoli, A | 1 |
| Islam, S; McLean, AJ | 1 |
208 review(s) available for bismuth and Helicobacter Infections
| Article | Year |
|---|---|
V Spanish Consensus Conference on Helicobacter pylori infection treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors | 2022 |
Treatment of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Hypersensitivity; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Penicillins; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2021 |
Nickel, an essential virulence determinant of Helicobacter pylori: Transport and trafficking pathways and their targeting by bismuth.
Topics: Animals; Bacterial Proteins; Bismuth; Helicobacter Infections; Helicobacter pylori; Mice; Nickel; Virulence; Virulence Factors | 2022 |
High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 2022 |
Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2023 |
The management of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Stomach Neoplasms; Treatment Outcome | 2022 |
The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Third-line and rescue therapy for refractory
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Rifabutin; Tetracycline | 2023 |
Bismuth nanoparticles against microbial infections.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metal Nanoparticles | 2022 |
Comparison of multiple treatment regimens in children with
Topics: Anti-Bacterial Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Network Meta-Analysis; Treatment Outcome | 2023 |
Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 2023 |
Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Minocycline; Randomized Controlled Trials as Topic; Tetracycline; Treatment Outcome | 2023 |
Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of
Topics: Anti-Bacterial Agents; Bismuth; Diarrhea; Dietary Supplements; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Probiotics; Treatment Outcome | 2023 |
Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations.
Topics: Anti-Bacterial Agents; Asian; Bismuth; Drug Therapy, Combination; Ethanol; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Failure | 2023 |
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 2023 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, Physiological; Adipates; Administration, Oral; Adolescent; Adrenal Glands; Adsorption; Adult; Aged; Aged, 80 and over; Aging; AIDS-Related Opportunistic Infections; Aldosterone; Amino Acids; Ammonia; Amoxicillin; AMP-Activated Protein Kinases; Animals; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Antirheumatic Agents; Apgar Score; Area Under Curve; ARNTL Transcription Factors; Arterial Pressure; Arthritis, Juvenile; Athletes; Attention; Biodegradation, Environmental; Biofilms; Biofuels; Biological Therapy; Biomass; Biomimetic Materials; Bioreactors; Birth Weight; Bismuth; Blood Flow Velocity; Bone and Bones; Brain Injuries, Traumatic; Calcium; Calcium Channels; Capsaicin; Carbon; Carcinoma, Hepatocellular; Cardiomegaly, Exercise-Induced; Cartilage; Cartilage, Articular; Case-Control Studies; Catalysis; Cats; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Charcoal; Chemokine CCL2; Child; Child, Preschool; Chondrogenesis; Chronic Disease; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Clarithromycin; Coccidioides; Coccidioidomycosis; Cognitive Behavioral Therapy; Coinfection; Color; Coloring Agents; Computer Simulation; Computers, Molecular; Consensus; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Density Functional Theory; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dialysis Solutions; Disease Models, Animal; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Electrolytes; Endocardium; Endocrine Disruptors; Endocytosis; Endoscopy, Gastrointestinal; Escherichia coli Proteins; Esters; Evolution, Molecular; Executive Function; Feasibility Studies; Female; Ferric Compounds; Fluorescence; Fluorescent Dyes; Fluorine Radioisotopes; Frailty; Free Radical Scavengers; Gabapentin; Geriatric Assessment; Glucaric Acid; Glucocorticoids; Glucose; Glucose Metabolism Disorders; Halogenated Diphenyl Ethers; Heart Rate; Heart Ventricles; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hep G2 Cells; Hepatocytes; Humans; Hungary; Hydrogen Sulfide; Hydrogen-Ion Concentration; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Independent Living; Indocyanine Green; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infant, Newborn, Diseases; Inflorescence; Insulin Resistance; Insulins; International Agencies; Iron; Isotonic Solutions; Kidney Failure, Chronic; Kinetics; Lactones; Leukocytes, Mononuclear; Liver Neoplasms; Macular Edema; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetosomes; Male; Medical Audit; Mesenchymal Stem Cells; Metabolic Syndrome; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Molecular Conformation; Molecular Targeted Therapy; Motor Activity; Multiple Sclerosis; Mycophenolic Acid; Netherlands; Neuropsychological Tests; Nuclear Energy; Organs at Risk; Osteoarthritis; Osteoarthritis, Hip; Oxidation-Reduction; Palladium; Pericardium; Perinatal Death; Peritoneal Dialysis; Phantoms, Imaging; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Physical Conditioning, Human; Physical Endurance; Pilot Projects; Polyketides; Polymers; Positron-Emission Tomography; Postoperative Period; Potassium; Powders; Pramipexole; Predictive Value of Tests; Pregabalin; Pregnancy; Pregnancy Outcome; Protein Structure, Secondary; Proton Pump Inhibitors; Puberty; Pulmonary Circulation; Quality Assurance, Health Care; Quantum Dots; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Transferrin; Regeneration; Registries; Renal Insufficiency, Chronic; Reproducibility of Results; Research Design; Restless Legs Syndrome; Retina; Retinoid X Receptor alpha; Retrospective Studies; Rhenium; Risk Factors; RNA, Messenger; Severity of Illness Index; Sex Factors; Sodium; Sodium Fluoride; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Stroke; Structure-Activity Relationship; Tachycardia, Ventricular; Tetracycline; Tetrahydrofolate Dehydrogenase; Tetrahydronaphthalenes; Thermodynamics; Thiophenes; Time Factors; Tinidazole; Tomography, Optical Coherence; Tomography, X-Ray Computed; Topiramate; Toxoplasma; Toxoplasmosis, Cerebral; Transferrin; Treatment Outcome; Up-Regulation; Upper Extremity; Uremia; Uveitis; Vascular Remodeling; Ventricular Fibrillation; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Verapamil; Veterans; Visual Acuity; Vitrectomy; Water Pollutants, Chemical; Zea mays; Zirconium | 2019 |
High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Chile; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prevalence; Prospective Studies | 2019 |
Recent progress in Helicobacter pylori treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Probiotics; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Vitamins | 2020 |
Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota.
Topics: Anti-Bacterial Agents; Asia; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin | 2020 |
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Biopsy; Bismuth; Breath Tests; Clarithromycin; Culture Techniques; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Feces; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Nitro Compounds; Organometallic Compounds; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors; Rifabutin; Salicylates; Salvage Therapy; Serologic Tests; Stomach Neoplasms; Tetracycline; Thiazoles; Treatment Outcome; Urea | 2020 |
Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Network Meta-Analysis; Proton Pump Inhibitors | 2021 |
Treatment of Helicobacter pylori infection: a clinical practice update.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Meta-Analysis as Topic; Practice Guidelines as Topic; Probiotics; Proton Pump Inhibitors; Salvage Therapy; Systematic Reviews as Topic | 2021 |
Efficacy of second-line regimens for
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Network Meta-Analysis; Outcome Assessment, Health Care; Practice Guidelines as Topic; Proton Pump Inhibitors; Quinolones; Randomized Controlled Trials as Topic; Tetracycline | 2020 |
Review - Treatment of Helicobacter pylori infection 2020.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2020 |
Topics: Amoxicillin; Anti-Bacterial Agents; Biological Products; Bismuth; Clarithromycin; Drug Therapy, Combination; Dysbiosis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Phytochemicals; Plant Extracts; Plants, Medicinal; Probiotics | 2020 |
Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Rifabutin; Tetracycline; Treatment Failure | 2021 |
Treatment of Refractory
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors | 2022 |
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Proton Pump Inhibitors; Quinolones | 2017 |
[Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Novel and Effective Therapeutic Regimens for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Mutation; Prevalence; Probiotics; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides; Tetracycline; Tetracycline Resistance | 2017 |
Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.
Topics: Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Iran; Treatment Outcome | 2017 |
[[Overview Basic Provisions Consensus of the III Working Italian Group for Diagnosis and Treatment of H.Pylory-Infection].]
Topics: Animals; Anti-Bacterial Agents; Bismuth; Breath Tests; Congresses as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Probiotics; Proton Pump Inhibitors; Stomach Neoplasms | 2016 |
[Drug susceptibility test guided therapy and novel empirical quadruple therapy for
Topics: Anti-Bacterial Agents; Asian People; Bismuth; Combined Modality Therapy; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Helicobacter pylori management in ASEAN: The Bangkok consensus report.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Consensus; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; Proton Pump Inhibitors; Taiwan; Tetracycline; Thailand; Treatment Outcome; United States | 2018 |
Treatment of Helicobacter pylori infection 2017.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2017 |
Treatment of Helicobacter pylori infection: A clinical practice update.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Practice Guidelines as Topic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Failure | 2018 |
Helicobacter Pylori Infection.
Topics: Adult; Antacids; Anti-Bacterial Agents; Antibodies, Monoclonal; Bismuth; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Urea | 2018 |
Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2018 |
Toward population specific and personalized treatment of Helicobacter pylori infection.
Topics: Algorithms; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Models, Theoretical | 2018 |
Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2019 |
High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Randomized Controlled Trials as Topic | 2019 |
Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2019 |
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Canada; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Tetracycline; United States | 2019 |
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Treatment Failure | 2013 |
Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2013 |
Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2013 |
Optimum duration of regimens for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Quinolones | 2013 |
Evidence-based recommendations for successful Helicobacter pylori treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2014 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors | 2014 |
[New guidelines for Helicobacter pylori treatment: comparisons between Korea and Japan].
Topics: Anti-Bacterial Agents; Antibodies; Bismuth; Disease Eradication; Drug Administration Schedule; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lymphoma, B-Cell, Marginal Zone; Republic of Korea; Stomach Neoplasms | 2014 |
Practical treatment of Helicobacter pylori: a balanced view in changing times.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Failure; Treatment Outcome | 2014 |
Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance.
Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Polymerase Chain Reaction; Proton Pump Inhibitors; Treatment Outcome | 2014 |
Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms | 2014 |
Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Humans; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Practical Aspects in Choosing a Helicobacter pylori Therapy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Probiotics; Proton Pump Inhibitors; Treatment Outcome | 2015 |
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2015 |
Helicobacter pylori treatment: Still a work in progress.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Practice Guidelines as Topic; Proton Pump Inhibitors; Treatment Outcome | 2016 |
Role of bismuth in improving Helicobacter pylori eradication with triple therapy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2016 |
Helicobacter pylori therapy: a paradigm shift.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Standard of Care; Treatment Outcome | 2016 |
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2016 |
Eradication of Helicobacter pylori Infection.
Topics: Anti-Bacterial Agents; Bismuth; Chronic Disease; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2016 |
IV Spanish Consensus Conference on Helicobacter pylori infection treatment.
Topics: Algorithms; Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Delphi Technique; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Meta-Analysis as Topic; Probiotics; Proton Pump Inhibitors; Recurrence; Salvage Therapy; Stomach Neoplasms; Stomach Ulcer; Treatment Failure | 2016 |
Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Network Meta-Analysis; Practice Guidelines as Topic; Proton Pump Inhibitors | 2016 |
Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Randomized Controlled Trials as Topic | 2008 |
Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Ranitidine; Tinidazole; Treatment Outcome | 2009 |
Helicobacter pylori: diagnosis and treatment.
Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Ofloxacin; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Treatment Failure | 2009 |
Pylera for the eradication of Helicobacter pylori infection.
Topics: Administration, Oral; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Randomized Controlled Trials as Topic; Tetracycline; Treatment Outcome | 2009 |
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Outcome Assessment, Health Care; Patient Compliance; Practice Guidelines as Topic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2010 |
Antimicrobial resistance and eradication strategies for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Mutation; Proton Pump Inhibitors | 2009 |
[Optimization of treatment of patients with diseases associated with Helicobacter pylori infection: justifying of bismuth preparations using].
Topics: Antacids; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans | 2009 |
Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Ranitidine; Tetracycline; Treatment Failure; Treatment Outcome | 2010 |
[The association between Helicobacter pylori and gastric cancer: the role of infection's eradication. Recent advances].
Topics: Anti-Bacterial Agents; Bismuth; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Randomized Controlled Trials as Topic; Risk Factors; Stomach Neoplasms | 2010 |
Iron deficiency anaemia can be improved after eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2010 |
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Retreatment | 2010 |
Treatment of Helicobacter pylori infection 2010.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Treatment Outcome | 2010 |
Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis.
Topics: Aza Compounds; Bismuth; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Humans; Moxifloxacin; Quinolines; Treatment Outcome | 2011 |
Diagnosis and treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Denmark; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Stomach Neoplasms; Tetracycline | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Tetracycline | 2011 |
The actions of bismuth in the treatment of Helicobacter pylori infections: an update.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans | 2012 |
Review article: bismuth-based therapy for Helicobacter pylori eradication in children.
Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2012 |
[Helicobacter pylori - 2012].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Emigrants and Immigrants; Endoscopy, Gastrointestinal; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Hungary; In Situ Hybridization, Fluorescence; Levofloxacin; Ofloxacin; Peptic Ulcer; Polymerase Chain Reaction; Stomach Neoplasms | 2012 |
Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Proton Pump Inhibitors; Ranitidine; Salicylates; Virulence | 2002 |
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Ditiocarb; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2003 |
Is it time for quadruple therapy to be first line?
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Ranitidine | 2003 |
Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2004 |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.
Topics: Antacids; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Guideline Adherence; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Tetracycline; Treatment Outcome | 2004 |
Treatment of H. pylori infection: a review.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Clarithromycin; Fluoroquinolones; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Macrolides; Ofloxacin; Polypharmacy; Ranitidine; Rifabutin | 2005 |
Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2005 |
Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine | 2005 |
Helicobacter pylori "rescue" therapy after failure of two eradication treatments.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure | 2005 |
[Anti-Helicobacter pylori quadruple therapy].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2005 |
Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Ofloxacin; Treatment Failure | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2006 |
First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004.
Topics: Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pumps; Ranitidine; Time Factors; Treatment Outcome | 2006 |
Nitrofuran-based regimens for the eradication of Helicobacter pylori infection.
Topics: Anti-Infective Agents, Local; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Proton Pump Inhibitors; Ranitidine | 2007 |
Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline | 2008 |
Review article: functional dyspepsia--should treatment be targeted on disturbed physiology?
Topics: Abdominal Pain; Antidepressive Agents; Bismuth; Calcium Channel Blockers; Cholecystokinin; Dyspepsia; Gastric Emptying; Helicobacter Infections; Humans; Narcotics; Nitric Oxide; Prostaglandins, Synthetic | 1995 |
The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Randomized Controlled Trials as Topic; Tetracycline | 1995 |
The treatment of Helicobacter pylori infection in the management of peptic ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Recurrence | 1995 |
[Helicobacter pylori infection and non-ulcer dyspepsia].
Topics: Bismuth; Chronic Disease; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans | 1995 |
Helicobacter pylori eradication up to date.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans | 1995 |
Eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Recurrence; Stomach Neoplasms; Stomach Ulcer | 1994 |
Treating peptic ulcer: an ongoing challenge.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline | 1995 |
[Status of ranitidine in eradication of Helicobacter pylori].
Topics: Amoxicillin; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Ranitidine | 1995 |
Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Peptic Ulcer; Treatment Outcome; Uncoupling Agents | 1995 |
Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tinidazole | 1994 |
[Controversies and trends in ulcer therapy. 2: Prevention of recurrence].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Long-Term Care; Male; Middle Aged; Omeprazole; Peptic Ulcer; Recurrence; Sucralfate | 1993 |
[Management of the peptic ulcer patient in the Helicobacter pylori age].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Breath Tests; Child; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Immunologic Techniques; Lymphoma, Non-Hodgkin; Metronidazole; Peptic Ulcer; Stomach Neoplasms | 1994 |
[How to eradicate Helicobacter pylori?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Macrolides; Omeprazole | 1994 |
Antibacterial therapy of Helicobacter pylori-associated peptic ulcer disease: a new strategy. The Swedes go for it.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1994 |
[Helicobacter pylori infection in children].
Topics: Adolescent; Adult; Amoxicillin; Bismuth; Child; Child, Preschool; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Prognosis | 1994 |
Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; United States | 1994 |
[Current therapy of Helicobacter pylori-induced chronic gastritis and/or peptic ulcer].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1994 |
Endoscopic and histologic resolution of gastric pseudolymphoma (reactive lymphoid hyperplasia) following treatment with bismuth and oral antibiotics.
Topics: Aged; Amoxicillin; Biopsy; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Metronidazole; Organometallic Compounds; Ranitidine; Salicylates; Stomach; Stomach Neoplasms | 1994 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1994 |
Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; United States | 1994 |
[Treatment of Helicobacter pylori infection in adults].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Metronidazole; Peptic Ulcer; Recurrence; Treatment Outcome | 1994 |
[Treatment of Helicobacter pylori infection in children].
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Metronidazole; Recurrence; Treatment Outcome | 1994 |
Duodenal ulcer treatment: progress from pH to HP.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Metronidazole; Tetracycline | 1994 |
A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia.
Topics: Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Patient Compliance; Random Allocation | 1994 |
[Alternatives of drug therapy in Helicobacter pylori infections].
Topics: Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Oxytetracycline | 1994 |
[Effective regimen for eradication of Helicobacter pylori].
Topics: Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 1993 |
[Helicobacter pylori infections].
Topics: Amphotericin B; Bismuth; Clarithromycin; Drug Resistance, Microbial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Tetracyclines | 1993 |
Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment.
Topics: Amoxicillin; Bismuth; Cimetidine; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Patient Compliance; Peptic Ulcer; Tinidazole | 1993 |
Helicobacter pylori and peptic ulcer disease. Reexamining the therapeutic approach.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates | 1993 |
Helicobacter pylori infection.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Stomach Neoplasms; Stomach Ulcer; Tetracycline | 1993 |
Treatment strategies for Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 1993 |
[Treatment of Helicobacter pylori infection: current status].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Time Factors | 1995 |
Eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 1995 |
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Contraindications; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Misoprostol; Peptic Ulcer; Predictive Value of Tests; Proton Pump Inhibitors; Recurrence | 1996 |
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Omeprazole; Penicillins; Regression Analysis; Stomach Ulcer; Tetracycline; Time Factors | 1996 |
Modern management of dyspepsia.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Child; Cholelithiasis; Chronic Disease; Cisapride; Diagnosis, Differential; Domperidone; Dopamine Antagonists; Dyspepsia; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metoclopramide; Peptic Ulcer; Piperidines; Stomach Neoplasms | 1996 |
Triple therapy and Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Stomach Neoplasms; Stomach Ulcer; Tetracycline; Time Factors | 1996 |
Helicobacter pylori and complicated ulcer disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer Hemorrhage; Risk Factors; Stomach Ulcer | 1996 |
[Treatment of Helicobacter pylori infection].
Topics: Adolescent; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Middle Aged; Omeprazole; Stomach Ulcer | 1996 |
Current indications for Helicobacter pylori eradication therapy.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Stomach Neoplasms; Stomach Ulcer | 1996 |
Review of Helicobacter pylori eradication regimens.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole | 1996 |
Eradication of Helicobacter pylori: omeprazole in combination with antibiotics.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Time Factors; Treatment Failure | 1996 |
[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Humans; Omeprazole; Penicillins; Ranitidine | 1996 |
How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1996 |
Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Hospitals, University; Humans; Metronidazole; Norway; Oxytetracycline; Peptic Ulcer; Stomach Diseases; Urea; Urease | 1996 |
Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Tetracyclines; Tinidazole | 1996 |
[Helicobacter pylori eradication: triple therapy versus dual therapy].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline; Tinidazole; Treatment Outcome | 1996 |
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Nitroimidazoles; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Risk Assessment; Tetracyclines | 1996 |
Helicobacter pylori infection. The importance of eradication in patients with gastric disease.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1996 |
Triple therapy as a cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 1996 |
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Monte Carlo Method; Organometallic Compounds; Patient Compliance; Proton Pump Inhibitors; Recurrence; Salicylates; Tetracycline; Treatment Outcome | 1997 |
Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1997 |
Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Salicylates; Tetracycline | 1997 |
Treatment of Helicobacter pylori infection: a review.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Patient Compliance; Vaccines | 1997 |
Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Proton Pump Inhibitors | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Metronidazole; Omeprazole; Penicillins; Proton Pump Inhibitors | 1997 |
The actions of bismuth in the treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Synergism; Duodenum; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Organometallic Compounds; Ranitidine; Salicylates; Treatment Outcome | 1997 |
The treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma; Proton Pump Inhibitors; Ranitidine; Risk Factors; Stomach Neoplasms | 1997 |
Treatment strategies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Protein Synthesis Inhibitors; Salicylates; Tetracycline | 1997 |
Review: Helicobacter pylori. Current issues and new directions.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Peptic Ulcer; Stomach Neoplasms | 1997 |
Peptic ulcer disease in the 1990s: an Asian perspective.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Asia; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer | 1997 |
New developments in Helicobacter pylori eradication therapy.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 1997 |
Guidelines for the treatment of Helicobacter pylori in the pediatric population.
Topics: Adolescent; Amoxicillin; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Tinidazole | 1997 |
Treatment of Helicobacter pylori infection: a review of the world literature.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Smoking; Tetracycline; Treatment Outcome | 1996 |
Therapy of H. pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Ranitidine; Tinidazole | 1997 |
Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 1997 |
Helicobacter pylori.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Bismuth; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma; Peptic Ulcer; Stomach Neoplasms | 1998 |
[Helicobacter infections].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Child; Chronic Disease; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Risk Factors; Stomach Neoplasms; Stomach Ulcer | 1997 |
New options in Helicobacter pylori eradication: efficacy, resistance and synergy.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 1998 |
[Treatment of Helicobacter pylori infections].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Penicillins; Tetracycline; Time Factors | 1998 |
Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection and duodenal ulcer.
Topics: Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Interactions; Duodenal Ulcer; Formularies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine | 1998 |
Management of Helicobacter pylori infection in children.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Patient Selection | 1998 |
Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine | 1998 |
Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Azithromycin; Bismuth; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine | 1998 |
Antimicrobial treatment of H. pylori infection--a pooled efficacy analysis of eradication therapies.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Meta-Analysis as Topic; Peptic Ulcer | 1998 |
[History of the treatment of Helicobacter pylori and clinical efficacy].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Practice Guidelines as Topic; Proton Pump Inhibitors | 1999 |
[Characteristics of anti-microbial agents and its clinical choice for H. pylori treatment].
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Nitroimidazoles | 1999 |
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Neoplasms; Endoscopy, Digestive System; Enzyme Inhibitors; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Organometallic Compounds; Peptic Ulcer; Practice Guidelines as Topic; Proton Pump Inhibitors; Ranitidine; Stomach Neoplasms | 1998 |
Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Multivariate Analysis; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors | 1999 |
Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Pilot Projects; Ranitidine; Treatment Outcome | 1999 |
Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Global Health; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Proton Pump Inhibitors; Regression Analysis | 1999 |
[A consensus on some problems of Helicobacter pylori (draft)].
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Stomach Ulcer | 1997 |
Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline; Treatment Outcome | 1999 |
[Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Duodenitis; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lymphoma, B-Cell, Marginal Zone; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Ranitidine; Stomach Neoplasms; Stomach Ulcer | 1999 |
Where are We with current therapy?
Topics: Adult; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine | 2000 |
Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Penicillins; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2000 |
Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine | 2000 |
Traditional and non-traditional antimicrobial agents for H. pylori infection.
Topics: Bismuth; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2000 |
Therapy for H. pylori infection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine; Stomach Diseases | 1999 |
How to treat Helicobacter pylori. First-line, second-line, and future therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Protocols; Costs and Cost Analysis; Drug Therapy, Combination; Forecasting; Genetics, Medical; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2000 |
Retreatment of Helicobacter pylori infection after initial treatment failure.
Topics: Anti-Ulcer Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine; Retreatment; Treatment Failure | 2001 |
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Odds Ratio; Omeprazole; Ranitidine; Research Design; Retrospective Studies; United States; United States Food and Drug Administration | 2001 |
Treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2001 |
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; MEDLINE; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer Hemorrhage; Randomized Controlled Trials as Topic; Ranitidine; Recurrence; Risk Factors; Salicylates; Sensitivity and Specificity | 2001 |
A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracyclines | 2001 |
[Classic triple therapy for Helicobacter pylori infection].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Salicylates; Tetracycline | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Histamine H2 Antagonists; Humans; Metronidazole; Patient Care Planning; Penicillins; Proton Pumps; Ranitidine; Recurrence | 2002 |
[Should Helicobacter infection be treated?].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 1991 |
Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cefixime; Cefotaxime; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Research Design; Sensitivity and Specificity | 1992 |
[Future perspectives of ulcer therapy].
Topics: Anti-Ulcer Agents; Bismuth; Forecasting; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1992 |
Therapeutic approaches to recurrent peptic ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Peptic Ulcer; Recurrence; Salicylates | 1992 |
Helicobacter pylori infection in children. A clinical overview.
Topics: Anti-Bacterial Agents; Biopsy; Bismuth; Child; Clinical Trials as Topic; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Evaluation Studies as Topic; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Prevalence; Salicylates | 1992 |
[Helicobacter pylori: can it be a contributing factor in peptic ulcer in childhood?].
Topics: Anti-Bacterial Agents; Bismuth; Child; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates | 1991 |
The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; History, 18th Century; History, 19th Century; History, 20th Century; Humans | 1991 |
[Bismuth therapy in gastroenterology].
Topics: Bismuth; Diarrhea; Gastritis; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1991 |
[Helicobacter pylori and gastroduodenal pathology. Second part: Clinical aspects and therapy].
Topics: Achlorhydria; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Stomach Ulcer | 1991 |
Helicobacter pylori: fact or fiction?
Topics: Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Prevalence | 1990 |
The who's and when's of therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1990 |
350 trial(s) available for bismuth and Helicobacter Infections
| Article | Year |
|---|---|
Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Treatment Failure; Treatment Outcome | 2021 |
Comparison of tailored
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Republic of Korea; Treatment Outcome | 2022 |
The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Capsules; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Potassium Citrate; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Tetracycline; Treatment Outcome | 2021 |
Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome | 2022 |
Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Rabeprazole; Treatment Outcome | 2022 |
A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Probiotics; Prospective Studies | 2022 |
Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2022 |
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Saccharomyces boulardii; Treatment Outcome | 2022 |
Metagenomic Changes of Gut Microbiota following Treatment of
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Metronidazole; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 16S; Tetracycline; Treatment Outcome | 2022 |
High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2023 |
The efficacy of bismuth quadruple therapy, sequential therapy, and hybrid therapy as a first-line regimen for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Treatment Outcome | 2022 |
Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Potassium Citrate; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2022 |
[The effectiveness of eradication therapy of the 1st line of Helicobacter pylori infection in patients with type 2 diabetes mellitus].
Topics: Anti-Bacterial Agents; Bismuth; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies; Treatment Outcome | 2022 |
[A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of
Topics: Amoxicillin; Anti-Bacterial Agents; Bifidobacterium longum; Bismuth; Clarithromycin; Drug Therapy, Combination; Enterococcus faecium; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin A, Secretory; Omeprazole; Probiotics; Prospective Studies; Urease | 2021 |
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline | 2023 |
Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Nausea; Pectins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Probiotics modulate gastrointestinal microbiota after
Topics: Anti-Bacterial Agents; Bacteroidetes; Bismuth; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Probiotics; RNA, Ribosomal, 16S | 2022 |
Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Pharmacokinetic Interaction of Anaprazole, Amoxicillin and Clarithromycin after Single-Dose Simultaneous Administration and the Effect of Adding Bismuth on Their Pharmacokinetics in Healthy Male Chinese Subjects.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Combinations; East Asian People; Helicobacter Infections; Humans; Male; Proton Pump Inhibitors | 2023 |
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Australia; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; RNA, Ribosomal, 16S; Young Adult | 2023 |
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Quinolones; Treatment Outcome | 2023 |
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cefuroxime; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Medication Adherence; Metronidazole; Minocycline; Penicillins; Tetracycline; Treatment Outcome | 2023 |
A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2023 |
Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Taiwan; Treatment Outcome | 2023 |
Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Pectins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Potassium Citrate; Tetracycline | 2023 |
Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2023 |
Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Polymerase Chain Reaction; Retrospective Studies; Treatment Outcome | 2023 |
Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2023 |
Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2023 |
Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Comparison of the efficacies of triple, quadruple and sequential antibiotic therapy in eradicating Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 2023 |
Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2023 |
Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
Topics: Adult; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 2023 |
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Berberine; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2023 |
Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; China; Clarithromycin; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Rabeprazole; Randomized Controlled Trials as Topic; Single-Blind Method | 2023 |
Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bismuth; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans | 2023 |
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Thailand | 2023 |
Effects of addition of probiotic and/or bismuth to triple therapy of H. pylori and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Asian People; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Esomeprazole; Female; Gene Frequency; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Polymorphism, Single Nucleotide; Probiotics; RNA, Ribosomal, 23S; Treatment Outcome | 2019 |
High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
Topics: Anti-Bacterial Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Probiotics; Prognosis; Proton Pump Inhibitors; Thailand | 2019 |
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
[The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Russia; Stomach Ulcer | 2019 |
Addition of bismuth to standard triple therapy for Helicobacter pylori eradication: a randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 2020 |
Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Disulfides; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Sulfinic Acids; Treatment Outcome | 2021 |
Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Treatment Outcome | 2020 |
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2020 |
The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Republic of Korea; RNA, Ribosomal, 23S; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2020 |
Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ofloxacin; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Republic of Korea | 2021 |
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2021 |
Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Endoscopy; Esomeprazole; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Microscopy, Electron, Transmission; Organometallic Compounds; Proton Pump Inhibitors; Salts | 2021 |
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
Topics: Abdominal Pain; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Metronidazole; Probiotics; Treatment Outcome | 2022 |
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Prospective Studies; Treatment Outcome | 2021 |
Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Syria; Tinidazole; Treatment Outcome; Young Adult | 2021 |
[A multicenter randomized controlled study of bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang in the treatment of patients newly diagnosed with
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome | 2021 |
Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Medication Adherence; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Failure; Urea | 2017 |
Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors | 2017 |
Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Taiwan; Tetracycline; Treatment Outcome | 2017 |
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Topics: Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Berberine; Bismuth; Body Mass Index; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Severity of Illness Index; Sex Factors | 2017 |
Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2018 |
Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Tetracycline; Young Adult | 2017 |
Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Republic of Korea | 2018 |
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates | 2018 |
New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; China; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Tetracycline; Young Adult | 2018 |
Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteriological Techniques; Bismuth; Breath Tests; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; United States; Young Adult | 2018 |
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2018 |
14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Treatment Outcome; Young Adult | 2018 |
Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.
Topics: Adult; Amoxicillin; Bismuth; Breath Tests; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2018 |
Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Tetracycline | 2018 |
Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Exanthema; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2018 |
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter,
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Young Adult | 2018 |
The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Metronidazole; Middle Aged; Probiotics; Proton Pump Inhibitors; Retrospective Studies; Tetracycline | 2018 |
Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2018 |
Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cross-Sectional Studies; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2019 |
Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Peptic Ulcer; Prospective Studies; Treatment Outcome | 2018 |
Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome | 2019 |
Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Patient Education as Topic; Pectins; Prospective Studies; Text Messaging; Young Adult | 2019 |
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2019 |
High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2019 |
[Influence of different timing of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Disease Eradication; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Saccharomyces boulardii; Treatment Outcome | 2019 |
Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duration of Therapy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Treatment Outcome | 2019 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Latin America; Male; Medication Adherence; Metronidazole; Middle Aged; Primary Prevention; Recurrence; Risk; Stomach Neoplasms; Young Adult | 2013 |
The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Female; Helicobacter Infections; Humans; Male; Middle Aged; Peptic Ulcer; Placebos; Probiotics; Treatment Outcome; Urea | 2013 |
Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pilot Projects; Prospective Studies; Treatment Outcome; Urea; Young Adult | 2013 |
The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Young Adult | 2013 |
Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Tetracycline; Time Factors; Treatment Outcome | 2014 |
A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome; Young Adult | 2013 |
[Non-bismuth quadruple therapy versus standard triple therapy for Helicobacter pylori eradication: a randomized controlled study].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome; Young Adult | 2014 |
Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Probiotics; Prognosis; Prospective Studies; Salicylates; Thailand | 2014 |
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Urea | 2015 |
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2015 |
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Turkey | 2014 |
High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
Topics: Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Clarithromycin; Cytochrome P-450 CYP2C19; Dexlansoprazole; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Thailand | 2015 |
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Tetracycline | 2015 |
Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Cytochrome P-450 CYP2C19; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tertiary Care Centers; Treatment Outcome; Young Adult | 2016 |
Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Bismuth; Breath Tests; Clinical Protocols; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Salicylates; Turkey | 2015 |
Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety.
Topics: Adult; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2016 |
Phytomedicine-based and Quadruple Therapies in Helicobacter pylori Infection: A Comparative, Randomized Trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Phytotherapy; Plant Extracts; Treatment Outcome; Young Adult | 2015 |
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Young Adult | 2015 |
[Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication: a perspective, multicenter, randomized controlled trial].
Topics: Amoxicillin; Antacids; Bismuth; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Gastritis; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Urea | 2016 |
Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Tetracycline; Treatment Failure | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Tetracycline; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2017 |
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Treatment Outcome; Young Adult | 2009 |
The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine; Tetracyclines; Treatment Outcome | 2009 |
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Tetracycline; Treatment Outcome; Young Adult | 2009 |
The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Ascorbic Acid; Bismuth; Dietary Supplements; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Young Adult | 2009 |
Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Ranitidine | 2009 |
A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; China; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Pilot Projects; Placebos; Rural Population; Tetracycline; Urea | 2010 |
Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Republic of Korea; Tetracycline; Time Factors; Treatment Outcome | 2010 |
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Case-Control Studies; Chi-Square Distribution; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Statistics, Nonparametric; Surveys and Questionnaires; Tetracycline; Treatment Outcome | 2010 |
Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Bismuth; Clarithromycin; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Omeprazole; Pectins; Prospective Studies | 2010 |
Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Peptic Ulcer; Treatment Outcome | 2011 |
[Effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dental Plaque; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Failure; Young Adult | 2011 |
[Efficacy of bismuth-based quadruple therapy as first-line treatment for Helicobacter pylori infection].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Humans; Male; Middle Aged; Treatment Outcome | 2011 |
Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Medication Adherence; Metronidazole; Middle Aged; Pantoprazole; Prospective Studies; Tetracycline; Time Factors; Treatment Outcome; Urea | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histocytochemistry; Humans; Italy; Male; Metronidazole; Middle Aged; Pantoprazole; Prospective Studies; Tetracycline; Time Factors; Treatment Outcome; Urea; Young Adult | 2011 |
A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Male; Middle Aged; Organometallic Compounds; Pantoprazole | 2012 |
Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Tetracycline; Young Adult | 2012 |
A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Treatment Failure; Treatment Outcome; Young Adult | 2012 |
Lycopene an adjunctive therapy for Helicobacter pylori eradication: a quasi-control trial.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Bismuth; Carotenoids; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lycopene; Male; Metronidazole; Middle Aged; Omeprazole; Treatment Outcome | 2012 |
Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Treatment Outcome; Urea; Young Adult | 2013 |
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Proton Pumps; Treatment Failure; Treatment Outcome | 2002 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pantoprazole; Peptic Ulcer; Prospective Studies; Sulfoxides; Tetracycline; Treatment Failure; Treatment Outcome | 2002 |
Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Stomach Diseases | 2002 |
The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine; Treatment Outcome | 2002 |
One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Treatment Outcome | 2002 |
Effectiveness of ranitidine bismuth citrate based triple therapy for treating Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Prospective Studies; Ranitidine; Stomach; Thailand; Treatment Outcome | 2002 |
Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Ranitidine; Tetracycline | 2002 |
Patients with endoscopic gastritis and/or duodenitis improve markedly following eradication of Helicobacter pylori, although less so than patients with ulcers.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenitis; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Ranitidine; Spiramycin; Time Factors | 2002 |
Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline; Treatment Outcome | 2003 |
Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment.
Topics: Adult; Amoxicillin; Antacids; Bismuth; Calcium Carbonate; Drug Therapy, Combination; Dyspepsia; Female; Gastric Acidity Determination; Gastritis, Atrophic; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Retrospective Studies; Risk Factors; Salicylates; Tetracycline | 2003 |
Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Gastric Mucosa; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Salvage Therapy; Tetracyclines; Urea | 2003 |
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Tetracycline; Urea | 2003 |
Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides; Tetracycline | 2003 |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Patient Compliance; Prospective Studies; Treatment Outcome | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Severity of Illness Index; Treatment Outcome | 2003 |
A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Ranitidine; Time Factors; Urea | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Pantoprazole; Prospective Studies; Ranitidine; Sulfoxides; Tinidazole; Treatment Failure; Urea | 2003 |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine; Tinidazole; Treatment Outcome | 2003 |
Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Proteins; Bismuth; Blood Pressure; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hypertension; Male; Middle Aged; Prevalence; Ranitidine | 2003 |
Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Oxytetracycline; Specimen Handling; Treatment Outcome | 2004 |
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Pilot Projects; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Salicylates; Tetracycline; Treatment Outcome | 2004 |
Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Drug Resistance, Bacterial; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Ranitidine; Tetracycline; Treatment Failure; Treatment Outcome | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pilot Projects; Ranitidine; Tetracycline; Treatment Outcome | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Tetracycline | 2004 |
[Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection].
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Aza Compounds; Bismuth; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Quinolines | 2005 |
Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Chi-Square Distribution; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Tetracycline; Treatment Outcome; Turkey | 2005 |
7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 2005 |
One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Brazil; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Ranitidine; Treatment Outcome | 2005 |
Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Citric Acid; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Predictive Value of Tests; Salicylates; Sensitivity and Specificity; Treatment Outcome; Urea | 2005 |
Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication.
Topics: Administration, Oral; Adolescent; Adult; Antacids; Anti-Bacterial Agents; Biological Availability; Bismuth; Cross-Over Studies; Drug Combinations; Food-Drug Interactions; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline | 2005 |
Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Minocycline; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Costs and Cost Analysis; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mass Screening; Middle Aged; Patient Acceptance of Health Care; Peptic Ulcer; Quality of Life; Ranitidine | 2006 |
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Peptic Ulcer; Prospective Studies; Ranitidine | 2006 |
Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Ranitidine; Tetracycline; Treatment Outcome; Urease; Young Adult | 2006 |
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Contraindications; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pantoprazole; Pyloric Antrum; Stomach Ulcer; Tetracycline; Treatment Failure | 2006 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; Double-Blind Method; Dyspepsia; Gastric Emptying; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Metronidazole; Omeprazole; Peptic Ulcer; Sucrose; Tetracycline; Treatment Outcome | 2006 |
Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Ranitidine; Treatment Failure; Treatment Outcome | 2007 |
Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Male; Middle Aged; Prospective Studies; Ranitidine; Tinidazole | 2007 |
First-line triple therapy with levofloxacin for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Ranitidine; Treatment Outcome | 2007 |
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Middle Aged; Single-Blind Method; Statistics, Nonparametric; Tetracycline; Treatment Outcome | 2007 |
Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Cross-Over Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Ranitidine; Urea | 2008 |
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult | 2008 |
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline; Treatment Outcome | 1995 |
Healing of gastric body ulcer with gastroprotective versus antisecretory treatment.
Topics: Adult; Antacids; Anti-Ulcer Agents; Bismuth; Cimetidine; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds; Ranitidine; Recurrence; Stomach Ulcer; Time Factors | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Recurrence | 1995 |
[Antibacterial treatment of gastric ulcers associated with Helicobacter pylori without acid suppression].
Topics: Aluminum Hydroxide; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Magnesium Hydroxide; Metronidazole; Omeprazole; Simethicone; Stomach Ulcer; Tetracycline | 1995 |
Bismuth salts and neurotoxicity. A randomised, single-blind and controlled study.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Electroencephalography; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Nervous System; Neurologic Examination; Organometallic Compounds; Single-Blind Method | 1995 |
Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up.
Topics: Adult; Aged; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Spiramycin; Treatment Outcome | 1995 |
Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients.
Topics: Adult; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Salicylates; Time Factors | 1995 |
Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Recurrence; Tetracycline; Time Factors | 1995 |
Effect of administration of ranitidine bismuth citrate with food on the suppression and eradication of Helicobacter pylori in infected volunteers.
Topics: Adult; Bismuth; Breath Tests; Carbon Radioisotopes; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Food; Headache; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Incidence; Male; Ranitidine; Time Factors; Urea | 1995 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Metronidazole; Nitrates; Omeprazole; Prospective Studies; Ranitidine; Recurrence; Tetracycline; Time Factors; Tinidazole | 1995 |
Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers.
Topics: Adult; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Sucralfate; Tetracycline | 1995 |
Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study.
Topics: Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 1995 |
Association of symptoms with Helicobacter pylori infection in children.
Topics: Adolescent; Biopsy; Bismuth; Child; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Duodenum; Female; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Prospective Studies | 1995 |
A 1-h topical therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Male; Metronidazole; Middle Aged; Pronase; Time Factors; Treatment Outcome | 1995 |
Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Antacids; Bismuth; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Prospective Studies; Quality of Life; Recurrence; Severity of Illness Index; Time Factors | 1994 |
Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients.
Topics: Antacids; Biopsy; Bismuth; DNA; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Female; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Male; Metronidazole; Middle Aged; Omeprazole; Oxytetracycline; Stomach | 1994 |
Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth.
Topics: Azithromycin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Peptic Ulcer; Ranitidine; Salicylates; Tetracycline | 1995 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Recurrence | 1994 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Leukocytes; Male; Metronidazole; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pumps; Recurrence | 1994 |
Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Tetracycline; Time Factors | 1994 |
Roxithromycin in the eradication of Helicobacter pylori.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole; Organometallic Compounds; Piperidines; Roxithromycin | 1994 |
Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 1994 |
Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Peptic Ulcer; Stomach Ulcer; Tetracycline | 1994 |
Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Time Factors | 1994 |
Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease.
Topics: Adult; Aged; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Recurrence | 1994 |
[The effect of the eradication of H. pylori on the intractable ulcer].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Recurrence | 1993 |
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline | 1993 |
Bismuth subsalicylate suppression of Helicobacter pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial.
Topics: Adult; Bismuth; Chronic Disease; Double-Blind Method; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Leukocyte Count; Organometallic Compounds; Salicylates; Treatment Outcome | 1993 |
Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Salicylates; Tetracycline | 1993 |
Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Cisapride; Double-Blind Method; Duodenum; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Piperidines; Pyloric Antrum | 1993 |
Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Stomach Ulcer; Tetracycline | 1993 |
Patient factors affecting Helicobacter pylori eradication with triple therapy.
Topics: Adult; Age Factors; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Marriage; Metronidazole; Middle Aged; Multivariate Analysis; Patient Compliance; Prospective Studies; Recurrence; Stomach Ulcer; Tetracycline | 1993 |
GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcer.
Topics: Adult; Bismuth; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Logistic Models; Male; Middle Aged; Ranitidine; Treatment Outcome | 1995 |
Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Penicillins; Recurrence; Salicylates | 1995 |
Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Palliative Care; Peptic Ulcer; Ranitidine; Treatment Outcome | 1996 |
Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Chile; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Recurrence; Salicylates; Single-Blind Method; Time Factors | 1996 |
Efficacy of ciprofloxacin in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Ciprofloxacin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies | 1996 |
Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Recurrence; Salicylates; Stomach Ulcer; Time Factors; Tinidazole | 1996 |
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Prospective Studies; Tetracycline | 1995 |
Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Patient Compliance; Ranitidine; Recurrence | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Premedication; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Time Factors | 1996 |
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Tetracycline | 1995 |
The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine | 1996 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Recurrence; Serologic Tests; Tetracycline | 1996 |
One-week therapy for Helicobacter pylori. A randomized trial of two treatment regimens.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Salicylates | 1996 |
Effects of ranitidine bismuth citrate on gastric acid secretion and gastrin release in subjects with and without Helicobacter pylori infection.
Topics: Administration, Oral; Adolescent; Adult; Antacids; Bismuth; Dose-Response Relationship, Drug; Double-Blind Method; Food; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Peptones; Placebos; Ranitidine; Stimulation, Chemical | 1996 |
Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Malaysia; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Recurrence; Time Factors | 1996 |
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Patient Compliance; Ranitidine | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Tetracycline | 1997 |
Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Topics: Activities of Daily Living; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Hospitalization; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer Hemorrhage; Stomach Ulcer; Tetracycline | 1997 |
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Oxytetracycline; Penicillins; Prospective Studies; Recurrence; Time Factors | 1997 |
One week treatment for Helicobacter pylori infection.
Topics: Adolescent; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Breath Tests; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Metronidazole; Organometallic Compounds | 1997 |
Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Nizatidine; Omeprazole; Organometallic Compounds; Penicillins; Ranitidine; Salicylates | 1997 |
Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Tetracycline; Time Factors | 1997 |
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Treatment Outcome | 1997 |
Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Life Tables; Male; Middle Aged; Ranitidine; Treatment Outcome; Wound Healing | 1997 |
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Pyloric Antrum; Ranitidine | 1997 |
Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine; Tetracycline | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Dyspepsia; Evaluation Studies as Topic; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Medical Records; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Taste Disorders | 1997 |
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Administration Schedule; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Naproxen; Organometallic Compounds; Prospective Studies; Stomach Ulcer; Tetracycline | 1997 |
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Smoking; Tetracycline; Tetracyclines | 1997 |
[Elimination of Helicobacter pylori in patients with recurrent abdominal pain with simultaneous administration of ranitidine, bismuth subsalicylate and clarithromycin].
Topics: Abdominal Pain; Anti-Ulcer Agents; Bismuth; Child; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Longitudinal Studies; Male; Prospective Studies; Ranitidine; Recurrence | 1996 |
Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Combinations; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Salicylates; Tetracycline; Urea | 1997 |
Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peru; Recurrence; Salicylates; Tetracycline; Tinidazole | 1997 |
[Hormonal changes and secretion and stomach mucosal microstructure in the course of H. pylori in patients with duodenal ulcer].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Somatostatin | 1997 |
[Endocrine and exocrine gastric mucosal secretion in the course of H. pylori eradication in patients with non-ulcer dyspepsia].
Topics: Amoxicillin; Bismuth; Dyspepsia; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Somatostatin; Stomach Ulcer | 1997 |
Sucralfate as an alternative to bismuth in quadruple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Sucralfate; Tetracycline | 1997 |
One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer Hemorrhage; Ranitidine; Recurrence; Tetracycline | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Placebos; Proton Pump Inhibitors; Ranitidine; Tetracycline | 1998 |
Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anus Diseases; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Diarrhea; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hallucinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nausea; Omeprazole; Peptic Ulcer; Pregnancy; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Taste Disorders; Time Factors; Tongue Diseases; Treatment Outcome; Urea; Vomiting | 1998 |
Comparison of enhanced elimination of bismuth in humans after treatment with meso-2,3-dimercaptosuccinic acid and D,L-2,3-dimercaptopropane-1-sulfonic acid.
Topics: Adult; Aged; Analysis of Variance; Antacids; Bismuth; Chelating Agents; Gastritis; Helicobacter Infections; Humans; Middle Aged; Organometallic Compounds; Single-Blind Method; Succimer; Unithiol | 1998 |
Maintenance therapy with colloidal bismuth subcitrate reduces duodenal ulcer relapse.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Ranitidine; Recurrence | 1997 |
Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study.
Topics: Adult; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer Hemorrhage; Prospective Studies; Recurrence | 1998 |
Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Treatment Outcome | 1998 |
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine | 1998 |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Ranitidine; Wound Healing | 1997 |
Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Stomach Ulcer; Tetracycline; Treatment Outcome | 1998 |
Helicobacter pylori eradication: kill the bug and save the pill?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Naproxen; Peptic Ulcer; Prospective Studies; Risk Factors; Single-Blind Method; Tetracycline | 1998 |
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins; Ranitidine; Tinidazole | 1998 |
One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Tinidazole | 1998 |
Addition of bismuth subnitrate to omeprazole plus amoxycillin improves eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Ranitidine; Stomach Ulcer | 1998 |
One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Ranitidine; Time Factors; Treatment Failure | 1998 |
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Combined Modality Therapy; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pumps; Ranitidine; Single-Blind Method; Treatment Outcome | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Tetracycline; Treatment Outcome | 1998 |
Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine; Recurrence; Treatment Outcome | 1998 |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 1998 |
Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Azithromycin; Bismuth; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine | 1998 |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome; Urea | 1999 |
Evaluation of effects of ethyl alcohol and bismuth subsalicylate on gastric mucosal barrier in man.
Topics: Adult; Bismuth; Ethanol; Female; Gastric Acid; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Organometallic Compounds; Salicylates | 1999 |
One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Tetracycline | 1999 |
[The treatment of chronic duodenal ulcer with accompanying Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clinical Protocols; Duodenal Ulcer; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Retrospective Studies; Treatment Outcome | 1998 |
Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy.
Topics: Adolescent; Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Proton Pump Inhibitors; Ranitidine | 1999 |
The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Penicillins; Ranitidine; Stomach Ulcer | 1999 |
Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Patient Compliance; Ranitidine; Tetracycline; Urea | 1999 |
Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori.
Topics: Adult; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Ranitidine; Time Factors | 1999 |
Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 1999 |
Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Penicillins; Ranitidine; Urea | 1999 |
Garlic or jalapeño peppers for treatment of Helicobacter pylori infection.
Topics: Adult; Bismuth; Capsicum; Cross-Over Studies; Female; Garlic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Phytotherapy; Plants, Medicinal; Prospective Studies; Salicylates | 1999 |
Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments.
Topics: Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 1999 |
Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Ranitidine | 1999 |
Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Double-Blind Method; Drug Therapy, Combination; Female; Ferrous Compounds; Helicobacter Infections; Helicobacter pylori; Hemoglobins; Humans; Intestinal Absorption; Male; Metronidazole; Nutritional Status; Organometallic Compounds; Placebos; Pyloric Antrum | 1999 |
Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; China; Colloids; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pectins | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Ranitidine; Treatment Outcome | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Salicylates; Treatment Outcome | 1999 |
Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline; Treatment Outcome | 1999 |
Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Ranitidine | 1999 |
One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Combinations; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Penicillins; Peptic Ulcer; Prospective Studies; Ranitidine; Treatment Outcome | 1999 |
Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine; Turkey | 1999 |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 1999 |
A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Maintenance Organizations; Helicobacter Infections; Helicobacter pylori; Humans; Male; Massachusetts; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Program Evaluation; Salicylates; Tetracycline; Treatment Outcome | 1999 |
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication].
Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Recurrence; Wound Healing | 1999 |
Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine; Tinidazole; Treatment Outcome; Urea | 1999 |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Penicillins; Prospective Studies; Ranitidine; Tinidazole; Urea | 2000 |
Efficacy of a multistep strategy for Helicobacter pylori eradication.
Topics: Algorithms; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins; Ranitidine; Tinidazole; Treatment Failure | 2000 |
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Enzyme Inhibitors; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Tetracycline | 2000 |
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Salvage Therapy | 2000 |
Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Bismuth; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin A; Male; Middle Aged; Omeprazole; Patient Compliance; Ranitidine; Urease; Vietnam | 2000 |
Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Outlet Obstruction; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; Treatment Outcome | 2000 |
Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Prospective Studies; Ranitidine; Single-Blind Method | 2000 |
Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Esophagitis, Peptic; Female; Follow-Up Studies; Gastroesophageal Reflux; Gastroscopy; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Treatment Failure | 2000 |
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Clarithromycin; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Pantoprazole; Ranitidine; Sulfoxides; Tinidazole | 2000 |
Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Female; Follow-Up Studies; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline; Treatment Outcome | 2000 |
Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets.
Topics: Animals; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Ferrets; Gastric Mucosa; Helicobacter; Helicobacter Infections; Ovariectomy; Ranitidine; Time Factors | 1999 |
Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Patient Compliance; Prospective Studies; Salicylates; Tetracycline; Treatment Outcome | 2000 |
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 2000 |
[Combination of ranitidine and bismuth citrate plus 2 antibiotics in the eradication of Helicobacter pylori].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Ranitidine; Time Factors | 2000 |
Double-blind comparison of absorbable colloidal bismuth subcitrate and nonabsorbable bismuth subnitrate in the eradication of Helicobacter pylori and the relief of nonulcer dyspepsia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Absorption; Middle Aged; Organometallic Compounds; Treatment Outcome | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome | 2000 |
Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage--a long-term randomized, controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Male; Metronidazole; Middle Aged; Peptic Ulcer Hemorrhage; Prognosis; Secondary Prevention | 2000 |
Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Costs and Cost Analysis; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2000 |
[Effect of Helicobacter pylori eradication on histological lesions of gastric mucosa. An 18-month follow-up study].
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Severity of Illness Index; Treatment Outcome | 2000 |
Helicobacter pylori infection in childhood: results of management with ranitidine bismuth citrate plus amoxicillin and tinidazole.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Peptic Ulcer; Ranitidine; Tinidazole | 2000 |
Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; Drug Synergism; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine | 2000 |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Hong Kong; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prevalence; Ranitidine; Treatment Outcome; Urea | 2001 |
Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline; Treatment Outcome; Urea | 2001 |
A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Treatment Outcome | 2001 |
Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Penicillins; Ranitidine; Veterans | 2001 |
Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Calcium Carbonate; Drug Therapy, Combination; Epithelium; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Male; Metronidazole; Middle Aged; Organometallic Compounds; Penicillins; Placebos; Risk Factors; Salicylates; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2001 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Headache; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pruritus; Ranitidine; Recurrence; Taste Disorders; Tinidazole; Treatment Outcome | 2001 |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Ranitidine; Recurrence; Sulfoxides; Tinidazole; Treatment Outcome; Urea | 2001 |
Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Safety | 2001 |
High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 2001 |
A triple therapy regimen after failed Helicobacter pylori treatments.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Bismuth; Breath Tests; Carbon Isotopes; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine; Tetracycline; Tinidazole; Urea; Urease | 2001 |
Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Ranitidine; Treatment Outcome; Urea; Urease | 2001 |
Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer Perforation; Prospective Studies; Ranitidine; Recurrence; Retrospective Studies; Tetracycline | 2001 |
Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy, Needle; Bismuth; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Esophagoscopy; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine; Urea | 2001 |
[Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine | 2001 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 2001 |
Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 2001 |
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Penicillins; Peptic Ulcer; Ranitidine; Retrospective Studies | 2001 |
One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Bismuth; Diarrhea; Dizziness; Double-Blind Method; Drug Therapy, Combination; Exanthema; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins; Prospective Studies; Pruritus; Ranitidine; Tetracycline; Treatment Outcome; Vomiting | 2001 |
Two new treatment regimens for Helicobacter pylori eradication: a randomised study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Tinidazole; Treatment Outcome | 2001 |
Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment.
Topics: Acute Disease; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Chronic Disease; Drug Therapy, Combination; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Male; Middle Aged; Serologic Tests; Time Factors | 2002 |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Omeprazole; Tetracycline; Treatment Failure | 2002 |
Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 2002 |
Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection.
Topics: Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Ranitidine | 2002 |
Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori.
Topics: Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Organometallic Compounds; Ranitidine; Salicylates; Time Factors | 1992 |
Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Dyspepsia; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Prospective Studies | 1992 |
Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Single-Blind Method; Tetracycline | 1992 |
Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Bismuth; Duodenal Ulcer; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Longitudinal Studies; Male; Metronidazole; Middle Aged; Ranitidine; Recurrence; Regression Analysis; Water | 1992 |
Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Bismuth; Circadian Rhythm; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Erythromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Stomach Ulcer | 1992 |
Double-blind randomized trial of bismuth subsalicylate and clindamycin for treatment of Helicobacter pylori infection.
Topics: Bismuth; Clindamycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Pain Measurement; Salicylates | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Ranitidine; Recurrence; Risk Factors; Salicylates; Stomach Ulcer; Tetracycline | 1992 |
Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy.
Topics: Adult; Aged; Antacids; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Tetracycline | 1992 |
Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies | 1991 |
Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate.
Topics: Adult; Antacids; Bismuth; Double-Blind Method; Dyspepsia; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds; Recurrence | 1991 |
The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Salicylates | 1991 |
Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Ranitidine; Salicylates; Single-Blind Method; Tetracycline | 1991 |
Duodenal ulcer relapse after eradication of Helicobacter pylori.
Topics: Amoxicillin; Antacids; Bismuth; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Recurrence; Tinidazole | 1991 |
Chronic alcoholic gastritis. Roles of alcohol and Helicobacter pylori.
Topics: Adult; Alcoholism; Aluminum Hydroxide; Amoxicillin; Bismuth; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Salicylates; Temperance | 1991 |
A placebo controlled trial of bismuth salicylate in Helicobacter pylori associated gastritis.
Topics: Adolescent; Adult; Bismuth; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Placebos; Prospective Studies; Salicylates; Salicylic Acid | 1990 |
Medical treatment of antral gastrin cell hyperfunction: role of nonantisecretory therapy.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Bismuth; Cimetidine; Duodenal Ulcer; Enterochromaffin Cells; Female; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Ranitidine | 1990 |
362 other study(ies) available for bismuth and Helicobacter Infections
| Article | Year |
|---|---|
Clinical audit of current
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Audit; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Singapore; Treatment Outcome | 2022 |
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastroenterologists; Gastroenterology; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Surveys and Questionnaires | 2022 |
Helicobacter pylori infection and eradication outcomes among Vietnamese patients in the same households: Findings from a non-randomized study.
Topics: Adolescent; Adult; Antacids; Anti-Bacterial Agents; Asian People; Bismuth; Child; Drug Therapy, Combination; Family Characteristics; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Tetracycline; Vietnam; Young Adult | 2021 |
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg).
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline | 2022 |
All-in-One Theranostic Platform Based on Hollow Microcapsules for Intragastric-Targeting Antiulcer Drug Delivery, CT Imaging, and Synergistically Healing Gastric Ulcer.
Topics: Anti-Bacterial Agents; Bismuth; Capsules; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Precision Medicine; Stomach Ulcer; Tetracycline; Tomography, X-Ray Computed | 2022 |
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Stomach Neoplasms; Systematic Reviews as Topic; Treatment Failure | 2022 |
Second-line Therapy for Helicobacter Pylori Eradication: State of the Art.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2022 |
Structure of the active pharmaceutical ingredient bismuth subsalicylate.
Topics: Bismuth; Helicobacter Infections; Humans; Organometallic Compounds; Pharmaceutical Preparations; Salicylates | 2022 |
Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Poland; Proton Pump Inhibitors; Retrospective Studies | 2022 |
Helicobacter pylori eradication in elderly patients: can we assume that a bismuth-based therapy is effective as in young people?
Topics: Adolescent; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2022 |
The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Treatment Outcome | 2022 |
Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross-sectional survey.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cross-Sectional Studies; Drug Therapy, Combination; Gastroenterologists; Helicobacter Infections; Helicobacter pylori; Humans; Penicillins; Proton Pump Inhibitors; Tertiary Care Centers; Urea | 2022 |
Bacterial Membrane Vesicles as a Novel Strategy for Extrusion of Antimicrobial Bismuth Drug in Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Polyphosphates; Stomach Neoplasms | 2022 |
Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Multiplex Polymerase Chain Reaction; Oligonucleotides; Retrospective Studies | 2023 |
Single-capsule bismuth-based quadruple therapy as a rescue therapy for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Microbiota; Probiotics; RNA, Ribosomal, 16S; Treatment Outcome | 2022 |
Effects of Quadruple Therapy Combined with Probiotics on
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Motilin; Pectins; Peptic Ulcer; Probiotics; Proton Pump Inhibitors; Somatostatin; Tablets, Enteric-Coated | 2022 |
Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2022 |
Vonoprazan on the Eradication of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Potassium Citrate; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Prospective Studies; Proton Pump Inhibitors; Registries | 2023 |
2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 2022 |
Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rifabutin; Treatment Outcome; United States | 2023 |
Clinical Effects of Biling Weitong Granules in Combination with Quadruple Therapy on Refractory Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Treatment Outcome | 2023 |
Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Retrospective Studies; Treatment Outcome | 2023 |
Can the optimal treatment duration be determined in bismuth-containing therapies for Helicobacter pylori eradication?
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duration of Therapy; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2023 |
Generalization and safety of the second-line levofl oxacin or Bismuth-based quadruple therapy for Helicobacter eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Failure; Treatment Outcome | 2023 |
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries | 2023 |
Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
Topics: Amoxicillin; Anti-Bacterial Agents; Asia, Southeastern; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Physicians; Proton Pump Inhibitors; Surveys and Questionnaires | 2023 |
Comparison of the management of Helicobacter pylori infection between the older and younger European populations.
Topics: Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Penicillins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Helicobacter pylori Empirical and Tailored Eradication Therapy and Factors Influencing Eradication Rate: a 4-Year Single-Center Study.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Retrospective Studies; Treatment Outcome | 2023 |
Clinical Efficacy of Diet Intervention Combined with Bismuth Potassium Citrate in Helicobacter pylori-Related Chronic Atrophic Gastritis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Potassium; Potassium Citrate; Treatment Outcome | 2023 |
Global research trends and hotspots of Helicobacter pylori eradication based on clinical trial registration platforms: A cross-sectional analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cross-Sectional Studies; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duration of Therapy; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Reply.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans | 2019 |
Addition of Bismuth to the Standard Triple Therapy for Helicobacter Pylori Infection.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2019 |
Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Child; China; Clarithromycin; Cross-Sectional Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Prospective Studies; Proton Pump Inhibitors | 2020 |
The effect of intracellular “depot” helicobacter pylori infection on the quality of eradication with monotheraphy of patients with chronic non-atrophic gastritis by the bismuth colloidal subcitrate
Topics: Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans | 2019 |
Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
Topics: Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Disease Eradication; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Republic of Korea; Tertiary Care Centers; Tetracycline; Tetracycline Resistance | 2020 |
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Hypersensitivity; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Registries; Tetracycline | 2020 |
Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Treatment Outcome | 2020 |
Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of H. pylori with bismuth quadruple regimen.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tetracycline | 2020 |
[European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Moscow; Prospective Studies; Proton Pump Inhibitors; Registries; Russia | 2020 |
Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2020 |
Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Drug Costs; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2020 |
Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Cross-Sectional Studies; Drug Hypersensitivity; Dysbiosis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors | 2020 |
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Combinations; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Spain; Tetracycline; Treatment Outcome; Young Adult | 2020 |
Helicobacter pylori and antibiotic resistance in the pediatric population: an update from Vietnam.
Topics: Amoxicillin; Bismuth; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Probiotics; Proton Pump Inhibitors; Vietnam | 2020 |
Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by
Topics: Amoxicillin; Animals; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Mice; Proton Pump Inhibitors; Rabeprazole; Sucralfate | 2020 |
Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome; Turkey | 2020 |
Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Health Plan Implementation; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries; Slovenia | 2021 |
Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Pilot Projects; Prospective Studies | 2021 |
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Resistance, Bacterial; Europe; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries; Tetracycline; Young Adult | 2021 |
Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Proton Pump Inhibitors | 2021 |
Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Retrospective Studies; Tetracycline; Treatment Outcome; Turkey | 2021 |
Prospective comparative study of the treatment of Helicobacter pylori with antibiotic susceptibility testing-guided triple therapy compared to quadruple therapy with bismuth-metronidazole-tetracycline subcitrate.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2021 |
Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Croatia; Cross-Sectional Studies; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Physicians, Primary Care; Proton Pump Inhibitors; Students, Medical | 2021 |
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Rifabutin; Stomach Neoplasms; Sulfonamides; Tetracycline; Treatment Outcome | 2021 |
Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors | 2021 |
Fixed drug eruption due to bismuth during Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Eruptions; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rhode Island; Rifabutin; Tetracycline; Young Adult | 2021 |
Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Liver Transplantation; Transplant Recipients | 2021 |
Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects.
Topics: Anti-Bacterial Agents; Benzene Derivatives; Bismuth; Cross-Over Studies; Drug Therapy, Combination; Healthy Volunteers; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Male; Metronidazole; Republic of Korea; Tetracycline | 2021 |
Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Treatment Outcome | 2021 |
Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report.
Topics: Anti-Bacterial Agents; Bismuth; DNA, Bacterial; Drug Hypersensitivity; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Middle Aged; Penicillins; Recurrence; Retreatment; Treatment Outcome | 2021 |
Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Retrospective Studies | 2022 |
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Male; Middle Aged; Proton Pump Inhibitors; Registries | 2021 |
Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; China; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; RNA, Ribosomal, 16S | 2021 |
Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020.
Topics: Amoxicillin; Anti-Bacterial Agents; Bibliometrics; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2021 |
Effect of gastric microbiota on quadruple
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Microbiota; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2021 |
Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proteomics | 2021 |
The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyloric Antrum; Stomach | 2017 |
Barry Marshall, MD: H pylori 35 Years Later.
Topics: Anniversaries and Special Events; Antacids; Anti-Bacterial Agents; Asthma; Bacterial Vaccines; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Nobel Prize; Organometallic Compounds; Peptic Ulcer; Probiotics; Salicylates; Stress, Psychological | 2017 |
The diagnosis and management of H. pylori infection in Singapore.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Singapore | 2017 |
Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hospitals; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Salvage Therapy; Spain; Surveys and Questionnaires; Treatment Outcome; Urea; Young Adult | 2017 |
Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Capsules; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Helicobacter Infections; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2017 |
Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Capsules; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Italy; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Tablets; Tetracycline; Time Factors; Treatment Failure | 2017 |
Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Salvage Therapy; Treatment Outcome; Young Adult | 2017 |
Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies | 2017 |
Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Hospitals; Humans; Macrolides; Male; Middle Aged; Retrospective Studies; Spain; Treatment Failure; Young Adult | 2018 |
Bismuth-Induced Inactivation of Ferric Uptake Regulator from Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bismuth; DNA, Bacterial; Enzyme Inhibitors; Enzyme Stability; Helicobacter Infections; Helicobacter pylori; Humans; Models, Molecular; Protein Conformation; Protein Multimerization; Repressor Proteins | 2017 |
Is Double-Dose Esomeprazole With Bismuth Really Safe?
Topics: Bismuth; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Proton Pump Inhibitors | 2017 |
Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure; United States | 2018 |
Comment on Helicobacter pylori eradication using metronidazole.
Topics: Amoxicillin; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Moxifloxacin | 2018 |
H. pylori Infection: ACG Updates Treatment Recommendations.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2018 |
Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Incidence; Levofloxacin; Male; Middle Aged; Protective Factors; Proton Pump Inhibitors; Registries; Retrospective Studies; Risk Factors; Stomach Neoplasms | 2018 |
Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study.
Topics: Anti-Bacterial Agents; Bismuth; Demography; Drug Therapy, Combination; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Retrospective Studies; Tetracycline; Treatment Outcome | 2018 |
[The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
Topics: Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Nausea; Patient Compliance; Proton Pump Inhibitors; Retrospective Studies; Treatment Failure; Treatment Outcome | 2018 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Adult; Anti-Bacterial Agents; Bacteroidetes; Bismuth; Drug Therapy, Combination; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proteobacteria; Proton Pump Inhibitors; Tetracycline; Young Adult | 2018 |
Bismuth-based quadruple Helicobacter pylori eradication regimen alters the composition of gut microbiota.
Topics: Anti-Bacterial Agents; Bismuth; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans | 2018 |
[Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tinidazole; Treatment Outcome | 2018 |
Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
Topics: Adult; Alcohol Drinking; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Proton Pump Inhibitors; Treatment Failure | 2018 |
Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Risk Factors; Tetracycline; Treatment Failure | 2019 |
[Amoxicillin-Clarithromycin-Containing Bismuth Quadruple Therapy for Primary Eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2019 |
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Europe; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Registries; Treatment Outcome; Young Adult | 2020 |
Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.
Topics: Aged; Bismuth; Cohort Studies; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Neurotoxicity Syndromes; Organometallic Compounds; Tetracycline; Treatment Failure | 2019 |
Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes.
Topics: Adult; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Macrolides; Male; Middle Aged; Prognosis; Proton Pump Inhibitors; Retrospective Studies | 2019 |
Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Rabeprazole; Young Adult | 2019 |
The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults.
Topics: Adult; Anti-Bacterial Agents; Asymptomatic Diseases; Bacteria; Bismuth; Female; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Young Adult | 2019 |
Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Outcome and Process Assessment, Health Care; Proton Pump Inhibitors; Retrospective Studies; Tetracycline; United States | 2019 |
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans | 2019 |
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment.
Topics: Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans | 2019 |
Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Macrolides; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Quinolones; Tetracycline; Young Adult | 2019 |
Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Cefuroxime; China; Drug Hypersensitivity; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Penicillins; Prospective Studies; Treatment Outcome | 2019 |
Synthesis and characterisation of bismuth(III) aminoarenesulfonate complexes and their powerful bactericidal activity against Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Microbial Sensitivity Tests; Organometallic Compounds | 2013 |
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Failure | 2014 |
Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Chlorides; Chronic Disease; Clarithromycin; Drug Resistance, Bacterial; Dyspepsia; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Peptic Ulcer; Salicylates; Zinc Compounds | 2014 |
[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
Topics: Amoxicillin; Anti-Bacterial Agents; Aspirin; Bismuth; Breath Tests; Clarithromycin; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metaplasia; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Republic of Korea; Stomach Neoplasms; Tetracycline | 2013 |
Functional disruption of HypB, a GTPase of Helicobacter pylori, by bismuth.
Topics: Anti-Bacterial Agents; Bismuth; GTP Phosphohydrolases; Helicobacter Infections; Helicobacter pylori; Humans; Models, Molecular; Protein Multimerization | 2014 |
Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Rabeprazole; Retrospective Studies; Tetracycline; Treatment Outcome; Young Adult | 2014 |
Preparation, characterization, and anti-Helicobacter pylori activity of Bi3+-Hericium erinaceus polysaccharide complex.
Topics: Anti-Bacterial Agents; Basidiomycota; Bismuth; Coordination Complexes; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Polysaccharides | 2014 |
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Tetracycline; Treatment Outcome | 2015 |
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Middle Aged; Omeprazole; Penicillins; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Spain; Tetracycline; Time Factors; Treatment Outcome | 2015 |
First-line Bismuth-containing Five-day Concomitant Quintuple Therapy for Helicobacter Pylori Eradication.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Time; Treatment Outcome; Young Adult | 2016 |
Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bacterial; Barrett Esophagus; Bismuth; Breath Tests; Clarithromycin; Disease Management; Drug Therapy, Combination; Dyspepsia; Feces; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Italy; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms; Urea | 2015 |
Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prognosis; Salicylates; Thailand | 2015 |
Synthesis and structural characterisation of bismuth(III) hydroxamates and their activity against Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Coordination Complexes; Crystallography, X-Ray; Helicobacter Infections; Helicobacter pylori; Humans; Hydrolysis; Hydroxamic Acids; Microbial Sensitivity Tests; Molecular Conformation | 2015 |
[Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Taste Disorders; Treatment Outcome; Young Adult | 2015 |
The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Treatment Outcome | 2015 |
Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Pantoprazole; Pilot Projects; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Treatment Outcome | 2016 |
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Outcome | 2016 |
The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Hospitals, Teaching; Humans; Levofloxacin; Logistic Models; Macrolides; Male; Middle Aged; Multivariate Analysis; Republic of Korea; Retrospective Studies; Tertiary Care Centers | 2016 |
Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prevalence; Proton Pump Inhibitors; Retrospective Studies; RNA, Ribosomal, 23S; Treatment Failure; United States; Young Adult | 2016 |
Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Humans; Male; Medication Adherence; Middle Aged; Minocycline; Prospective Studies; Rabeprazole; Treatment Outcome | 2016 |
[Quadruple therapy is more effective against H. pylori].
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Proton Pump Inhibitors | 2016 |
[Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2016 |
Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Canada; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Salvage Therapy; Tetracycline; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Early Detection of Cancer; Evidence-Based Medicine; Fluoroquinolones; Gastritis; Gastrointestinal Microbiome; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Nitroimidazoles; Practice Guidelines as Topic; Proton Pump Inhibitors; Risk Factors; Stomach; Stomach Neoplasms | 2017 |
Bismuth and Non-bismuth Quadruple Therapy for Helicobacter pylori Eradication: Time to Make the Switch in Clinical Practice?
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure | 2017 |
New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Urea | 2017 |
Second-line bismuth-containing quadruple therapy for
Topics: Adult; Aged; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Diabetes Mellitus, Type 2; Disease Eradication; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Republic of Korea; Retrospective Studies; Risk Factors; Tetracycline; Treatment Failure; Treatment Outcome | 2017 |
Oral and intravenous eradication of Helicobacter pylori.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Hemorrhage; Humans; Infusions, Intravenous; Male; Metronidazole; Middle Aged; Pilot Projects; Ranitidine; Treatment Outcome | 2009 |
[Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Enzyme-Linked Immunosorbent Assay; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Stomach Neoplasms; Tetracycline | 2009 |
[Guidelines of treatment for non-bleeding peptic ulcer disease].
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Histamine Antagonists; Humans; Peptic Ulcer; Proton Pump Inhibitors | 2009 |
Bismuth salts in the treatment of Helicobacter pylori infection in children.
Topics: Adolescent; Bismuth; Child; Child, Preschool; Helicobacter Infections; Humans; Organometallic Compounds; Treatment Outcome | 2010 |
Bismuth(III) complexes derived from non-steroidal anti-inflammatory drugs and their activity against Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Calorimetry, Differential Scanning; Coordination Complexes; Drug Stability; Helicobacter Infections; Helicobacter pylori; Ketoprofen; Microbial Sensitivity Tests; Sulindac; Thermogravimetry | 2010 |
Contribution to the study of the chemical constitution of dermatol and airol.
Topics: Antacids; Antidiarrheals; Bismuth; Helicobacter Infections | 1947 |
The C terminus of HspA--a potential target for native Ni(II) and Bi(III) anti-ulcer drugs.
Topics: Amino Acid Sequence; Antacids; Anti-Ulcer Agents; Bacterial Proteins; Binding Sites; Bismuth; Circular Dichroism; Heat-Shock Proteins; Helicobacter Infections; Helicobacter pylori; Histidine; Humans; Nickel; Nuclear Magnetic Resonance, Biomolecular; Oligopeptides; Potentiometry; Protein Structure, Tertiary; Spectrophotometry, Ultraviolet | 2010 |
Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Humans; Organometallic Compounds; Proton Pump Inhibitors; Salicylates | 2010 |
Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; China; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Treatment Outcome | 2010 |
Empiric therapies for Helicobacter pylori infections.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors | 2011 |
Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy.
Topics: Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tetracycline; Treatment Outcome | 2011 |
Ranitidine bismuth citrate in the first-line of Helicobacter pylori treatment.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2011 |
Inhibition of fumarase by bismuth(III): implications for the tricarboxylic acid cycle as a potential target of bismuth drugs in Helicobacter pylori.
Topics: Bacterial Proteins; Bismuth; Citric Acid Cycle; Fumarate Hydratase; Helicobacter Infections; Helicobacter pylori; Humans; Models, Molecular; Protein Structure, Tertiary | 2012 |
Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Metronidazole; Middle Aged; Patient Compliance; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2011 |
Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Bismuth; Breath Tests; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Minocycline; Phenotype; Proton Pump Inhibitors; Time Factors | 2012 |
Double-liposome-based dual-drug delivery system as vectors for effective management of peptic ulcer.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Delayed-Action Preparations; Drug Carriers; Drug Combinations; Drug Stability; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Liposomes; Male; Microbial Sensitivity Tests; Particle Size; Peptic Ulcer; Ranitidine; Rats | 2012 |
Remarkable in vitro bactericidal activity of bismuth(III) sulfonates against Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Coordination Complexes; Crystallography, X-Ray; Helicobacter Infections; Helicobacter pylori; Microbial Sensitivity Tests; Molecular Conformation; Sulfonic Acids | 2012 |
Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hispanic or Latino; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pilot Projects; Tetracycline; Texas; Time Factors; Treatment Outcome; Urea | 2012 |
[The difference of the bismuth absorption from a single colloidal bismuth pectin therapy and quadruple therapy for eradicating Helicobacter pylori infection].
Topics: Absorption; Animals; Bismuth; Colloids; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Male; Pectins; Rats; Rats, Wistar | 2002 |
[Ranitidine-bismuth citrate versus omeprazole plus two antibiotics for seven days for the eradication of Helicobacter pylori: a non-concluding clinical essay].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Ranitidine | 2002 |
Bismuth subcitrate/metronidazole/ tetracycline--Axcan Pharma. Bismuth triple therapy--Axcan Pharma, Helicide.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Tetracycline | 2002 |
Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine | 2003 |
Therapeutic efficacy of ranitidine bismuth citrate with clarithromycin for seven days in the eradication of Helicobacter pylori in Brazilian peptic ulcer patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Brazil; Clarithromycin; Cross-Sectional Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Ranitidine | 2003 |
[Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Treatment Outcome | 2003 |
Information from your family doctor. Ulcers and Helicobacter pylori infection.
Topics: Abdominal Pain; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Family Practice; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Ranitidine | 2003 |
[Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Retreatment; Tetracycline | 2004 |
Sequential therapy for H. pylori: an 'aberrant' therapy ready for general use.
Topics: Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine | 2004 |
[Effect of acid suppression therapy for eradicating Helicobacter pylori infection on bismuth absorption from colloidal bismuth pectin].
Topics: Amoxicillin; Animals; Antacids; Bismuth; Colloids; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Kidney; Male; Metronidazole; Pectins; Random Allocation; Rats; Rats, Sprague-Dawley | 2005 |
[The effect of Helicobacter pylori eradication therapy on bismuth absorption of colloidal bismuth subcitrate].
Topics: Absorption; Amoxicillin; Animals; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Kidney; Male; Metronidazole; Omeprazole; Organometallic Compounds; Random Allocation; Rats; Rats, Sprague-Dawley | 2005 |
[The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years].
Topics: Adult; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Tetracycline | 2005 |
How effective are quadruple therapies as first-line H. pylori eradication therapies?
Topics: Adult; Anti-Infective Agents; Australia; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Metronidazole; Netherlands; Omeprazole; Tetracycline; Treatment Outcome | 2005 |
Inhibition of jack bean urease by organobismuth compounds.
Topics: Antifungal Agents; Bismuth; Fabaceae; Helicobacter Infections; Helicobacter pylori; Microbial Sensitivity Tests; Molecular Structure; Organometallic Compounds; Saccharomyces cerevisiae; Structure-Activity Relationship; Urease | 2006 |
Helicobacter pylori treatment: a practical approach.
Topics: Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Humans; Ofloxacin; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Polymerase Chain Reaction; Ranitidine; Treatment Outcome | 2005 |
Review of successful treatment for Helicobacter species in laboratory mice.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Infective Agents; Bismuth; DNA, Bacterial; Drug Therapy, Combination; Feces; Female; Helicobacter; Helicobacter Infections; Metronidazole; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Transgenic; Polymerase Chain Reaction; Pregnancy; Rodent Diseases | 2006 |
Helicobacter pylori eradication in peptic dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine | 2005 |
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Omeprazole; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
Inhibition of urease by bismuth(III): implications for the mechanism of action of bismuth drugs.
Topics: Amino Acid Sequence; Anti-Ulcer Agents; Bacterial Proteins; Binding Sites; Bismuth; Cysteine; Helicobacter Infections; Klebsiella; Models, Molecular; Molecular Sequence Data; Nuclear Magnetic Resonance, Biomolecular; Plant Proteins; Protein Conformation; Sequence Alignment; Sulfhydryl Compounds; Urease | 2006 |
Comparison of stool enzyme immunoassay and immunochromatographic method for detecting Helicobacter pylori antigens before and after eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antigens, Bacterial; Bismuth; Chromatography; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoenzyme Techniques; Male; Middle Aged; Proton Pump Inhibitors; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2006 |
Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Retrospective Studies; Salicylates; Treatment Outcome | 2006 |
Results from the pediatric European register for treatment of Helicobacter pylori (PERTH).
Topics: Adolescent; Antacids; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Europe; Female; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Male; Microbial Sensitivity Tests; Omeprazole; Registries; Treatment Outcome | 2007 |
What is the best first choice treatment option for Helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Humans; Medication Adherence; Metronidazole; Pantoprazole; Tetracycline | 2007 |
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Ranitidine; Tetracycline; Treatment Failure | 2006 |
Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Colombia; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metaplasia; Metronidazole; Organometallic Compounds; Precancerous Conditions; Regression Analysis; Salicylates; Smoking; Treatment Failure | 2007 |
A histidine-rich and cysteine-rich metal-binding domain at the C terminus of heat shock protein A from Helicobacter pylori: implication for nickel homeostasis and bismuth susceptibility.
Topics: Bacterial Proteins; Bismuth; Chaperonins; Dimerization; Edetic Acid; Escherichia coli; Heat-Shock Proteins; Helicobacter Infections; Helicobacter pylori; Histidine; Hydrogen-Ion Concentration; Metalloproteins; Nickel; Protein Binding; Protein Structure, Quaternary; Protein Structure, Tertiary; Recombinant Proteins | 2008 |
Use of antibiotics to prevent hepatitis and typhlitis in male scid mice spontaneously infected with Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Cecal Diseases; Cecum; Chronic Disease; Helicobacter; Helicobacter Infections; Hepatitis, Animal; Inflammation; Liver; Male; Metronidazole; Mice; Mice, SCID; Neomycin; Rodent Diseases; Tetracycline | 1995 |
[Is measurement of basal levels of serum pepsinogen II useful in proving the eradication of Helicobacter pylori by treatment?].
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pepsinogens; Prospective Studies; Radioimmunoassay; ROC Curve; Sensitivity and Specificity; Stomach; Tetracycline; Time Factors | 1995 |
[The importance of obtaining biopsies of the gastric body in the follow-up after eradicating treatment of Helicobacter pylori].
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Penicillins; Prospective Studies; Pyloric Antrum; Stomach; Tetracycline; Time Factors | 1995 |
[Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine; Salicylates; Tetracycline | 1995 |
Eczema responsive to treatment for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Eczema; Gastroenteritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Recurrence; Salicylates; Tetracycline | 1995 |
Evaluation of antibiotic therapies for eradication of Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Base Sequence; Bismuth; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Helicobacter Infections; Male; Metronidazole; Mice; Mice, Inbred Strains; Molecular Sequence Data; Random Allocation; Stomach Diseases; Tetracycline | 1995 |
The role of serology in the diagnosis of Helicobacter pylori infection in children.
Topics: Adolescent; Age Factors; Amoxicillin; Bismuth; Child; Child, Preschool; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Immunologic Tests; Infant; Korea; Male; Penicillins | 1995 |
Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Gastroenterology; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medical Staff, Hospital; Microbial Sensitivity Tests; Middle Aged; Patient Selection; Practice Patterns, Physicians'; Recurrence; Stomach Ulcer; United Kingdom | 1995 |
[Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Duodenitis; Evaluation Studies as Topic; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Stomach Ulcer; Time Factors | 1995 |
Helicobacter pylori infection in recurrent abdominal pain in childhood: comparison of diagnostic tests and therapy.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Antibodies, Bacterial; Bismuth; Child; Child, Preschool; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Male; Metronidazole; Organometallic Compounds; Polymerase Chain Reaction; Recurrence; Salicylates; Stomach Ulcer | 1995 |
"Cure" of Helicobacter pylori and "cure" of peptic ulcer: do they mean the same thing?
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Recurrence; Tetracycline; Time Factors | 1995 |
Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child.
Topics: Adolescent; Amoxicillin; Bismuth; Chronic Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Remission Induction; Stomach Neoplasms | 1995 |
90% cure: which anti-Helicobacter therapy can achieve this treatment goal?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Tetracycline | 1995 |
Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests | 1995 |
Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers.
Topics: Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Peptic Ulcer Hemorrhage; Recurrence | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline | 1995 |
Factors affecting growth and susceptibility testing of Helicobacter pylori in liquid media.
Topics: Agar; Animals; Bacteriological Techniques; Bismuth; Blood; Cattle; Culture Media; Evaluation Studies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Sheep; Starch | 1995 |
Helicobacter pylori: a human pathogen.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1995 |
Treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tetracycline | 1995 |
Helicobacter pylori infection and gastric juice vitamin C levels. Impact of eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; Bismuth; Drug Therapy, Combination; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Stomach Neoplasms | 1995 |
Duodenal ulcer healing drugs.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acid; Gastrin-Releasing Peptide; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptides | 1994 |
Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation.
Topics: Adult; Aged; Bismuth; Cell Division; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Longitudinal Studies; Male; Metaplasia; Metronidazole; Middle Aged; Nuclear Proteins; Proliferating Cell Nuclear Antigen; Pyloric Antrum; Tetracycline | 1994 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline; Treatment Failure; Treatment Outcome | 1994 |
Short report: evaluation of Helicobacter pylori eradication with bismuth sucralfate.
Topics: Administration, Oral; Adult; Aged; Bismuth; Drug Administration Schedule; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pilot Projects; Sucralfate; Treatment Failure | 1994 |
[Cost-benefit analysis of conservative therapy of gastritis and peptic ulcer].
Topics: Absenteeism; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans | 1994 |
[10 days of triple treatment of Helicobacter pylori infection and peptic ulcer. Status after treatment of 4 weeks and of one year].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Time Factors | 1994 |
[A Norwegian conference on updating of the treatment of Helicobacter pylori in peptic ulcer. Interessegruppe for Gastroenterologi].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Norway; Omeprazole; Oxytetracycline; Peptic Ulcer | 1994 |
Phospholipase A2 activity in gastric juice from patients with active and H. pylori-eradicated healed duodenal ulcer.
Topics: Adult; Aged; Bile Acids and Salts; Bismuth; Choline; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Juice; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Oxytetracycline; Phospholipases A; Phospholipases A2; Phospholipids | 1994 |
Preservation of gastric antral mucus is associated with failure of eradication of Helicobacter pylori by bismuth, metronidazole and tetracycline.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Administration Schedule; Female; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Neutrophils; Pyloric Antrum; Tetracycline | 1994 |
Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Peptic Ulcer; Ranitidine; Salicylates; Tetracycline; Time Factors | 1994 |
Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pepsinogens; Peptic Ulcer; Salicylates | 1994 |
Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: a 12-month follow-up study.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Insulin; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pepsinogens; Time Factors | 1994 |
Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Protein-Losing Enteropathies; Salicylates | 1994 |
H. pylori and ulcers.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates | 1994 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prospective Studies; Ranitidine; Recurrence; Salicylates; Stomach Ulcer | 1994 |
Vitamin C concentration in gastric juice before and after anti-Helicobacter pylori treatment.
Topics: Amoxicillin; Ascorbic Acid; Bismuth; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Organometallic Compounds; Salicylates; Smoking | 1994 |
[Helicobacter and peptic ulcer: history, diagnosis and therapy--when, in whom and how?].
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1994 |
Omeprazole/amoxicillin versus ranitidine/triple therapy for duodenal ulcer: when is the "same" the same?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Ranitidine; Salicylates; Tetracycline | 1994 |
Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing.
Topics: Adult; Bismuth; Female; Food; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Peptic Ulcer; Protein Precursors; Protein Processing, Post-Translational; Salicylates; Tetracycline | 1993 |
Phospholipase activity of Helicobacter pylori and its inhibition by bismuth salts. Biochemical and biophysical studies.
Topics: Anti-Bacterial Agents; Bismuth; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Organometallic Compounds; Phospholipases A; Phospholipases A1; Phospholipases A2; Stomach Ulcer; Type C Phospholipases | 1993 |
Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis.
Topics: Adult; Biopsy; Bismuth; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Organometallic Compounds; Pepsinogens; Salicylates | 1993 |
[Helicobacter pylori infection and peptic ulcer].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Tetracycline | 1993 |
Detection of H. pylori in saliva using a monoclonal antibody.
Topics: Adolescent; Adult; Amoxicillin; Antibodies, Bacterial; Antibodies, Monoclonal; Bismuth; Child; Child, Preschool; Fluorescent Antibody Technique; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Mouth Mucosa; Saliva | 1993 |
Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children.
Topics: Adolescent; Amoxicillin; Biopsy; Bismuth; Child; Child, Preschool; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds; Pyloric Antrum; Recurrence; Salicylates; Time Factors; Treatment Outcome | 1993 |
[Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease].
Topics: Administration, Oral; Adult; Aged; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Ranitidine; Salicylates; Tetracycline | 1993 |
Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Tetracycline | 1993 |
Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori.
Topics: Acute Disease; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Parietal Cells, Gastric; Tetracycline | 1993 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Metronidazole; Neutrophils; Prospective Studies; Recurrence; Stomach Ulcer | 1993 |
Long-term Helicobacter pylori recurrence after successful eradication with triple therapy.
Topics: Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Recurrence; Salicylates; Tetracycline | 1993 |
Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate.
Topics: Animals; Anti-Ulcer Agents; Bismuth; Citrates; Dogs; Ethanol; Female; Ferrets; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Indomethacin; Isoenzymes; Male; Microbial Sensitivity Tests; Organometallic Compounds; Pepsin A; Ranitidine; Rats; Stomach Ulcer | 1993 |
[The effect of colloidal bismuth and its combination with amoxicillin on the elimination of Helicobacter pylori in patients with a duodenal ulcer and chronic antral gastritis].
Topics: Adult; Aged; Amoxicillin; Bismuth; Chronic Disease; Colloids; Drug Evaluation; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pyloric Antrum | 1993 |
Development of a 14C-urea breath test in ferrets colonised with Helicobacter mustelae: effects of treatment with bismuth, antibiotics, and urease inhibitors.
Topics: Animals; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; Disease Models, Animal; Ferrets; Helicobacter Infections; Urease | 1993 |
Eradication of Helicobacter pylori normalizes serum gastrin concentration and antral gastrin cell number in a patient with primary gastrin cell hyperplasia.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enterochromaffin Cells; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Male; Metronidazole; Middle Aged; Pyloric Antrum; Tetracycline | 1993 |
Esophagitis and Helicobacter pylori in children: incidence and therapeutic implications.
Topics: Adolescent; Amoxicillin; Bismuth; Child; Cimetidine; Esophagitis; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Peptic Ulcer; Pyloric Antrum; Ranitidine | 1993 |
Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulins; Male; Metronidazole; Middle Aged; Omeprazole; Pyloric Antrum; T-Lymphocytes; Tetracycline | 1993 |
Response to article by Forné et al.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Colloids; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Remission Induction | 1996 |
[Eradication of Helicobacter pylori and hemorrhagic recurrence of duodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer Hemorrhage; Tetracycline; Time Factors | 1995 |
Evaluation of a new bismuth-free triple therapy in nude mice and humans.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Colony Count, Microbial; Contraindications; Disease Models, Animal; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Mice; Mice, Inbred BALB C; Mice, Nude; Penicillins; Peptic Ulcer; Recurrence; Severity of Illness Index; Treatment Outcome | 1995 |
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Omeprazole; Patient Compliance; Penicillins; Recurrence; Tetracycline; Time Factors | 1996 |
[What factors influence healing of duodenal ulcer when Helicobacter pylori eradication treatment is used?].
Topics: Adult; Age Factors; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Evaluation Studies as Topic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Multivariate Analysis; Omeprazole; Penicillins; Sex Factors; Smoking; Tetracycline; Time Factors; Wound Healing | 1996 |
Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori.
Topics: Bismuth; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Middle Aged; Omeprazole; Salivary Gland Neoplasms | 1996 |
Management of Helicobacter pylori-positive peptic ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1996 |
Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Ranitidine; Recurrence; Time Factors | 1996 |
Helicobacter pylori reinfection after apparent eradication--the Ipswich experience.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Case-Control Studies; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; England; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Recurrence; Stomach Ulcer; Time Factors; Urea | 1996 |
Treatment of Helicobacter pylori infection by topical administration of antimicrobial agents.
Topics: Administration, Topical; Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Intubation, Gastrointestinal; Metronidazole; Penicillins | 1996 |
Evaluation of various oral antimicrobial formulations for eradication of Helicobacter hepaticus.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Base Sequence; Bismuth; Diet; Drinking; Female; Helicobacter; Helicobacter Infections; Male; Metronidazole; Mice; Mice, Inbred A; Mice, Inbred DBA; Molecular Sequence Data; Polymerase Chain Reaction; Rodent Diseases; Tetracycline | 1996 |
[Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori?].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Pyloric Antrum; Stomach; Tetracycline | 1996 |
[Diagnosis and therapy of Helicobacter pylori infection. Guidelines of the German Society of Digestive and Metabolic Diseases].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, Combination; Gastritis; Germany; Helicobacter Infections; Humans; Peptic Ulcer; Stomach Neoplasms; Treatment Outcome | 1996 |
Reflections on gastric ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Recurrence; Salicylates; Stomach Ulcer | 1996 |
[Triple-therapy treatment during 1 month versus 2 weeks in gastroduodenal disease due to Helicobacter pylori in children].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Time Factors | 1996 |
The influence of isolated doses of drugs, feeding and colonic bacterial ureolysis on urea breath test results.
Topics: Adult; Amoxicillin; Bacteria; Bismuth; Breath Tests; Colon; Drug Therapy, Combination; Eating; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Sucralfate; Urea | 1995 |
Practice guidelines for treatment of peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Peptic Ulcer; Practice Guidelines as Topic; Ranitidine | 1996 |
Insulin-like growth factor-I in Helicobacter pylori gastritis and response to eradication using bismuth based triple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Gastric Juice; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Insulin-Like Growth Factor I; Male; Metronidazole; Middle Aged | 1996 |
Pylorid, H. pylori and peptic ulcer.
Topics: Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Randomized Controlled Trials as Topic; Ranitidine | 1996 |
[Connection between Helicobacter pylori infection and chronic gastrointestinal urticaria].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Bismuth; Chronic Disease; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Penicillins; Urticaria | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Pronase | 1996 |
Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy.
Topics: Antacids; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Treatment Outcome | 1996 |
Ranitidine bismuth citrate therapy.
Topics: Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 1996 |
[Anti-Helicobacter pylori therapy. Who should be treated, how, how long?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Treatment Outcome | 1996 |
[Is gastric acid secretion inhibition necessary for successful eradication of Helicobacter pylori?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastric Acidity Determination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 1996 |
Helicobacter pylori reinfection is rare in peptic ulcer patients cured by antimicrobial therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Recurrence; Salicylates; Stomach Ulcer; Time Factors; Tinidazole | 1996 |
Six months' experience with a pharmacist-run Helicobacter pylori treatment clinic.
Topics: Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Cost of Illness; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Pilot Projects; Salicylates; Tetracycline | 1996 |
Treating Helicobacter pylori--the best is yet to come?
Topics: Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Tetracycline | 1996 |
A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Tetracycline | 1997 |
Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Recurrence; Risk Factors; Smoking; Stomach Ulcer; Sucralfate; Wound Healing | 1997 |
Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis.
Topics: Amoxicillin; Bismuth; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged | 1997 |
Triple-drug therapy of Helicobacter pylori infection in duodenal ulcer disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Recurrence; Tetracycline; Time Factors | 1997 |
Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection.
Topics: Adult; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline | 1997 |
Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment.
Topics: Amoxicillin; Bicarbonates; Bismuth; Carbon Isotopes; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mass Spectrometry; Metronidazole; Middle Aged; Omeprazole; Sensitivity and Specificity; Tetracycline | 1997 |
Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged | 1997 |
Pharmacological therapy of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Costs; Drug Resistance, Microbial; Drug Therapy, Combination; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Compliance; Penicillins; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Vaccination | 1997 |
Identification and eradication of Helicobacter pylori in an isolated patient population.
Topics: Amoxicillin; Bismuth; Cost Savings; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Military Personnel; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; United States; Utah | 1997 |
Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular?
Topics: Adult; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antitrichomonal Agents; Bismuth; Chaperonin 60; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epithelium; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; HLA-DR Antigens; Humans; Immunohistochemistry; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Tetracycline; Time Factors | 1997 |
Treatment of gastritis in cheetahs (Acinonyx jubatus).
Topics: Acinonyx; Animals; Anti-Bacterial Agents; Antitrichomonal Agents; Biopsy; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Gram-Negative Bacterial Infections; Helicobacter; Helicobacter Infections; Lymphocytes; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Salicylates; Sensitivity and Specificity; Tetracycline; Time Factors | 1997 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline; Tinidazole | 1996 |
Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets.
Topics: Amoxicillin; Animals; Antacids; Bacterial Proteins; Biopsy; Bismuth; DNA, Bacterial; Drug Therapy, Combination; Ferrets; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter; Helicobacter Infections; Metronidazole; Organometallic Compounds; Recurrence; Salicylates; Time Factors; Urease | 1996 |
Characterization and therapy for experimental infection by Helicobacter mustelae in ferrets.
Topics: Amoxicillin; Animals; Antacids; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Female; Ferrets; Gastritis; Helicobacter; Helicobacter Infections; Male; Metronidazole; Organometallic Compounds; Salicylates; Specific Pathogen-Free Organisms | 1996 |
An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Imipenem; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Tetracycline | 1996 |
Cure of Helicobacter pylori: a hidden curse?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Esophagitis, Peptic; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Risk Factors; Salicylates; Sex Factors; Weight Gain | 1997 |
Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer | 1998 |
Helicobacter pylori: challenges for the paediatrician.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Urea | 1997 |
Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Gastritis; Helicobacter Infections; Helicobacter pylori; Macaca mulatta; Male; Omeprazole; Organometallic Compounds; Penicillins; Salicylates | 1998 |
Significance of a tetracycline and Pepto-Bismol interaction in the management of Helicobacter pylori-induced peptic ulcer disease.
Topics: Bismuth; Drug Interactions; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline | 1998 |
The ideal therapy must be defined in each geographical area: experience with a quadruple therapy in Spain.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Spain; Tetracycline | 1998 |
Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Time Factors | 1998 |
Peptic ulcer treatment today--is there a role for maintenance therapy?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer; Peptic Ulcer Hemorrhage; Recurrence | 1997 |
[Polyneuropathy caused by vitamin B12 deficiency secondary to chronic atrophic gastritis and giardiasis].
Topics: Amoxicillin; Anemia, Pernicious; Anti-Bacterial Agents; Antiprotozoal Agents; Bismuth; Duodenitis; Enzyme Inhibitors; Evoked Potentials, Somatosensory; Female; Gastritis, Atrophic; Giardiasis; Helicobacter Infections; Helicobacter pylori; Humans; Hydroxocobalamin; Malabsorption Syndromes; Metronidazole; Middle Aged; Neural Conduction; Omeprazole; Peripheral Nervous System Diseases; Remission Induction; Vitamin B 12 Deficiency | 1998 |
Clostridium difficile colitis associated with treatment of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Organometallic Compounds; Penicillins; Salicylates; Stomach Diseases | 1998 |
[Evaluation of results of surgical treatment of peptic ulcer associated with Helicobacter pylori].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Evaluation Studies as Topic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Stomach Ulcer | 1998 |
National surveillance of Helicobacter pylori eradication therapy in Denmark. Results from registration of 34,582 prescriptions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Child; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Health Care Surveys; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Imidazoles; Macrolides; Male; Middle Aged; Penicillins; Proton Pump Inhibitors; Tetracyclines | 1998 |
The European meeting on Helicobacter pylori: therapeutic news from Lisbon.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Portugal; Proton Pump Inhibitors; Ranitidine | 1998 |
Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bacterial Vaccines; Bismuth; Drug Design; Drug Therapy, Combination; Duodenitis; Forecasting; Gastritis; Genome, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine | 1998 |
Helicobacter pylori eradication failure--'salvage' therapies needed.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Penicillins; Treatment Failure | 1998 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine | 1998 |
In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Nitrofurantoin; Tetracycline | 1998 |
The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; New York City; Organometallic Compounds; Peptic Ulcer; Prisons; Ranitidine; Retrospective Studies; Salicylates; Tetracycline; Urban Health | 1998 |
Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Child; Disease Progression; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 1999 |
A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation.
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Delivery Systems; Helicobacter Infections; Metronidazole; Solubility; Stomach Ulcer; Tablets, Enteric-Coated; Tetracycline | 1999 |
Attenuation of hydrophobic phospholipid barrier is an early event in Helicobacter felis-induced gastritis in mice.
Topics: Animals; Bismuth; Disease Models, Animal; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Hydrogen-Ion Concentration; Mice; Mice, Inbred C57BL; Organ Size; Phosphatidylcholines; Phospholipases A; Phospholipases A2; Phospholipids; Stomach | 1999 |
Helicobacter pylori eradication treatment reduces the severity of rosacea.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin A; Immunoglobulin G; Male; Metronidazole; Middle Aged; Organometallic Compounds; Rosacea; Treatment Outcome | 1999 |
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection.
Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Tetracycline | 1999 |
Duodenal ulcer disease: to treat H. pylori infection or not?
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Ranitidine; Tetracycline; United States | 1992 |
Organobismuth compounds: activity against Helicobacter pylori.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Inorganic Chemicals; Microbial Sensitivity Tests; Organic Chemicals; Peptic Ulcer | 1999 |
Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Toxins; Bacterial Vaccines; Bismuth; Clarithromycin; Drug Therapy, Combination; Enterotoxins; Enzyme-Linked Immunosorbent Assay; Escherichia coli Proteins; Helicobacter Infections; Helicobacter pylori; Macaca mulatta; Metronidazole; Omeprazole; Organometallic Compounds; Recombinant Proteins; Salicylates; Saliva; Urease | 1999 |
Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Ranitidine; Tetracycline | 1999 |
[Intensifying the study of the proper treatment of digestive ulceration].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Peptic Ulcer | 1997 |
Effect of ranitidine bismuth citrate on the phospholipase A2 activity of Naja naja venom and Helicobacter pylori: a biochemical analysis.
Topics: Animals; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Elapid Venoms; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Phospholipases A; Phospholipases A2; Ranitidine | 1999 |
The effect of Helicobacter pylori eradication on gastro-oesophageal reflux.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Esophagitis; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Oxytetracycline; Severity of Illness Index | 1999 |
Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii.
Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; Biopsy; Bismuth; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; Cat Diseases; Cats; Clarithromycin; Female; Gas Chromatography-Mass Spectrometry; Helicobacter; Helicobacter Infections; Male; Metronidazole; Polymerase Chain Reaction; Prospective Studies; Random Allocation; Ranitidine; Stomach Diseases; Tinidazole; Urea | 1999 |
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Staging; Omeprazole; Organometallic Compounds; Prospective Studies; Remission Induction; Salicylates; Stomach Neoplasms | 1999 |
Role of Hpn and NixA of Helicobacter pylori in susceptibility and resistance to bismuth and other metal ions.
Topics: Bacterial Proteins; Bismuth; Carrier Proteins; Cation Transport Proteins; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Membrane Proteins; Metals, Heavy; Microbial Sensitivity Tests; Organometallic Compounds; Proteins; Ranitidine | 1999 |
Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antigens, Bacterial; Bismuth; Breath Tests; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Ranitidine; Salicylates; Sensitivity and Specificity; Urea | 1999 |
Treatment of Helicobacter pylori: where are we now? What are the key questions?
Topics: Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole; Ranitidine; Stomach Ulcer; Treatment Outcome; United Kingdom | 1999 |
Re-treatment after Helicobacter pylori eradication failure.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Treatment Failure | 1999 |
Eradication of Helicobacter pylori normalizes elevated mucosal levels of epidermal growth factor and its receptor.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Chronic Disease; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Salicylates | 1999 |
Therapy and diagnostic tests used for Helicobacter pylori infection in the Scandinavian countries in 1998.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Diseases; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Practice Patterns, Physicians'; Proton Pump Inhibitors; Scandinavian and Nordic Countries; Serologic Tests | 1999 |
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Mixed Function Oxygenases; Omeprazole; Penicillins; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Synthesis Inhibitors; Treatment Outcome | 1999 |
Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion compound.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Disease Models, Animal; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lactose; Liver Function Tests; Macaca mulatta; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Sialic Acids | 1999 |
[Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of Helicobacter pylori].
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; Bismuth; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; L-Lactate Dehydrogenase; Metronidazole; Omeprazole; Organometallic Compounds; Purpura, Thrombocytopenic, Idiopathic; Salicylates; Tetracycline | 1999 |
Unsuccessful treatment results in survival of less virulent genotypes of Helicobacter pylori in Colombian patients.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Chemoprevention; Colombia; Follow-Up Studies; Gastritis, Atrophic; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Penicillins; Precancerous Conditions; Salicylates; Stomach Neoplasms; Treatment Failure; Virulence | 2000 |
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Treatment Outcome; United States | 2000 |
Helicobacter pylori eradication in clinical practice: retreatment rates and costs of competing regimens.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Multivariate Analysis; Proton Pump Inhibitors; Retrospective Studies | 2000 |
[IgG and IgA immunoglobulins in helicobacter pylori infections of children with chronic dyspepsia before and after two week triple drug therapy].
Topics: Adolescent; Amoxicillin; Bismuth; Blotting, Western; Child; Chronic Disease; Drug Therapy, Combination; Dyspepsia; Enzyme-Linked Immunosorbent Assay; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Monitoring, Physiologic; Ranitidine; Serologic Tests | 1999 |
Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
Topics: Anti-Bacterial Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Absorption; Male; Microbial Sensitivity Tests; Organometallic Compounds; Predictive Value of Tests; Solubility | 2000 |
Single drug therapy for Helicobacter pylori infection.
Topics: Bismuth; Capsules; Drug Combinations; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline | 2000 |
Pooled analysis of Helicobacter pylori eradication regimes in Asia.
Topics: Asia; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2000 |
Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Ranitidine; Salicylates | 2000 |
Strategies to treat patients with antibiotic resistant Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2000 |
[Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin].
Topics: Anti-Ulcer Agents; Bismuth; Combined Modality Therapy; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Tetracycline; Treatment Failure | 2000 |
Dual therapy with ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Peptic Ulcer; Ranitidine | 2001 |
Optimal strategy of treatment of Helicobacter pylori infection: renaissance of antisecretory drugs?
Topics: Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine | 2001 |
A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Costs; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Patient Care Planning; Penicillins; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine; Treatment Outcome | 2001 |
In search of the Holy Grail of Heliocobacter pylori remedies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Humans; Metronidazole; Pilot Projects; Ranitidine; Spain | 2001 |
Efficacy of Helicobacter pylori eradication therapies: a single centre observational study.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Nitroimidazoles; Ranitidine; Treatment Outcome | 2001 |
Diagnostic methods for detecting forms and strains of Helicobacter pylori and evaluation of its eradication.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Bismuth; DNA Fingerprinting; Duodenal Ulcer; Female; Flagellin; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Ranitidine; Recurrence; Restriction Mapping; Species Specificity; Time Factors; Urease | 2001 |
What is the most effective regimen for eradication of Helicobacter pylori in patients who have failed a first eradication attempt?
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Costs; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Meta-Analysis as Topic; Proton Pump Inhibitors; Ranitidine | 2002 |
Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model.
Topics: Animals; Bismuth; Disease Models, Animal; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Mice; Mice, Inbred C57BL; Organometallic Compounds; Salicylates; Tetracycline | 2002 |
Use of an ammonia electrode for rapid quantification of Helicobacter pylori urease: its use in the endoscopy room and in the assessment of urease inhibition by bismuth subsalicylate.
Topics: Ammonia; Bismuth; Electrodes; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; In Vitro Techniques; Male; Middle Aged; Organometallic Compounds; Salicylates; Sensitivity and Specificity; Urease | 1992 |
Eradicating Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 1992 |
Eradicating Helicobacter pylori.
Topics: Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 1992 |
Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Gastric Mucins; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Middle Aged; Organometallic Compounds; Solubility | 1992 |
Quantitative assessment of histological changes in chronic gastritis after eradication of Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Chronic Disease; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Tinidazole | 1992 |
Clinicopathological assessment of gastric biopsy samples of patients with Helicobacter pylori infection--metronidazole resistance and compliance problems in the United Arab Emirates.
Topics: Adolescent; Adult; Antacids; Bacteriological Techniques; Bismuth; Doxycycline; Drug Resistance, Microbial; Dyspepsia; Female; Follow-Up Studies; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Prevalence; Prospective Studies; Stomach; Tinidazole; United Arab Emirates | 1992 |
Eradication of Helicobacter pylori reduces gastric and duodenal ulcer recurrence.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Ranitidine; Recurrence; Salicylates; Tetracycline | 1992 |
[Eradicate Helicobacter pylori at any price?].
Topics: Bismuth; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Recurrence | 1992 |
Management and response to treatment of Helicobacter pylori gastritis.
Topics: Age Factors; Ampicillin; Antacids; Biopsy; Bismuth; Child; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Prevalence; Prospective Studies; Sex Factors; Socioeconomic Factors | 1992 |
Short report: short-term triple therapy for H. pylori-associated duodenal ulcer disease.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Tetracycline | 1992 |
[Helicobacter pylori: from harmless commensal to clinically significant disease factor].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Recurrence; Stomach Ulcer; Tetracycline | 1992 |
[Helicobacter pylori infections in children].
Topics: Adolescent; Amoxicillin; Antacids; Biopsy; Bismuth; Breath Tests; Child; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds | 1992 |
Factors influencing the eradication of Helicobacter pylori with triple therapy.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Regression Analysis; Salicylates; Stomach Ulcer; Tetracycline | 1992 |
[Helicobacter pylori and erosive lesions of the gastric mucosa in cirrhosis].
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Liver Cirrhosis; Stomach Diseases | 1991 |
Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Circadian Rhythm; Duodenal Ulcer; Female; Gastric Acid; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Organometallic Compounds; Stomach; Time Factors | 1991 |
Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin.
Topics: Adult; Bismuth; Breath Tests; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Nitrofurantoin; Organometallic Compounds; Salicylates; Urea | 1991 |
Helicobacter pylori infection in uraemic patients.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Prevalence; Uremia | 1991 |
Epidemiology and treatment of gastric Campylobacter pylori infection: more questions than answers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Diagnosis, Differential; Drug Therapy, Combination; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Organometallic Compounds; Prevalence; Salicylates; Tinidazole; Urease | 1990 |
Long-term follow-up of voluntary ingestion of Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Organometallic Compounds; Recurrence; Salicylates | 1991 |
Gastroduodenal mucosal prostaglandin generation in patients with Helicobacter pylori before and after treatment with bismuth subsalicylate.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Dinoprostone; Duodenitis; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Salicylates | 1991 |
Helicobacter pylori.
Topics: Bismuth; Child; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Salicylates | 1991 |
[Assessment of the efficacy of de-nol and bismuth subnitrate treatment of patients with associated peptic ulcer and pyloric Helicobacter infection (experimental and clinical studies)].
Topics: Adult; Animals; Anti-Ulcer Agents; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Microscopy, Electron, Scanning; Middle Aged; Organometallic Compounds; Peptic Ulcer; Pyloric Antrum; Rats | 1991 |
On: The who's and when's of therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans | 1991 |
[Helicobacter pylori, peptic diseases and colloid bismuth].
Topics: Bismuth; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer | 1990 |
Systemic chemotherapy for Helicobacter pylori eradication?
Topics: Administration, Oral; Bismuth; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Salicylates | 1990 |